#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Altered resting state functional connectivity in early course schizophrenia
#Text=Impaired connectivity is proposed to underlie pathophysiology of schizophrenia.
1-1	0-7	Altered	_	
1-2	8-15	resting	_	
1-3	16-21	state	_	
1-4	22-32	functional	_	
1-5	33-45	connectivity	_	
1-6	46-48	in	_	
1-7	49-54	early	_	
1-8	55-61	course	_	
1-9	62-75	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-10	76-84	Impaired	_	
1-11	85-97	connectivity	_	
1-12	98-100	is	_	
1-13	101-109	proposed	_	
1-14	110-112	to	_	
1-15	113-121	underlie	_	
1-16	122-137	pathophysiology	_	
1-17	138-140	of	_	
1-18	141-154	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-19	154-155	.	_	

#Text=Existing studies on functional connectivity show inconsistent results.
2-1	156-164	Existing	_	
2-2	165-172	studies	_	
2-3	173-175	on	_	
2-4	176-186	functional	_	
2-5	187-199	connectivity	_	
2-6	200-204	show	_	
2-7	205-217	inconsistent	_	
2-8	218-225	results	_	
2-9	225-226	.	_	

#Text=We examined functional connectivity in a clinically homogenous sample of 34 early course schizophrenia patients compared with/to 19 healthy controls using resting state functional magnetic resonance imaging (rsfMRI).
3-1	227-229	We	_	
3-2	230-238	examined	_	
3-3	239-249	functional	_	
3-4	250-262	connectivity	_	
3-5	263-265	in	_	
3-6	266-267	a	_	
3-7	268-278	clinically	_	
3-8	279-289	homogenous	_	
3-9	290-296	sample	_	
3-10	297-299	of	_	
3-11	300-302	34	_	
3-12	303-308	early	_	
3-13	309-315	course	_	
3-14	316-329	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
3-15	330-338	patients	_	
3-16	339-347	compared	_	
3-17	348-352	with	_	
3-18	352-353	/	_	
3-19	353-355	to	_	
3-20	356-358	19	_	
3-21	359-366	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
3-22	367-375	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
3-23	376-381	using	_	
3-24	382-389	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
3-25	390-395	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
3-26	396-406	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
3-27	407-415	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
3-28	416-425	resonance	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
3-29	426-433	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
3-30	434-435	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
3-31	435-441	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
3-32	441-442	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
3-33	442-443	.	_	

#Text=Mean duration of illness for schizophrenia patients was 4 ± 1.78 years.
4-1	444-448	Mean	_	
4-2	449-457	duration	_	
4-3	458-460	of	_	
4-4	461-468	illness	_	
4-5	469-472	for	_	
4-6	473-486	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
4-7	487-495	patients	_	
4-8	496-499	was	_	
4-9	500-501	4	_	
4-10	502-503	±	_	
4-11	504-508	1.78	_	
4-12	509-514	years	_	
4-13	514-515	.	_	

#Text=Following a comprehensive clinical assessment, rsfMRI data were acquired using a 3.0 T magnetic resonance imaging scanner, and analyzed using FSL version 5.01 software (FMRIB’s Software Library, www.fmrib.ox.ac.uk/fsl).
5-1	516-525	Following	_	
5-2	526-527	a	_	
5-3	528-541	comprehensive	_	
5-4	542-550	clinical	_	
5-5	551-561	assessment	_	
5-6	561-562	,	_	
5-7	563-569	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	
5-8	570-574	data	_	
5-9	575-579	were	_	
5-10	580-588	acquired	_	
5-11	589-594	using	_	
5-12	595-596	a	_	
5-13	597-600	3.0	_	
5-14	601-602	T	_	
5-15	603-611	magnetic	_	
5-16	612-621	resonance	_	
5-17	622-629	imaging	_	
5-18	630-637	scanner	_	
5-19	637-638	,	_	
5-20	639-642	and	_	
5-21	643-651	analyzed	_	
5-22	652-657	using	_	
5-23	658-661	FSL	_	
5-24	662-669	version	_	
5-25	670-674	5.01	_	
5-26	675-683	software	_	
5-27	684-685	(	_	
5-28	685-690	FMRIB	_	
5-29	690-691	’	_	
5-30	691-692	s	_	
5-31	693-701	Software	_	
5-32	702-709	Library	_	
5-33	709-710	,	_	
5-34	711-729	www.fmrib.ox.ac.uk	_	
5-35	729-730	/	_	
5-36	730-733	fsl	_	
5-37	733-734	)	_	
5-38	734-735	.	_	

#Text=Compared to healthy controls, schizophrenia patients had significantly decreased functional connectivity in the left fronto-parietal network, lateral and medial visual network, motor network, default mode network and auditory network.
6-1	736-744	Compared	_	
6-2	745-747	to	_	
6-3	748-755	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
6-4	756-764	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
6-5	764-765	,	_	
6-6	766-779	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
6-7	780-788	patients	_	
6-8	789-792	had	_	
6-9	793-806	significantly	_	
6-10	807-816	decreased	_	
6-11	817-827	functional	_	
6-12	828-840	connectivity	_	
6-13	841-843	in	_	
6-14	844-847	the	_	
6-15	848-852	left	_	
6-16	853-868	fronto-parietal	_	
6-17	869-876	network	_	
6-18	876-877	,	_	
6-19	878-885	lateral	_	
6-20	886-889	and	_	
6-21	890-896	medial	_	
6-22	897-903	visual	_	
6-23	904-911	network	_	
6-24	911-912	,	_	
6-25	913-918	motor	_	
6-26	919-926	network	_	
6-27	926-927	,	_	
6-28	928-935	default	_	
6-29	936-940	mode	_	
6-30	941-948	network	_	
6-31	949-952	and	_	
6-32	953-961	auditory	_	
6-33	962-969	network	_	
6-34	969-970	.	_	

#Text=Our data suggests significant functional hypoconnectivity in selected brain networks in early schizophrenia patients compared to controls.
7-1	971-974	Our	_	
7-2	975-979	data	_	
7-3	980-988	suggests	_	
7-4	989-1000	significant	_	
7-5	1001-1011	functional	_	
7-6	1012-1028	hypoconnectivity	_	
7-7	1029-1031	in	_	
7-8	1032-1040	selected	_	
7-9	1041-1046	brain	_	
7-10	1047-1055	networks	_	
7-11	1056-1058	in	_	
7-12	1059-1064	early	_	
7-13	1065-1078	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
7-14	1079-1087	patients	_	
7-15	1088-1096	compared	_	
7-16	1097-1099	to	_	
7-17	1100-1108	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
7-18	1108-1109	.	_	

#Text=It is likely that the observed functional hypoconnectivity may be associated with features of schizophrenia other than those examined in this study.
8-1	1110-1112	It	_	
8-2	1113-1115	is	_	
8-3	1116-1122	likely	_	
8-4	1123-1127	that	_	
8-5	1128-1131	the	_	
8-6	1132-1140	observed	_	
8-7	1141-1151	functional	_	
8-8	1152-1168	hypoconnectivity	_	
8-9	1169-1172	may	_	
8-10	1173-1175	be	_	
8-11	1176-1186	associated	_	
8-12	1187-1191	with	_	
8-13	1192-1200	features	_	
8-14	1201-1203	of	_	
8-15	1204-1217	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
8-16	1218-1223	other	_	
8-17	1224-1228	than	_	
8-18	1229-1234	those	_	
8-19	1235-1243	examined	_	
8-20	1244-1246	in	_	
8-21	1247-1251	this	_	
8-22	1252-1257	study	_	
8-23	1257-1258	.	_	

#Text=It is possible that hypoconnectivity is necessary but not sufficient to the clinical manifestation of schizophrenia.
9-1	1259-1261	It	_	
9-2	1262-1264	is	_	
9-3	1265-1273	possible	_	
9-4	1274-1278	that	_	
9-5	1279-1295	hypoconnectivity	_	
9-6	1296-1298	is	_	
9-7	1299-1308	necessary	_	
9-8	1309-1312	but	_	
9-9	1313-1316	not	_	
9-10	1317-1327	sufficient	_	
9-11	1328-1330	to	_	
9-12	1331-1334	the	_	
9-13	1335-1343	clinical	_	
9-14	1344-1357	manifestation	_	
9-15	1358-1360	of	_	
9-16	1361-1374	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
9-17	1374-1375	.	_	

#Text=The examination of functional connectivity as a biomarker should be extended to a wider array of disease phenotypes to better understand its significance.
#Text=1.
10-1	1376-1379	The	_	
10-2	1380-1391	examination	_	
10-3	1392-1394	of	_	
10-4	1395-1405	functional	_	
10-5	1406-1418	connectivity	_	
10-6	1419-1421	as	_	
10-7	1422-1423	a	_	
10-8	1424-1433	biomarker	_	
10-9	1434-1440	should	_	
10-10	1441-1443	be	_	
10-11	1444-1452	extended	_	
10-12	1453-1455	to	_	
10-13	1456-1457	a	_	
10-14	1458-1463	wider	_	
10-15	1464-1469	array	_	
10-16	1470-1472	of	_	
10-17	1473-1480	disease	_	
10-18	1481-1491	phenotypes	_	
10-19	1492-1494	to	_	
10-20	1495-1501	better	_	
10-21	1502-1512	understand	_	
10-22	1513-1516	its	_	
10-23	1517-1529	significance	_	
10-24	1529-1530	.	_	
10-25	1531-1532	1	_	
10-26	1532-1533	.	_	

#Text=Introduction
#Text=Impaired neural connectivity is implicated in schizophrenia.
11-1	1534-1546	Introduction	_	
11-2	1547-1555	Impaired	_	
11-3	1556-1562	neural	_	
11-4	1563-1575	connectivity	_	
11-5	1576-1578	is	_	
11-6	1579-1589	implicated	_	
11-7	1590-1592	in	_	
11-8	1593-1606	schizophrenia	_	
11-9	1606-1607	.	_	

#Text=Functional imaging has been extensively used to highlight such connectivity deficits.
12-1	1608-1618	Functional	_	
12-2	1619-1626	imaging	_	
12-3	1627-1630	has	_	
12-4	1631-1635	been	_	
12-5	1636-1647	extensively	_	
12-6	1648-1652	used	_	
12-7	1653-1655	to	_	
12-8	1656-1665	highlight	_	
12-9	1666-1670	such	_	
12-10	1671-1683	connectivity	_	
12-11	1684-1692	deficits	_	
12-12	1692-1693	.	_	

#Text=Schizophrenia patients and their relatives show aberrant functional connectivity in default mode networks, like the medial prefrontal, cingulate and inferior parietal cortices, and regions regulating executive functions such as the dorsolateral prefrontal cortex (DLPFC).
13-1	1694-1707	Schizophrenia	_	
13-2	1708-1716	patients	_	
13-3	1717-1720	and	_	
13-4	1721-1726	their	_	
13-5	1727-1736	relatives	_	
13-6	1737-1741	show	_	
13-7	1742-1750	aberrant	_	
13-8	1751-1761	functional	_	
13-9	1762-1774	connectivity	_	
13-10	1775-1777	in	_	
13-11	1778-1785	default	_	
13-12	1786-1790	mode	_	
13-13	1791-1799	networks	_	
13-14	1799-1800	,	_	
13-15	1801-1805	like	_	
13-16	1806-1809	the	_	
13-17	1810-1816	medial	_	
13-18	1817-1827	prefrontal	_	
13-19	1827-1828	,	_	
13-20	1829-1838	cingulate	_	
13-21	1839-1842	and	_	
13-22	1843-1851	inferior	_	
13-23	1852-1860	parietal	_	
13-24	1861-1869	cortices	_	
13-25	1869-1870	,	_	
13-26	1871-1874	and	_	
13-27	1875-1882	regions	_	
13-28	1883-1893	regulating	_	
13-29	1894-1903	executive	_	
13-30	1904-1913	functions	_	
13-31	1914-1918	such	_	
13-32	1919-1921	as	_	
13-33	1922-1925	the	_	
13-34	1926-1938	dorsolateral	_	
13-35	1939-1949	prefrontal	_	
13-36	1950-1956	cortex	_	
13-37	1957-1958	(	_	
13-38	1958-1963	DLPFC	_	
13-39	1963-1964	)	_	
13-40	1964-1965	.	_	

#Text=Amongst novel functional imaging approaches, resting state functional MRI (rsfMRI) may help unravel some neurobiological abnormalities associated with neuropsychiatric disorders.
14-1	1966-1973	Amongst	_	
14-2	1974-1979	novel	_	
14-3	1980-1990	functional	_	
14-4	1991-1998	imaging	_	
14-5	1999-2009	approaches	_	
14-6	2009-2010	,	_	
14-7	2011-2018	resting	_	
14-8	2019-2024	state	_	
14-9	2025-2035	functional	_	
14-10	2036-2039	MRI	_	
14-11	2040-2041	(	_	
14-12	2041-2047	rsfMRI	_	
14-13	2047-2048	)	_	
14-14	2049-2052	may	_	
14-15	2053-2057	help	_	
14-16	2058-2065	unravel	_	
14-17	2066-2070	some	_	
14-18	2071-2086	neurobiological	_	
14-19	2087-2100	abnormalities	_	
14-20	2101-2111	associated	_	
14-21	2112-2116	with	_	
14-22	2117-2133	neuropsychiatric	_	
14-23	2134-2143	disorders	_	
14-24	2143-2144	.	_	

#Text=Resting state fMRI (rsfMRI) is an imaging technique that measures Spontaneous Low-Frequency Fluctuations (SLFFs) in the blood oxygenation level dependent (BOLD) signal during the resting condition.
15-1	2145-2152	Resting	_	
15-2	2153-2158	state	_	
15-3	2159-2163	fMRI	_	
15-4	2164-2165	(	_	
15-5	2165-2171	rsfMRI	_	
15-6	2171-2172	)	_	
15-7	2173-2175	is	_	
15-8	2176-2178	an	_	
15-9	2179-2186	imaging	_	
15-10	2187-2196	technique	_	
15-11	2197-2201	that	_	
15-12	2202-2210	measures	_	
15-13	2211-2222	Spontaneous	_	
15-14	2223-2236	Low-Frequency	_	
15-15	2237-2249	Fluctuations	_	
15-16	2250-2251	(	_	
15-17	2251-2256	SLFFs	_	
15-18	2256-2257	)	_	
15-19	2258-2260	in	_	
15-20	2261-2264	the	_	
15-21	2265-2270	blood	_	
15-22	2271-2282	oxygenation	_	
15-23	2283-2288	level	_	
15-24	2289-2298	dependent	_	
15-25	2299-2300	(	_	
15-26	2300-2304	BOLD	_	
15-27	2304-2305	)	_	
15-28	2306-2312	signal	_	
15-29	2313-2319	during	_	
15-30	2320-2323	the	_	
15-31	2324-2331	resting	_	
15-32	2332-2341	condition	_	
15-33	2341-2342	.	_	

#Text=RsfMRI experiments are less prone to multisite variability and uninfluenced by task performance with low signal-to-noise ratio leading to higher probability of acquiring more reliable data.
16-1	2343-2349	RsfMRI	_	
16-2	2350-2361	experiments	_	
16-3	2362-2365	are	_	
16-4	2366-2370	less	_	
16-5	2371-2376	prone	_	
16-6	2377-2379	to	_	
16-7	2380-2389	multisite	_	
16-8	2390-2401	variability	_	
16-9	2402-2405	and	_	
16-10	2406-2418	uninfluenced	_	
16-11	2419-2421	by	_	
16-12	2422-2426	task	_	
16-13	2427-2438	performance	_	
16-14	2439-2443	with	_	
16-15	2444-2447	low	_	
16-16	2448-2463	signal-to-noise	_	
16-17	2464-2469	ratio	_	
16-18	2470-2477	leading	_	
16-19	2478-2480	to	_	
16-20	2481-2487	higher	_	
16-21	2488-2499	probability	_	
16-22	2500-2502	of	_	
16-23	2503-2512	acquiring	_	
16-24	2513-2517	more	_	
16-25	2518-2526	reliable	_	
16-26	2527-2531	data	_	
16-27	2531-2532	.	_	

#Text=SLFF are postulated to reflect neural synchrony among brain regions.
17-1	2533-2537	SLFF	_	
17-2	2538-2541	are	_	
17-3	2542-2552	postulated	_	
17-4	2553-2555	to	_	
17-5	2556-2563	reflect	_	
17-6	2564-2570	neural	_	
17-7	2571-2580	synchrony	_	
17-8	2581-2586	among	_	
17-9	2587-2592	brain	_	
17-10	2593-2600	regions	_	
17-11	2600-2601	.	_	

#Text=Since reporting of functional significance of SLFFs by Biswal et al., functional connectivity of the brain in the resting state has gained increasing attention.
18-1	2602-2607	Since	_	
18-2	2608-2617	reporting	_	
18-3	2618-2620	of	_	
18-4	2621-2631	functional	_	
18-5	2632-2644	significance	_	
18-6	2645-2647	of	_	
18-7	2648-2653	SLFFs	_	
18-8	2654-2656	by	_	
18-9	2657-2663	Biswal	_	
18-10	2664-2666	et	_	
18-11	2667-2669	al	_	
18-12	2669-2670	.	_	
18-13	2670-2671	,	_	
18-14	2672-2682	functional	_	
18-15	2683-2695	connectivity	_	
18-16	2696-2698	of	_	
18-17	2699-2702	the	_	
18-18	2703-2708	brain	_	
18-19	2709-2711	in	_	
18-20	2712-2715	the	_	
18-21	2716-2723	resting	_	
18-22	2724-2729	state	_	
18-23	2730-2733	has	_	
18-24	2734-2740	gained	_	
18-25	2741-2751	increasing	_	
18-26	2752-2761	attention	_	
18-27	2761-2762	.	_	

#Text=Variations in spontaneous brain activity reflected by these SLFFs can be considered a putative biomarker of schizophrenia.
19-1	2763-2773	Variations	_	
19-2	2774-2776	in	_	
19-3	2777-2788	spontaneous	_	
19-4	2789-2794	brain	_	
19-5	2795-2803	activity	_	
19-6	2804-2813	reflected	_	
19-7	2814-2816	by	_	
19-8	2817-2822	these	_	
19-9	2823-2828	SLFFs	_	
19-10	2829-2832	can	_	
19-11	2833-2835	be	_	
19-12	2836-2846	considered	_	
19-13	2847-2848	a	_	
19-14	2849-2857	putative	_	
19-15	2858-2867	biomarker	_	
19-16	2868-2870	of	_	
19-17	2871-2884	schizophrenia	_	
19-18	2884-2885	.	_	

#Text=Impaired connectivity leading to dysfunctional information processing may underlie clinical symptoms of schizophrenia.
20-1	2886-2894	Impaired	_	
20-2	2895-2907	connectivity	_	
20-3	2908-2915	leading	_	
20-4	2916-2918	to	_	
20-5	2919-2932	dysfunctional	_	
20-6	2933-2944	information	_	
20-7	2945-2955	processing	_	
20-8	2956-2959	may	_	
20-9	2960-2968	underlie	_	
20-10	2969-2977	clinical	_	
20-11	2978-2986	symptoms	_	
20-12	2987-2989	of	_	
20-13	2990-3003	schizophrenia	_	
20-14	3003-3004	.	_	

#Text=Deranged communication among critical regions of the brain networks may underlie impairments in multiple cognitive domains, such as executive functions, working memory, language and speed of processing.
21-1	3005-3013	Deranged	_	
21-2	3014-3027	communication	_	
21-3	3028-3033	among	_	
21-4	3034-3042	critical	_	
21-5	3043-3050	regions	_	
21-6	3051-3053	of	_	
21-7	3054-3057	the	_	
21-8	3058-3063	brain	_	
21-9	3064-3072	networks	_	
21-10	3073-3076	may	_	
21-11	3077-3085	underlie	_	
21-12	3086-3097	impairments	_	
21-13	3098-3100	in	_	
21-14	3101-3109	multiple	_	
21-15	3110-3119	cognitive	_	
21-16	3120-3127	domains	_	
21-17	3127-3128	,	_	
21-18	3129-3133	such	_	
21-19	3134-3136	as	_	
21-20	3137-3146	executive	_	
21-21	3147-3156	functions	_	
21-22	3156-3157	,	_	
21-23	3158-3165	working	_	
21-24	3166-3172	memory	_	
21-25	3172-3173	,	_	
21-26	3174-3182	language	_	
21-27	3183-3186	and	_	
21-28	3187-3192	speed	_	
21-29	3193-3195	of	_	
21-30	3196-3206	processing	_	
21-31	3206-3207	.	_	

#Text=RsfMRI data may identify such altered functional connectivity.
22-1	3208-3214	RsfMRI	_	
22-2	3215-3219	data	_	
22-3	3220-3223	may	_	
22-4	3224-3232	identify	_	
22-5	3233-3237	such	_	
22-6	3238-3245	altered	_	
22-7	3246-3256	functional	_	
22-8	3257-3269	connectivity	_	
22-9	3269-3270	.	_	

#Text=Although diffusion tensor imaging (DTI) can elegantly show the differences in anatomical connectivity, actual functional significance and flow of neural signals across the regions is difficult to infer.
23-1	3271-3279	Although	_	
23-2	3280-3289	diffusion	_	
23-3	3290-3296	tensor	_	
23-4	3297-3304	imaging	_	
23-5	3305-3306	(	_	
23-6	3306-3309	DTI	_	
23-7	3309-3310	)	_	
23-8	3311-3314	can	_	
23-9	3315-3324	elegantly	_	
23-10	3325-3329	show	_	
23-11	3330-3333	the	_	
23-12	3334-3345	differences	_	
23-13	3346-3348	in	_	
23-14	3349-3359	anatomical	_	
23-15	3360-3372	connectivity	_	
23-16	3372-3373	,	_	
23-17	3374-3380	actual	_	
23-18	3381-3391	functional	_	
23-19	3392-3404	significance	_	
23-20	3405-3408	and	_	
23-21	3409-3413	flow	_	
23-22	3414-3416	of	_	
23-23	3417-3423	neural	_	
23-24	3424-3431	signals	_	
23-25	3432-3438	across	_	
23-26	3439-3442	the	_	
23-27	3443-3450	regions	_	
23-28	3451-3453	is	_	
23-29	3454-3463	difficult	_	
23-30	3464-3466	to	_	
23-31	3467-3472	infer	_	
23-32	3472-3473	.	_	

#Text=Prior studies showed impaired fronto-temporal and prefrontal commissural anatomical connectivity.
24-1	3474-3479	Prior	_	
24-2	3480-3487	studies	_	
24-3	3488-3494	showed	_	
24-4	3495-3503	impaired	_	
24-5	3504-3519	fronto-temporal	_	
24-6	3520-3523	and	_	
24-7	3524-3534	prefrontal	_	
24-8	3535-3546	commissural	_	
24-9	3547-3557	anatomical	_	
24-10	3558-3570	connectivity	_	
24-11	3570-3571	.	_	

#Text=Thus, impaired functional connectivity could illustrate a predictable pattern of synchronous activations that underlie clinical symptoms.
25-1	3572-3576	Thus	_	
25-2	3576-3577	,	_	
25-3	3578-3586	impaired	_	
25-4	3587-3597	functional	_	
25-5	3598-3610	connectivity	_	
25-6	3611-3616	could	_	
25-7	3617-3627	illustrate	_	
25-8	3628-3629	a	_	
25-9	3630-3641	predictable	_	
25-10	3642-3649	pattern	_	
25-11	3650-3652	of	_	
25-12	3653-3664	synchronous	_	
25-13	3665-3676	activations	_	
25-14	3677-3681	that	_	
25-15	3682-3690	underlie	_	
25-16	3691-3699	clinical	_	
25-17	3700-3708	symptoms	_	
25-18	3708-3709	.	_	

#Text=Inconsistent data from existing rsfMRI studies may be due to the examination of a clinically non-homogenous sample of patients.
26-1	3710-3722	Inconsistent	_	
26-2	3723-3727	data	_	
26-3	3728-3732	from	_	
26-4	3733-3741	existing	_	
26-5	3742-3748	rsfMRI	_	
26-6	3749-3756	studies	_	
26-7	3757-3760	may	_	
26-8	3761-3763	be	_	
26-9	3764-3767	due	_	
26-10	3768-3770	to	_	
26-11	3771-3774	the	_	
26-12	3775-3786	examination	_	
26-13	3787-3789	of	_	
26-14	3790-3791	a	_	
26-15	3792-3802	clinically	_	
26-16	3803-3817	non-homogenous	_	
26-17	3818-3824	sample	_	
26-18	3825-3827	of	_	
26-19	3828-3836	patients	_	
26-20	3836-3837	.	_	

#Text=Most authors agreed that there was altered functional connectivity in schizophrenia compared to healthy controls in many areas of the brain like default mode network (DMN), medial temporal and prefrontal regions as well as decreased interhemispheric connectivity.
27-1	3838-3842	Most	_	
27-2	3843-3850	authors	_	
27-3	3851-3857	agreed	_	
27-4	3858-3862	that	_	
27-5	3863-3868	there	_	
27-6	3869-3872	was	_	
27-7	3873-3880	altered	_	
27-8	3881-3891	functional	_	
27-9	3892-3904	connectivity	_	
27-10	3905-3907	in	_	
27-11	3908-3921	schizophrenia	_	
27-12	3922-3930	compared	_	
27-13	3931-3933	to	_	
27-14	3934-3941	healthy	_	
27-15	3942-3950	controls	_	
27-16	3951-3953	in	_	
27-17	3954-3958	many	_	
27-18	3959-3964	areas	_	
27-19	3965-3967	of	_	
27-20	3968-3971	the	_	
27-21	3972-3977	brain	_	
27-22	3978-3982	like	_	
27-23	3983-3990	default	_	
27-24	3991-3995	mode	_	
27-25	3996-4003	network	_	
27-26	4004-4005	(	_	
27-27	4005-4008	DMN	_	
27-28	4008-4009	)	_	
27-29	4009-4010	,	_	
27-30	4011-4017	medial	_	
27-31	4018-4026	temporal	_	
27-32	4027-4030	and	_	
27-33	4031-4041	prefrontal	_	
27-34	4042-4049	regions	_	
27-35	4050-4052	as	_	
27-36	4053-4057	well	_	
27-37	4058-4060	as	_	
27-38	4061-4070	decreased	_	
27-39	4071-4087	interhemispheric	_	
27-40	4088-4100	connectivity	_	
27-41	4100-4101	.	_	

#Text=Examination of patients in the early course of the illness helps avoid some of the confounders such as the duration and course of illness.
28-1	4102-4113	Examination	_	
28-2	4114-4116	of	_	
28-3	4117-4125	patients	_	
28-4	4126-4128	in	_	
28-5	4129-4132	the	_	
28-6	4133-4138	early	_	
28-7	4139-4145	course	_	
28-8	4146-4148	of	_	
28-9	4149-4152	the	_	
28-10	4153-4160	illness	_	
28-11	4161-4166	helps	_	
28-12	4167-4172	avoid	_	
28-13	4173-4177	some	_	
28-14	4178-4180	of	_	
28-15	4181-4184	the	_	
28-16	4185-4196	confounders	_	
28-17	4197-4201	such	_	
28-18	4202-4204	as	_	
28-19	4205-4208	the	_	
28-20	4209-4217	duration	_	
28-21	4218-4221	and	_	
28-22	4222-4228	course	_	
28-23	4229-4231	of	_	
28-24	4232-4239	illness	_	
28-25	4239-4240	.	_	

#Text=Our aim in this study was to examine altered functional connectivity in early course schizophrenia compared to healthy control subjects using rsfMRI.
29-1	4241-4244	Our	_	
29-2	4245-4248	aim	_	
29-3	4249-4251	in	_	
29-4	4252-4256	this	_	
29-5	4257-4262	study	_	
29-6	4263-4266	was	_	
29-7	4267-4269	to	_	
29-8	4270-4277	examine	_	
29-9	4278-4285	altered	_	
29-10	4286-4296	functional	_	
29-11	4297-4309	connectivity	_	
29-12	4310-4312	in	_	
29-13	4313-4318	early	_	
29-14	4319-4325	course	_	
29-15	4326-4339	schizophrenia	_	
29-16	4340-4348	compared	_	
29-17	4349-4351	to	_	
29-18	4352-4359	healthy	_	
29-19	4360-4367	control	_	
29-20	4368-4376	subjects	_	
29-21	4377-4382	using	_	
29-22	4383-4389	rsfMRI	_	
29-23	4389-4390	.	_	

#Text=We hypothesize that alteration in resting state networks will appear in brain areas that control cognitive and mood functions deficient in schizophrenia.
#Text=2.
30-1	4391-4393	We	_	
30-2	4394-4405	hypothesize	_	
30-3	4406-4410	that	_	
30-4	4411-4421	alteration	_	
30-5	4422-4424	in	_	
30-6	4425-4432	resting	_	
30-7	4433-4438	state	_	
30-8	4439-4447	networks	_	
30-9	4448-4452	will	_	
30-10	4453-4459	appear	_	
30-11	4460-4462	in	_	
30-12	4463-4468	brain	_	
30-13	4469-4474	areas	_	
30-14	4475-4479	that	_	
30-15	4480-4487	control	_	
30-16	4488-4497	cognitive	_	
30-17	4498-4501	and	_	
30-18	4502-4506	mood	_	
30-19	4507-4516	functions	_	
30-20	4517-4526	deficient	_	
30-21	4527-4529	in	_	
30-22	4530-4543	schizophrenia	_	
30-23	4543-4544	.	_	
30-24	4545-4546	2	_	
30-25	4546-4547	.	_	

#Text=Methods
#Text=2.1.
31-1	4548-4555	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
31-2	4556-4559	2.1	_	
31-3	4559-4560	.	_	

#Text=Clinical assessments
#Text=Persons with early course schizophrenia seeking treatment at the Department of Psychiatry, Dr.
32-1	4561-4569	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-2	4570-4581	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-3	4582-4589	Persons	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-4	4590-4594	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-5	4595-4600	early	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-6	4601-4607	course	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-7	4608-4621	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[5]	
32-8	4622-4629	seeking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-9	4630-4639	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-10	4640-4642	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-11	4643-4646	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-12	4647-4657	Department	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-13	4658-4660	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-14	4661-4671	Psychiatry	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-15	4671-4672	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-16	4673-4675	Dr	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-17	4675-4676	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Ram Manohar Lohia Hospital, New Delhi, India were enrolled through their treating clinicians.
33-1	4677-4680	Ram	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
33-2	4681-4688	Manohar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
33-3	4689-4694	Lohia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
33-4	4695-4703	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
33-5	4703-4704	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
33-6	4705-4708	New	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
33-7	4709-4714	Delhi	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
33-8	4714-4715	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
33-9	4716-4721	India	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
33-10	4722-4726	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
33-11	4727-4735	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
33-12	4736-4743	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
33-13	4744-4749	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
33-14	4750-4758	treating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
33-15	4759-4769	clinicians	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
33-16	4769-4770	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=Eligible subjects with early course schizophrenia of both sexes between 18 and 50 years, and controls were explained about all study procedures and written informed consent was obtained.
34-1	4771-4779	Eligible	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-2	4780-4788	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-3	4789-4793	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-4	4794-4799	early	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-5	4800-4806	course	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-6	4807-4820	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[8]	
34-7	4821-4823	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-8	4824-4828	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-9	4829-4834	sexes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-10	4835-4842	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-11	4843-4845	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-12	4846-4849	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-13	4850-4852	50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-14	4853-4858	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-15	4858-4859	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-16	4860-4863	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-17	4864-4872	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
34-18	4873-4877	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-19	4878-4887	explained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-20	4888-4893	about	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-21	4894-4897	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-22	4898-4903	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-23	4904-4914	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-24	4915-4918	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-25	4919-4926	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-26	4927-4935	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-27	4936-4943	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-28	4944-4947	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-29	4948-4956	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
34-30	4956-4957	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=Controls were selected to match age and sex (highlighted in results).
35-1	4958-4966	Controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject[11]	
35-2	4967-4971	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-3	4972-4980	selected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-4	4981-4983	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-5	4984-4989	match	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-6	4990-4993	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-7	4994-4997	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-8	4998-5001	sex	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-9	5002-5003	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-10	5003-5014	highlighted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-11	5015-5017	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-12	5018-5025	results	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-13	5025-5026	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-14	5026-5027	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=The diagnosis was confirmed by administering a structured interview using the Hindi version of the Diagnostic Interview for Genetic Studies (DIGS), which has been validated previously.
36-1	5028-5031	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-2	5032-5041	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-3	5042-5045	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-4	5046-5055	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-5	5056-5058	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-6	5059-5072	administering	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-7	5073-5074	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-8	5075-5085	structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-9	5086-5095	interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-10	5096-5101	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-11	5102-5105	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-12	5106-5111	Hindi	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-13	5112-5119	version	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-14	5120-5122	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-15	5123-5126	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-16	5127-5137	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[13]	
36-17	5138-5147	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[13]	
36-18	5148-5151	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[13]	
36-19	5152-5159	Genetic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[13]	
36-20	5160-5167	Studies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[13]	
36-21	5168-5169	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[13]	
36-22	5169-5173	DIGS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[13]	
36-23	5173-5174	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[13]	
36-24	5174-5175	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-25	5176-5181	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-26	5182-5185	has	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-27	5186-5190	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-28	5191-5200	validated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-29	5201-5211	previously	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
36-30	5211-5212	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	

#Text=The DIGS includes the Global Assessment Scale (GAS), the Schedule for Assessment of Positive Symptoms (SAPS), and the Schedule for Assessment of Negative Symptoms (SANS).
37-1	5213-5216	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-2	5217-5221	DIGS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies[15]	
37-3	5222-5230	includes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-4	5231-5234	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-5	5235-5241	Global	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://www.case.edu/ProvCaRe/provcare#Scale[16]	
37-6	5242-5252	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://www.case.edu/ProvCaRe/provcare#Scale[16]	
37-7	5253-5258	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://www.case.edu/ProvCaRe/provcare#Scale[16]	
37-8	5259-5260	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://www.case.edu/ProvCaRe/provcare#Scale[16]	
37-9	5260-5263	GAS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://www.case.edu/ProvCaRe/provcare#Scale[16]	
37-10	5263-5264	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://www.case.edu/ProvCaRe/provcare#Scale[16]	
37-11	5264-5265	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-12	5266-5269	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-13	5270-5278	Schedule	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[17]	
37-14	5279-5282	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[17]	
37-15	5283-5293	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[17]	
37-16	5294-5296	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[17]	
37-17	5297-5305	Positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[17]	
37-18	5306-5314	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[17]	
37-19	5315-5316	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[17]	
37-20	5316-5320	SAPS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[17]	
37-21	5320-5321	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms[17]	
37-22	5321-5322	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-23	5323-5326	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-24	5327-5330	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
37-25	5331-5339	Schedule	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[18]	
37-26	5340-5343	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[18]	
37-27	5344-5354	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[18]	
37-28	5355-5357	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[18]	
37-29	5358-5366	Negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[18]	
37-30	5367-5375	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[18]	
37-31	5376-5377	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[18]	
37-32	5377-5381	SANS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[18]	
37-33	5381-5382	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms[18]	
37-34	5382-5383	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	

#Text=The SANS and SAPS assess the severity of negative and positive symptoms on a six-point scale in the previous month.
38-1	5384-5387	The	_	
38-2	5388-5392	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms	
38-3	5393-5396	and	_	
38-4	5397-5401	SAPS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms	
38-5	5402-5408	assess	_	
38-6	5409-5412	the	_	
38-7	5413-5421	severity	_	
38-8	5422-5424	of	_	
38-9	5425-5433	negative	_	
38-10	5434-5437	and	_	
38-11	5438-5446	positive	_	
38-12	5447-5455	symptoms	_	
38-13	5456-5458	on	_	
38-14	5459-5460	a	_	
38-15	5461-5470	six-point	_	
38-16	5471-5476	scale	_	
38-17	5477-5479	in	_	
38-18	5480-5483	the	_	
38-19	5484-5492	previous	_	
38-20	5493-5498	month	_	
38-21	5498-5499	.	_	

#Text=Inter-rater reliability of scoring was 0.83–0.92.
39-1	5500-5511	Inter-rater	_	
39-2	5512-5523	reliability	_	
39-3	5524-5526	of	_	
39-4	5527-5534	scoring	_	
39-5	5535-5538	was	_	
39-6	5539-5543	0.83	_	
39-7	5543-5544	–	_	
39-8	5544-5548	0.92	_	
39-9	5548-5549	.	_	

#Text=In addition to structured patient interview, collateral information was obtained through caregivers.
40-1	5550-5552	In	_	
40-2	5553-5561	addition	_	
40-3	5562-5564	to	_	
40-4	5565-5575	structured	_	
40-5	5576-5583	patient	_	
40-6	5584-5593	interview	_	
40-7	5593-5594	,	_	
40-8	5595-5605	collateral	_	
40-9	5606-5617	information	_	
40-10	5618-5621	was	_	
40-11	5622-5630	obtained	_	
40-12	5631-5638	through	_	
40-13	5639-5649	caregivers	_	
40-14	5649-5650	.	_	

#Text=We defined early course schizophrenia as the illness duration of 7 years or less from the onset of first psychotic symptoms.
41-1	5651-5653	We	_	
41-2	5654-5661	defined	_	
41-3	5662-5667	early	_	
41-4	5668-5674	course	_	
41-5	5675-5688	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
41-6	5689-5691	as	_	
41-7	5692-5695	the	_	
41-8	5696-5703	illness	_	
41-9	5704-5712	duration	_	
41-10	5713-5715	of	_	
41-11	5716-5717	7	_	
41-12	5718-5723	years	_	
41-13	5724-5726	or	_	
41-14	5727-5731	less	_	
41-15	5732-5736	from	_	
41-16	5737-5740	the	_	
41-17	5741-5746	onset	_	
41-18	5747-5749	of	_	
41-19	5750-5755	first	_	
41-20	5756-5765	psychotic	_	
41-21	5766-5774	symptoms	_	
41-22	5774-5775	.	_	

#Text=The Positive and Negative Syndrome Scale (PANSS) was administered to rate the presence and severity of psychotic symptoms.
42-1	5776-5779	The	_	
42-2	5780-5788	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[19]	
42-3	5789-5792	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[19]	
42-4	5793-5801	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[19]	
42-5	5802-5810	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[19]	
42-6	5811-5816	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[19]	
42-7	5817-5818	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[19]	
42-8	5818-5823	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[19]	
42-9	5823-5824	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[19]	
42-10	5825-5828	was	_	
42-11	5829-5841	administered	_	
42-12	5842-5844	to	_	
42-13	5845-5849	rate	_	
42-14	5850-5853	the	_	
42-15	5854-5862	presence	_	
42-16	5863-5866	and	_	
42-17	5867-5875	severity	_	
42-18	5876-5878	of	_	
42-19	5879-5888	psychotic	_	
42-20	5889-5897	symptoms	_	
42-21	5897-5898	.	_	

#Text=Participants were required to have a score of 4 or more on one or more items of the PANSS, and be on a stable dose of antipsychotics for at least 1 month prior to experimental procedures.
43-1	5899-5911	Participants	_	
43-2	5912-5916	were	_	
43-3	5917-5925	required	_	
43-4	5926-5928	to	_	
43-5	5929-5933	have	_	
43-6	5934-5935	a	_	
43-7	5936-5941	score	_	
43-8	5942-5944	of	_	
43-9	5945-5946	4	_	
43-10	5947-5949	or	_	
43-11	5950-5954	more	_	
43-12	5955-5957	on	_	
43-13	5958-5961	one	_	
43-14	5962-5964	or	_	
43-15	5965-5969	more	_	
43-16	5970-5975	items	_	
43-17	5976-5978	of	_	
43-18	5979-5982	the	_	
43-19	5983-5988	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
43-20	5988-5989	,	_	
43-21	5990-5993	and	_	
43-22	5994-5996	be	_	
43-23	5997-5999	on	_	
43-24	6000-6001	a	_	
43-25	6002-6008	stable	_	
43-26	6009-6013	dose	_	
43-27	6014-6016	of	_	
43-28	6017-6031	antipsychotics	_	
43-29	6032-6035	for	_	
43-30	6036-6038	at	_	
43-31	6039-6044	least	_	
43-32	6045-6046	1	_	
43-33	6047-6052	month	_	
43-34	6053-6058	prior	_	
43-35	6059-6061	to	_	
43-36	6062-6074	experimental	_	
43-37	6075-6085	procedures	_	
43-38	6085-6086	.	_	

#Text=For the control group, comparable participants not suffering from any psychiatric illness were enrolled from similar neighborhoods.
44-1	6087-6090	For	_	
44-2	6091-6094	the	_	
44-3	6095-6102	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
44-4	6103-6108	group	_	
44-5	6108-6109	,	_	
44-6	6110-6120	comparable	_	
44-7	6121-6133	participants	_	
44-8	6134-6137	not	_	
44-9	6138-6147	suffering	_	
44-10	6148-6152	from	_	
44-11	6153-6156	any	_	
44-12	6157-6168	psychiatric	_	
44-13	6169-6176	illness	_	
44-14	6177-6181	were	_	
44-15	6182-6190	enrolled	_	
44-16	6191-6195	from	_	
44-17	6196-6203	similar	_	
44-18	6204-6217	neighborhoods	_	
44-19	6217-6218	.	_	

#Text=Participants with a history of substance dependence in the past 6 months, excluding nicotine dependence, those with a history of or current medical/neurological illnesses, e.g. epilepsy were excluded.
45-1	6219-6231	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-2	6232-6236	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-3	6237-6238	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-4	6239-6246	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-5	6247-6249	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-6	6250-6259	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-7	6260-6270	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-8	6271-6273	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-9	6274-6277	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-10	6278-6282	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-11	6283-6284	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-12	6285-6291	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-13	6291-6292	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-14	6293-6302	excluding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-15	6303-6311	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-16	6312-6322	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-17	6322-6323	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-18	6324-6329	those	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-19	6330-6334	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-20	6335-6336	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-21	6337-6344	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-22	6345-6347	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-23	6348-6350	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-24	6351-6358	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-25	6359-6366	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-26	6366-6367	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-27	6367-6379	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-28	6380-6389	illnesses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-29	6389-6390	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-30	6391-6394	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-31	6394-6395	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-32	6396-6404	epilepsy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-33	6405-6409	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-34	6410-6418	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
45-35	6418-6419	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	

#Text=Pregnancy, mental retardation (DSM-IV) or any contraindication to MRI procedures, such as having pacemakers or metal fragments/shrapnel were the other exclusion criteria.
#Text=2.2.
46-1	6420-6429	Pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-2	6429-6430	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-3	6431-6437	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-4	6438-6449	retardation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-5	6450-6451	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-6	6451-6457	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-7	6457-6458	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-8	6459-6461	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-9	6462-6465	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-10	6466-6482	contraindication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-11	6483-6485	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-12	6486-6489	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[22]	
46-13	6490-6500	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-14	6500-6501	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-15	6502-6506	such	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-16	6507-6509	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-17	6510-6516	having	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-18	6517-6527	pacemakers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-19	6528-6530	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-20	6531-6536	metal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-21	6537-6546	fragments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-22	6546-6547	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-23	6547-6555	shrapnel	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-24	6556-6560	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-25	6561-6564	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-26	6565-6570	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-27	6571-6580	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-28	6581-6589	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-29	6589-6590	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-30	6591-6594	2.2	_	
46-31	6594-6595	.	_	

#Text=Imaging methods
#Text=Brain images were acquired using a 3 T whole-body MRI scanner (Magnetom Skyra, Siemens) while participants lay supine.
47-1	6596-6603	Imaging	_	
47-2	6604-6611	methods	_	
47-3	6612-6617	Brain	_	
47-4	6618-6624	images	_	
47-5	6625-6629	were	_	
47-6	6630-6638	acquired	_	
47-7	6639-6644	using	_	
47-8	6645-6646	a	_	
47-9	6647-6648	3	_	
47-10	6649-6650	T	_	
47-11	6651-6661	whole-body	_	
47-12	6662-6665	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
47-13	6666-6673	scanner	_	
47-14	6674-6675	(	_	
47-15	6675-6683	Magnetom	_	
47-16	6684-6689	Skyra	_	
47-17	6689-6690	,	_	
47-18	6691-6698	Siemens	_	
47-19	6698-6699	)	_	
47-20	6700-6705	while	_	
47-21	6706-6718	participants	_	
47-22	6719-6722	lay	_	
47-23	6723-6729	supine	_	
47-24	6729-6730	.	_	

#Text=Foam pads on either side of the head were used to minimize head movement.
48-1	6731-6735	Foam	_	
48-2	6736-6740	pads	_	
48-3	6741-6743	on	_	
48-4	6744-6750	either	_	
48-5	6751-6755	side	_	
48-6	6756-6758	of	_	
48-7	6759-6762	the	_	
48-8	6763-6767	head	_	
48-9	6768-6772	were	_	
48-10	6773-6777	used	_	
48-11	6778-6780	to	_	
48-12	6781-6789	minimize	_	
48-13	6790-6794	head	_	
48-14	6795-6803	movement	_	
48-15	6803-6804	.	_	

#Text=Participants were instructed not to move, and to lie quietly awake, with closed eyes and not engaged in any specific cognitive activity during the experiment.
49-1	6805-6817	Participants	_	
49-2	6818-6822	were	_	
49-3	6823-6833	instructed	_	
49-4	6834-6837	not	_	
49-5	6838-6840	to	_	
49-6	6841-6845	move	_	
49-7	6845-6846	,	_	
49-8	6847-6850	and	_	
49-9	6851-6853	to	_	
49-10	6854-6857	lie	_	
49-11	6858-6865	quietly	_	
49-12	6866-6871	awake	_	
49-13	6871-6872	,	_	
49-14	6873-6877	with	_	
49-15	6878-6884	closed	_	
49-16	6885-6889	eyes	_	
49-17	6890-6893	and	_	
49-18	6894-6897	not	_	
49-19	6898-6905	engaged	_	
49-20	6906-6908	in	_	
49-21	6909-6912	any	_	
49-22	6913-6921	specific	_	
49-23	6922-6931	cognitive	_	
49-24	6932-6940	activity	_	
49-25	6941-6947	during	_	
49-26	6948-6951	the	_	
49-27	6952-6962	experiment	_	
49-28	6962-6963	.	_	

#Text=We collected high-resolution T1-weighted images using a magnetization prepared rapid acquisition gradient-echo (MPRAGE) sequence (TR = 1900 ms; TE = 2.07 ms; inversion time = 900 ms; flip angle (FA) = 9°; FOV = 256 × 256 mm; slice thickness = 1 mm; number of slices = 160).
50-1	6964-6966	We	_	
50-2	6967-6976	collected	_	
50-3	6977-6992	high-resolution	_	
50-4	6993-6995	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[23]	
50-5	6995-6996	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[23]	
50-6	6996-7004	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[23]	
50-7	7005-7011	images	_	
50-8	7012-7017	using	_	
50-9	7018-7019	a	_	
50-10	7020-7033	magnetization	_	
50-11	7034-7042	prepared	_	
50-12	7043-7048	rapid	_	
50-13	7049-7060	acquisition	_	
50-14	7061-7074	gradient-echo	_	
50-15	7075-7076	(	_	
50-16	7076-7082	MPRAGE	_	
50-17	7082-7083	)	_	
50-18	7084-7092	sequence	_	
50-19	7093-7094	(	_	
50-20	7094-7096	TR	_	
50-21	7097-7098	=	_	
50-22	7099-7103	1900	_	
50-23	7104-7106	ms	_	
50-24	7106-7107	;	_	
50-25	7108-7110	TE	_	
50-26	7111-7112	=	_	
50-27	7113-7117	2.07	_	
50-28	7118-7120	ms	_	
50-29	7120-7121	;	_	
50-30	7122-7131	inversion	_	
50-31	7132-7136	time	_	
50-32	7137-7138	=	_	
50-33	7139-7142	900	_	
50-34	7143-7145	ms	_	
50-35	7145-7146	;	_	
50-36	7147-7151	flip	_	
50-37	7152-7157	angle	_	
50-38	7158-7159	(	_	
50-39	7159-7161	FA	_	
50-40	7161-7162	)	_	
50-41	7163-7164	=	_	
50-42	7165-7166	9	_	
50-43	7166-7167	°	_	
50-44	7167-7168	;	_	
50-45	7169-7172	FOV	_	
50-46	7173-7174	=	_	
50-47	7175-7178	256	_	
50-48	7179-7180	×	_	
50-49	7181-7184	256	_	
50-50	7185-7187	mm	_	
50-51	7187-7188	;	_	
50-52	7189-7194	slice	_	
50-53	7195-7204	thickness	_	
50-54	7205-7206	=	_	
50-55	7207-7208	1	_	
50-56	7209-7211	mm	_	
50-57	7211-7212	;	_	
50-58	7213-7219	number	_	
50-59	7220-7222	of	_	
50-60	7223-7229	slices	_	
50-61	7230-7231	=	_	
50-62	7232-7235	160	_	
50-63	7235-7236	)	_	
50-64	7236-7237	.	_	

#Text=We acquired T2-weighted images [repetition time (TR) = 10,000 ms; TE = 100 ms; FA = 150°] using a dual-echo turbo spin-echo sequence in the axial plane, with a 256 × 256 matrix size, 220×220 mm field of view (FOV), 4.0 mm slice thickness, and 1.2 mm interslice gap to aid in anatomical identification and evaluation for any anatomical defects.
51-1	7238-7240	We	_	
51-2	7241-7249	acquired	_	
51-3	7250-7252	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[24]	
51-4	7252-7253	-	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[24]	
51-5	7253-7261	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[24]	
51-6	7262-7268	images	_	
51-7	7269-7270	[	_	
51-8	7270-7280	repetition	_	
51-9	7281-7285	time	_	
51-10	7286-7287	(	_	
51-11	7287-7289	TR	_	
51-12	7289-7290	)	_	
51-13	7291-7292	=	_	
51-14	7293-7299	10,000	_	
51-15	7300-7302	ms	_	
51-16	7302-7303	;	_	
51-17	7304-7306	TE	_	
51-18	7307-7308	=	_	
51-19	7309-7312	100	_	
51-20	7313-7315	ms	_	
51-21	7315-7316	;	_	
51-22	7317-7319	FA	_	
51-23	7320-7321	=	_	
51-24	7322-7325	150	_	
51-25	7325-7326	°	_	
51-26	7326-7327	]	_	
51-27	7328-7333	using	_	
51-28	7334-7335	a	_	
51-29	7336-7345	dual-echo	_	
51-30	7346-7351	turbo	_	
51-31	7352-7361	spin-echo	_	
51-32	7362-7370	sequence	_	
51-33	7371-7373	in	_	
51-34	7374-7377	the	_	
51-35	7378-7383	axial	_	
51-36	7384-7389	plane	_	
51-37	7389-7390	,	_	
51-38	7391-7395	with	_	
51-39	7396-7397	a	_	
51-40	7398-7401	256	_	
51-41	7402-7403	×	_	
51-42	7404-7407	256	_	
51-43	7408-7414	matrix	_	
51-44	7415-7419	size	_	
51-45	7419-7420	,	_	
51-46	7421-7424	220	_	
51-47	7424-7425	×	_	
51-48	7425-7428	220	_	
51-49	7429-7431	mm	_	
51-50	7432-7437	field	_	
51-51	7438-7440	of	_	
51-52	7441-7445	view	_	
51-53	7446-7447	(	_	
51-54	7447-7450	FOV	_	
51-55	7450-7451	)	_	
51-56	7451-7452	,	_	
51-57	7453-7456	4.0	_	
51-58	7457-7459	mm	_	
51-59	7460-7465	slice	_	
51-60	7466-7475	thickness	_	
51-61	7475-7476	,	_	
51-62	7477-7480	and	_	
51-63	7481-7484	1.2	_	
51-64	7485-7487	mm	_	
51-65	7488-7498	interslice	_	
51-66	7499-7502	gap	_	
51-67	7503-7505	to	_	
51-68	7506-7509	aid	_	
51-69	7510-7512	in	_	
51-70	7513-7523	anatomical	_	
51-71	7524-7538	identification	_	
51-72	7539-7542	and	_	
51-73	7543-7553	evaluation	_	
51-74	7554-7557	for	_	
51-75	7558-7561	any	_	
51-76	7562-7572	anatomical	_	
51-77	7573-7580	defects	_	
51-78	7580-7581	.	_	

#Text=We also collected functional brain volumes using an echo-planar T2*-weighted imaging sequence.
52-1	7582-7584	We	_	
52-2	7585-7589	also	_	
52-3	7590-7599	collected	_	
52-4	7600-7610	functional	_	
52-5	7611-7616	brain	_	
52-6	7617-7624	volumes	_	
52-7	7625-7630	using	_	
52-8	7631-7633	an	_	
52-9	7634-7645	echo-planar	_	
52-10	7646-7648	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[25]	
52-11	7648-7649	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[25]	
52-12	7649-7650	-	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[25]	
52-13	7650-7658	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[25]	
52-14	7659-7666	imaging	_	
52-15	7667-7675	sequence	_	
52-16	7675-7676	.	_	

#Text=Each volume consisted of 30 interleaved 5-mm thick slices without interslice gap (TE = 30 ms, TR = 2000 ms, FOV = 240 mm, flip angle = 90°, voxel size = 3.75 × 3.75 × 5 mm3).
53-1	7677-7681	Each	_	
53-2	7682-7688	volume	_	
53-3	7689-7698	consisted	_	
53-4	7699-7701	of	_	
53-5	7702-7704	30	_	
53-6	7705-7716	interleaved	_	
53-7	7717-7718	5	_	
53-8	7718-7719	-	_	
53-9	7719-7721	mm	_	
53-10	7722-7727	thick	_	
53-11	7728-7734	slices	_	
53-12	7735-7742	without	_	
53-13	7743-7753	interslice	_	
53-14	7754-7757	gap	_	
53-15	7758-7759	(	_	
53-16	7759-7761	TE	_	
53-17	7762-7763	=	_	
53-18	7764-7766	30	_	
53-19	7767-7769	ms	_	
53-20	7769-7770	,	_	
53-21	7771-7773	TR	_	
53-22	7774-7775	=	_	
53-23	7776-7780	2000	_	
53-24	7781-7783	ms	_	
53-25	7783-7784	,	_	
53-26	7785-7788	FOV	_	
53-27	7789-7790	=	_	
53-28	7791-7794	240	_	
53-29	7795-7797	mm	_	
53-30	7797-7798	,	_	
53-31	7799-7803	flip	_	
53-32	7804-7809	angle	_	
53-33	7810-7811	=	_	
53-34	7812-7814	90	_	
53-35	7814-7815	°	_	
53-36	7815-7816	,	_	
53-37	7817-7822	voxel	_	
53-38	7823-7827	size	_	
53-39	7828-7829	=	_	
53-40	7830-7834	3.75	_	
53-41	7835-7836	×	_	
53-42	7837-7841	3.75	_	
53-43	7842-7843	×	_	
53-44	7844-7845	5	_	
53-45	7846-7849	mm3	_	
53-46	7849-7850	)	_	
53-47	7850-7851	.	_	

#Text=Total scanning time for fMRI was 6.83 min (205 brain volumes).
54-1	7852-7857	Total	_	
54-2	7858-7866	scanning	_	
54-3	7867-7871	time	_	
54-4	7872-7875	for	_	
54-5	7876-7880	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
54-6	7881-7884	was	_	
54-7	7885-7889	6.83	_	
54-8	7890-7893	min	_	
54-9	7894-7895	(	_	
54-10	7895-7898	205	_	
54-11	7899-7904	brain	_	
54-12	7905-7912	volumes	_	
54-13	7912-7913	)	_	
54-14	7913-7914	.	_	

#Text=Images were re-checked for quality at the end of every scan, and if any head movement was noticeable, the scan was repeated.
#Text=2.3.
55-1	7915-7921	Images	_	
55-2	7922-7926	were	_	
55-3	7927-7937	re-checked	_	
55-4	7938-7941	for	_	
55-5	7942-7949	quality	_	
55-6	7950-7952	at	_	
55-7	7953-7956	the	_	
55-8	7957-7960	end	_	
55-9	7961-7963	of	_	
55-10	7964-7969	every	_	
55-11	7970-7974	scan	_	
55-12	7974-7975	,	_	
55-13	7976-7979	and	_	
55-14	7980-7982	if	_	
55-15	7983-7986	any	_	
55-16	7987-7991	head	_	
55-17	7992-8000	movement	_	
55-18	8001-8004	was	_	
55-19	8005-8015	noticeable	_	
55-20	8015-8016	,	_	
55-21	8017-8020	the	_	
55-22	8021-8025	scan	_	
55-23	8026-8029	was	_	
55-24	8030-8038	repeated	_	
55-25	8038-8039	.	_	
55-26	8040-8043	2.3	_	
55-27	8043-8044	.	_	

#Text=Plan of analysis
#Text=We used the Statistical Package for Social Sciences (SPSS v21) for assessment of demographic and clinical data.
56-1	8045-8049	Plan	_	
56-2	8050-8052	of	_	
56-3	8053-8061	analysis	_	
56-4	8062-8064	We	_	
56-5	8065-8069	used	_	
56-6	8070-8073	the	_	
56-7	8074-8085	Statistical	_	
56-8	8086-8093	Package	_	
56-9	8094-8097	for	_	
56-10	8098-8104	Social	_	
56-11	8105-8113	Sciences	_	
56-12	8114-8115	(	_	
56-13	8115-8119	SPSS	_	
56-14	8120-8123	v21	_	
56-15	8123-8124	)	_	
56-16	8125-8128	for	_	
56-17	8129-8139	assessment	_	
56-18	8140-8142	of	_	
56-19	8143-8154	demographic	_	
56-20	8155-8158	and	_	
56-21	8159-8167	clinical	_	
56-22	8168-8172	data	_	
56-23	8172-8173	.	_	

#Text=The numerical demographic data and characteristics of schizophrenia and control subjects were compared with independent samples t-tests, and categorical characteristics were compared using the Chi-square test.
57-1	8174-8177	The	_	
57-2	8178-8187	numerical	_	
57-3	8188-8199	demographic	_	
57-4	8200-8204	data	_	
57-5	8205-8208	and	_	
57-6	8209-8224	characteristics	_	
57-7	8225-8227	of	_	
57-8	8228-8241	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
57-9	8242-8245	and	_	
57-10	8246-8253	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]	
57-11	8254-8262	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]	
57-12	8263-8267	were	_	
57-13	8268-8276	compared	_	
57-14	8277-8281	with	_	
57-15	8282-8293	independent	_	
57-16	8294-8301	samples	_	
57-17	8302-8309	t-tests	_	
57-18	8309-8310	,	_	
57-19	8311-8314	and	_	
57-20	8315-8326	categorical	_	
57-21	8327-8342	characteristics	_	
57-22	8343-8347	were	_	
57-23	8348-8356	compared	_	
57-24	8357-8362	using	_	
57-25	8363-8366	the	_	
57-26	8367-8377	Chi-square	_	
57-27	8378-8382	test	_	
57-28	8382-8383	.	_	

#Text=Statistical threshold values of p < 0.05 were considered a significant difference.
58-1	8384-8395	Statistical	_	
58-2	8396-8405	threshold	_	
58-3	8406-8412	values	_	
58-4	8413-8415	of	_	
58-5	8416-8417	p	_	
58-6	8418-8419	<	_	
58-7	8420-8424	0.05	_	
58-8	8425-8429	were	_	
58-9	8430-8440	considered	_	
58-10	8441-8442	a	_	
58-11	8443-8454	significant	_	
58-12	8455-8465	difference	_	
58-13	8465-8466	.	_	

#Text=For resting state fMRI data analysis, we used FSL version 5.01 software (www.fmrib.ox.ac.uk).
59-1	8467-8470	For	_	
59-2	8471-8478	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[27]	
59-3	8479-8484	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[27]	
59-4	8485-8489	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[27]	
59-5	8490-8494	data	_	
59-6	8495-8503	analysis	_	
59-7	8503-8504	,	_	
59-8	8505-8507	we	_	
59-9	8508-8512	used	_	
59-10	8513-8516	FSL	_	
59-11	8517-8524	version	_	
59-12	8525-8529	5.01	_	
59-13	8530-8538	software	_	
59-14	8539-8540	(	_	
59-15	8540-8558	www.fmrib.ox.ac.uk	_	
59-16	8558-8559	)	_	
59-17	8559-8560	.	_	

#Text=Firstly, standard preprocessing steps were followed for individual data.
60-1	8561-8568	Firstly	_	
60-2	8568-8569	,	_	
60-3	8570-8578	standard	_	
60-4	8579-8592	preprocessing	_	
60-5	8593-8598	steps	_	
60-6	8599-8603	were	_	
60-7	8604-8612	followed	_	
60-8	8613-8616	for	_	
60-9	8617-8627	individual	_	
60-10	8628-8632	data	_	
60-11	8632-8633	.	_	

#Text=This step includes removal of the first 5 brain volumes, high-pass temporal filtering (100 s), motion correction, slice timing, brain-extraction and spatial smoothing (5 mm full width at half-maximum Gaussian kernel).
61-1	8634-8638	This	_	
61-2	8639-8643	step	_	
61-3	8644-8652	includes	_	
61-4	8653-8660	removal	_	
61-5	8661-8663	of	_	
61-6	8664-8667	the	_	
61-7	8668-8673	first	_	
61-8	8674-8675	5	_	
61-9	8676-8681	brain	_	
61-10	8682-8689	volumes	_	
61-11	8689-8690	,	_	
61-12	8691-8700	high-pass	_	
61-13	8701-8709	temporal	_	
61-14	8710-8719	filtering	_	
61-15	8720-8721	(	_	
61-16	8721-8724	100	_	
61-17	8725-8726	s	_	
61-18	8726-8727	)	_	
61-19	8727-8728	,	_	
61-20	8729-8735	motion	_	
61-21	8736-8746	correction	_	
61-22	8746-8747	,	_	
61-23	8748-8753	slice	_	
61-24	8754-8760	timing	_	
61-25	8760-8761	,	_	
61-26	8762-8778	brain-extraction	_	
61-27	8779-8782	and	_	
61-28	8783-8790	spatial	_	
61-29	8791-8800	smoothing	_	
61-30	8801-8802	(	_	
61-31	8802-8803	5	_	
61-32	8804-8806	mm	_	
61-33	8807-8811	full	_	
61-34	8812-8817	width	_	
61-35	8818-8820	at	_	
61-36	8821-8833	half-maximum	_	
61-37	8834-8842	Gaussian	_	
61-38	8843-8849	kernel	_	
61-39	8849-8850	)	_	
61-40	8850-8851	.	_	

#Text=Each fMRI volume was registered on individual structural scans and on the Montreal Regional Institute (MNI152) template using the FMRIB Linear Image Registration Tool (FLIRT).
62-1	8852-8856	Each	_	
62-2	8857-8861	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
62-3	8862-8868	volume	_	
62-4	8869-8872	was	_	
62-5	8873-8883	registered	_	
62-6	8884-8886	on	_	
62-7	8887-8897	individual	_	
62-8	8898-8908	structural	_	
62-9	8909-8914	scans	_	
62-10	8915-8918	and	_	
62-11	8919-8921	on	_	
62-12	8922-8925	the	_	
62-13	8926-8934	Montreal	_	
62-14	8935-8943	Regional	_	
62-15	8944-8953	Institute	_	
62-16	8954-8955	(	_	
62-17	8955-8961	MNI152	_	
62-18	8961-8962	)	_	
62-19	8963-8971	template	_	
62-20	8972-8977	using	_	
62-21	8978-8981	the	_	
62-22	8982-8987	FMRIB	_	
62-23	8988-8994	Linear	_	
62-24	8995-9000	Image	_	
62-25	9001-9013	Registration	_	
62-26	9014-9018	Tool	_	
62-27	9019-9020	(	_	
62-28	9020-9025	FLIRT	_	
62-29	9025-9026	)	_	
62-30	9026-9027	.	_	

#Text=Finally, the registered fMRI sequences were temporally concatenated into a single four-dimensional dataset.
63-1	9028-9035	Finally	_	
63-2	9035-9036	,	_	
63-3	9037-9040	the	_	
63-4	9041-9051	registered	_	
63-5	9052-9056	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
63-6	9057-9066	sequences	_	
63-7	9067-9071	were	_	
63-8	9072-9082	temporally	_	
63-9	9083-9095	concatenated	_	
63-10	9096-9100	into	_	
63-11	9101-9102	a	_	
63-12	9103-9109	single	_	
63-13	9110-9126	four-dimensional	_	
63-14	9127-9134	dataset	_	
63-15	9134-9135	.	_	

#Text=The data set was decomposed into independent components, with a free estimation for the number of components.
64-1	9136-9139	The	_	
64-2	9140-9144	data	_	
64-3	9145-9148	set	_	
64-4	9149-9152	was	_	
64-5	9153-9163	decomposed	_	
64-6	9164-9168	into	_	
64-7	9169-9180	independent	_	
64-8	9181-9191	components	_	
64-9	9191-9192	,	_	
64-10	9193-9197	with	_	
64-11	9198-9199	a	_	
64-12	9200-9204	free	_	
64-13	9205-9215	estimation	_	
64-14	9216-9219	for	_	
64-15	9220-9223	the	_	
64-16	9224-9230	number	_	
64-17	9231-9233	of	_	
64-18	9234-9244	components	_	
64-19	9244-9245	.	_	

#Text=We selected components of interest by visual inspection based on previous literature and the frequency spectra of the time courses of the components.
65-1	9246-9248	We	_	
65-2	9249-9257	selected	_	
65-3	9258-9268	components	_	
65-4	9269-9271	of	_	
65-5	9272-9280	interest	_	
65-6	9281-9283	by	_	
65-7	9284-9290	visual	_	
65-8	9291-9301	inspection	_	
65-9	9302-9307	based	_	
65-10	9308-9310	on	_	
65-11	9311-9319	previous	_	
65-12	9320-9330	literature	_	
65-13	9331-9334	and	_	
65-14	9335-9338	the	_	
65-15	9339-9348	frequency	_	
65-16	9349-9356	spectra	_	
65-17	9357-9359	of	_	
65-18	9360-9363	the	_	
65-19	9364-9368	time	_	
65-20	9369-9376	courses	_	
65-21	9377-9379	of	_	
65-22	9380-9383	the	_	
65-23	9384-9394	components	_	
65-24	9394-9395	.	_	

#Text=After these preprocessing steps, dual regression analysis was performed for a voxel-wise comparison of the resting functional connectivity for between-group analysis.
66-1	9396-9401	After	_	
66-2	9402-9407	these	_	
66-3	9408-9421	preprocessing	_	
66-4	9422-9427	steps	_	
66-5	9427-9428	,	_	
66-6	9429-9433	dual	_	
66-7	9434-9444	regression	_	
66-8	9445-9453	analysis	_	
66-9	9454-9457	was	_	
66-10	9458-9467	performed	_	
66-11	9468-9471	for	_	
66-12	9472-9473	a	_	
66-13	9474-9484	voxel-wise	_	
66-14	9485-9495	comparison	_	
66-15	9496-9498	of	_	
66-16	9499-9502	the	_	
66-17	9503-9510	resting	_	
66-18	9511-9521	functional	_	
66-19	9522-9534	connectivity	_	
66-20	9535-9538	for	_	
66-21	9539-9552	between-group	_	
66-22	9553-9561	analysis	_	
66-23	9561-9562	.	_	

#Text=Spatial maps of the group independent component analysis (ICA) were used in general linear model to generate subject-specific versions of the spatial maps, and associated time-series, using dual regression into the subject’s 4D dataset.
67-1	9563-9570	Spatial	_	
67-2	9571-9575	maps	_	
67-3	9576-9578	of	_	
67-4	9579-9582	the	_	
67-5	9583-9588	group	_	
67-6	9589-9600	independent	_	
67-7	9601-9610	component	_	
67-8	9611-9619	analysis	_	
67-9	9620-9621	(	_	
67-10	9621-9624	ICA	_	
67-11	9624-9625	)	_	
67-12	9626-9630	were	_	
67-13	9631-9635	used	_	
67-14	9636-9638	in	_	
67-15	9639-9646	general	_	
67-16	9647-9653	linear	_	
67-17	9654-9659	model	_	
67-18	9660-9662	to	_	
67-19	9663-9671	generate	_	
67-20	9672-9688	subject-specific	_	
67-21	9689-9697	versions	_	
67-22	9698-9700	of	_	
67-23	9701-9704	the	_	
67-24	9705-9712	spatial	_	
67-25	9713-9717	maps	_	
67-26	9717-9718	,	_	
67-27	9719-9722	and	_	
67-28	9723-9733	associated	_	
67-29	9734-9745	time-series	_	
67-30	9745-9746	,	_	
67-31	9747-9752	using	_	
67-32	9753-9757	dual	_	
67-33	9758-9768	regression	_	
67-34	9769-9773	into	_	
67-35	9774-9777	the	_	
67-36	9778-9785	subject	_	
67-37	9785-9786	’	_	
67-38	9786-9787	s	_	
67-39	9788-9790	4D	_	
67-40	9791-9798	dataset	_	
67-41	9798-9799	.	_	

#Text=Thereafter, spatial maps of all subjects were collected into single 4-dimensional files for each original independent component.
68-1	9800-9810	Thereafter	_	
68-2	9810-9811	,	_	
68-3	9812-9819	spatial	_	
68-4	9820-9824	maps	_	
68-5	9825-9827	of	_	
68-6	9828-9831	all	_	
68-7	9832-9840	subjects	_	
68-8	9841-9845	were	_	
68-9	9846-9855	collected	_	
68-10	9856-9860	into	_	
68-11	9861-9867	single	_	
68-12	9868-9869	4	_	
68-13	9869-9870	-	_	
68-14	9870-9881	dimensional	_	
68-15	9882-9887	files	_	
68-16	9888-9891	for	_	
68-17	9892-9896	each	_	
68-18	9897-9905	original	_	
68-19	9906-9917	independent	_	
68-20	9918-9927	component	_	
68-21	9927-9928	.	_	

#Text=Then we performed voxel-wise group difference analyses between subjects and controls using nonparametric permutation testing with 10,000 permutations.
69-1	9929-9933	Then	_	
69-2	9934-9936	we	_	
69-3	9937-9946	performed	_	
69-4	9947-9957	voxel-wise	_	
69-5	9958-9963	group	_	
69-6	9964-9974	difference	_	
69-7	9975-9983	analyses	_	
69-8	9984-9991	between	_	
69-9	9992-10000	subjects	_	
69-10	10001-10004	and	_	
69-11	10005-10013	controls	_	
69-12	10014-10019	using	_	
69-13	10020-10033	nonparametric	_	
69-14	10034-10045	permutation	_	
69-15	10046-10053	testing	_	
69-16	10054-10058	with	_	
69-17	10059-10065	10,000	_	
69-18	10066-10078	permutations	_	
69-19	10078-10079	.	_	

#Text=Finally, for multiple comparisons, we conducted a family-wise error (FWE) correction with a significance threshold of p < 0.05.
70-1	10080-10087	Finally	_	
70-2	10087-10088	,	_	
70-3	10089-10092	for	_	
70-4	10093-10101	multiple	_	
70-5	10102-10113	comparisons	_	
70-6	10113-10114	,	_	
70-7	10115-10117	we	_	
70-8	10118-10127	conducted	_	
70-9	10128-10129	a	_	
70-10	10130-10141	family-wise	_	
70-11	10142-10147	error	_	
70-12	10148-10149	(	_	
70-13	10149-10152	FWE	_	
70-14	10152-10153	)	_	
70-15	10154-10164	correction	_	
70-16	10165-10169	with	_	
70-17	10170-10171	a	_	
70-18	10172-10184	significance	_	
70-19	10185-10194	threshold	_	
70-20	10195-10197	of	_	
70-21	10198-10199	p	_	
70-22	10200-10201	<	_	
70-23	10202-10206	0.05	_	
70-24	10206-10207	.	_	

#Text=We used the Harvard–Oxford cortical and subcortical atlases (Harvard Centre for Morphometric Analysis) to identify anatomical representations of clusters of the resulting probabilistic independent component analysis maps, which indicated significant differences between the two groups.
71-1	10208-10210	We	_	
71-2	10211-10215	used	_	
71-3	10216-10219	the	_	
71-4	10220-10234	Harvard–Oxford	_	
71-5	10235-10243	cortical	_	
71-6	10244-10247	and	_	
71-7	10248-10259	subcortical	_	
71-8	10260-10267	atlases	_	
71-9	10268-10269	(	_	
71-10	10269-10276	Harvard	_	
71-11	10277-10283	Centre	_	
71-12	10284-10287	for	_	
71-13	10288-10300	Morphometric	_	
71-14	10301-10309	Analysis	_	
71-15	10309-10310	)	_	
71-16	10311-10313	to	_	
71-17	10314-10322	identify	_	
71-18	10323-10333	anatomical	_	
71-19	10334-10349	representations	_	
71-20	10350-10352	of	_	
71-21	10353-10361	clusters	_	
71-22	10362-10364	of	_	
71-23	10365-10368	the	_	
71-24	10369-10378	resulting	_	
71-25	10379-10392	probabilistic	_	
71-26	10393-10404	independent	_	
71-27	10405-10414	component	_	
71-28	10415-10423	analysis	_	
71-29	10424-10428	maps	_	
71-30	10428-10429	,	_	
71-31	10430-10435	which	_	
71-32	10436-10445	indicated	_	
71-33	10446-10457	significant	_	
71-34	10458-10469	differences	_	
71-35	10470-10477	between	_	
71-36	10478-10481	the	_	
71-37	10482-10485	two	_	
71-38	10486-10492	groups	_	
71-39	10492-10493	.	_	

#Text=The correlation between clinical symptoms and occupation status with between-network resting state functional connectivity were also assessed using partial correlation.
72-1	10494-10497	The	_	
72-2	10498-10509	correlation	_	
72-3	10510-10517	between	_	
72-4	10518-10526	clinical	_	
72-5	10527-10535	symptoms	_	
72-6	10536-10539	and	_	
72-7	10540-10550	occupation	_	
72-8	10551-10557	status	_	
72-9	10558-10562	with	_	
72-10	10563-10578	between-network	_	
72-11	10579-10586	resting	_	
72-12	10587-10592	state	_	
72-13	10593-10603	functional	_	
72-14	10604-10616	connectivity	_	
72-15	10617-10621	were	_	
72-16	10622-10626	also	_	
72-17	10627-10635	assessed	_	
72-18	10636-10641	using	_	
72-19	10642-10649	partial	_	
72-20	10650-10661	correlation	_	
72-21	10661-10662	.	_	

#Text=The statistical significance threshold was set at p < 0.05, FWE corrected.
#Text=3.
73-1	10663-10666	The	_	
73-2	10667-10678	statistical	_	
73-3	10679-10691	significance	_	
73-4	10692-10701	threshold	_	
73-5	10702-10705	was	_	
73-6	10706-10709	set	_	
73-7	10710-10712	at	_	
73-8	10713-10714	p	_	
73-9	10715-10716	<	_	
73-10	10717-10721	0.05	_	
73-11	10721-10722	,	_	
73-12	10723-10726	FWE	_	
73-13	10727-10736	corrected	_	
73-14	10736-10737	.	_	
73-15	10738-10739	3	_	
73-16	10739-10740	.	_	

#Text=Results
#Text=3.1.
74-1	10741-10748	Results	_	
74-2	10749-10752	3.1	_	
74-3	10752-10753	.	_	

#Text=Sample characteristics
#Text=Demographic and head movement parameters of schizophrenia patients and controls are summarized in Tables 1 and 2.
75-1	10754-10760	Sample	_	
75-2	10761-10776	characteristics	_	
75-3	10777-10788	Demographic	_	
75-4	10789-10792	and	_	
75-5	10793-10797	head	_	
75-6	10798-10806	movement	_	
75-7	10807-10817	parameters	_	
75-8	10818-10820	of	_	
75-9	10821-10834	schizophrenia	_	
75-10	10835-10843	patients	_	
75-11	10844-10847	and	_	
75-12	10848-10856	controls	_	
75-13	10857-10860	are	_	
75-14	10861-10871	summarized	_	
75-15	10872-10874	in	_	
75-16	10875-10881	Tables	_	
75-17	10882-10883	1	_	
75-18	10884-10887	and	_	
75-19	10888-10889	2	_	
75-20	10889-10890	.	_	

#Text=No significant differences in age (p = 0.280), gender (p = 1.0), and marital status (p = 0.401) were present.
76-1	10891-10893	No	_	
76-2	10894-10905	significant	_	
76-3	10906-10917	differences	_	
76-4	10918-10920	in	_	
76-5	10921-10924	age	_	
76-6	10925-10926	(	_	
76-7	10926-10927	p	_	
76-8	10928-10929	=	_	
76-9	10930-10935	0.280	_	
76-10	10935-10936	)	_	
76-11	10936-10937	,	_	
76-12	10938-10944	gender	_	
76-13	10945-10946	(	_	
76-14	10946-10947	p	_	
76-15	10948-10949	=	_	
76-16	10950-10953	1.0	_	
76-17	10953-10954	)	_	
76-18	10954-10955	,	_	
76-19	10956-10959	and	_	
76-20	10960-10967	marital	_	
76-21	10968-10974	status	_	
76-22	10975-10976	(	_	
76-23	10976-10977	p	_	
76-24	10978-10979	=	_	
76-25	10980-10985	0.401	_	
76-26	10985-10986	)	_	
76-27	10987-10991	were	_	
76-28	10992-10999	present	_	
76-29	10999-11000	.	_	

#Text=There is no significant difference between head movement parameters between patients and controls.
77-1	11001-11006	There	_	
77-2	11007-11009	is	_	
77-3	11010-11012	no	_	
77-4	11013-11024	significant	_	
77-5	11025-11035	difference	_	
77-6	11036-11043	between	_	
77-7	11044-11048	head	_	
77-8	11049-11057	movement	_	
77-9	11058-11068	parameters	_	
77-10	11069-11076	between	_	
77-11	11077-11085	patients	_	
77-12	11086-11089	and	_	
77-13	11090-11098	controls	_	
77-14	11098-11099	.	_	

#Text=Clinical profile of schizophrenia participants is tabulated in Table 2.
78-1	11100-11108	Clinical	_	
78-2	11109-11116	profile	_	
78-3	11117-11119	of	_	
78-4	11120-11133	schizophrenia	_	
78-5	11134-11146	participants	_	
78-6	11147-11149	is	_	
78-7	11150-11159	tabulated	_	
78-8	11160-11162	in	_	
78-9	11163-11168	Table	_	
78-10	11169-11170	2	_	
78-11	11170-11171	.	_	

#Text=Although schizophrenia participants experienced symptoms of psychosis (mean SAPS score=15 ± 10.55; mean SANS score = 31.74 ± 18.51) with a mean GAF score of 31.77 ± 9.22 in the past month, they were cooperative for structured clinical interview and fMRI (Table 2).
#Text=3.2.
79-1	11172-11180	Although	_	
79-2	11181-11194	schizophrenia	_	
79-3	11195-11207	participants	_	
79-4	11208-11219	experienced	_	
79-5	11220-11228	symptoms	_	
79-6	11229-11231	of	_	
79-7	11232-11241	psychosis	_	
79-8	11242-11243	(	_	
79-9	11243-11247	mean	_	
79-10	11248-11252	SAPS	_	
79-11	11253-11258	score	_	
79-12	11258-11259	=	_	
79-13	11259-11261	15	_	
79-14	11262-11263	±	_	
79-15	11264-11269	10.55	_	
79-16	11269-11270	;	_	
79-17	11271-11275	mean	_	
79-18	11276-11280	SANS	_	
79-19	11281-11286	score	_	
79-20	11287-11288	=	_	
79-21	11289-11294	31.74	_	
79-22	11295-11296	±	_	
79-23	11297-11302	18.51	_	
79-24	11302-11303	)	_	
79-25	11304-11308	with	_	
79-26	11309-11310	a	_	
79-27	11311-11315	mean	_	
79-28	11316-11319	GAF	_	
79-29	11320-11325	score	_	
79-30	11326-11328	of	_	
79-31	11329-11334	31.77	_	
79-32	11335-11336	±	_	
79-33	11337-11341	9.22	_	
79-34	11342-11344	in	_	
79-35	11345-11348	the	_	
79-36	11349-11353	past	_	
79-37	11354-11359	month	_	
79-38	11359-11360	,	_	
79-39	11361-11365	they	_	
79-40	11366-11370	were	_	
79-41	11371-11382	cooperative	_	
79-42	11383-11386	for	_	
79-43	11387-11397	structured	_	
79-44	11398-11406	clinical	_	
79-45	11407-11416	interview	_	
79-46	11417-11420	and	_	
79-47	11421-11425	fMRI	_	
79-48	11426-11427	(	_	
79-49	11427-11432	Table	_	
79-50	11433-11434	2	_	
79-51	11434-11435	)	_	
79-52	11435-11436	.	_	
79-53	11437-11440	3.2	_	
79-54	11440-11441	.	_	

#Text=Resting State Networks
#Text=Seven resting state networks (RSNs) were identified from the group MELODIC output which included the right frontoparietal network, left frontoparietal network, default mode network (DMN), medial visual network, lateral visual network, motor network and auditory network (Supplementary figures 1–7).
80-1	11442-11449	Resting	_	
80-2	11450-11455	State	_	
80-3	11456-11464	Networks	_	
80-4	11465-11470	Seven	_	
80-5	11471-11478	resting	_	
80-6	11479-11484	state	_	
80-7	11485-11493	networks	_	
80-8	11494-11495	(	_	
80-9	11495-11499	RSNs	_	
80-10	11499-11500	)	_	
80-11	11501-11505	were	_	
80-12	11506-11516	identified	_	
80-13	11517-11521	from	_	
80-14	11522-11525	the	_	
80-15	11526-11531	group	_	
80-16	11532-11539	MELODIC	_	
80-17	11540-11546	output	_	
80-18	11547-11552	which	_	
80-19	11553-11561	included	_	
80-20	11562-11565	the	_	
80-21	11566-11571	right	_	
80-22	11572-11586	frontoparietal	_	
80-23	11587-11594	network	_	
80-24	11594-11595	,	_	
80-25	11596-11600	left	_	
80-26	11601-11615	frontoparietal	_	
80-27	11616-11623	network	_	
80-28	11623-11624	,	_	
80-29	11625-11632	default	_	
80-30	11633-11637	mode	_	
80-31	11638-11645	network	_	
80-32	11646-11647	(	_	
80-33	11647-11650	DMN	_	
80-34	11650-11651	)	_	
80-35	11651-11652	,	_	
80-36	11653-11659	medial	_	
80-37	11660-11666	visual	_	
80-38	11667-11674	network	_	
80-39	11674-11675	,	_	
80-40	11676-11683	lateral	_	
80-41	11684-11690	visual	_	
80-42	11691-11698	network	_	
80-43	11698-11699	,	_	
80-44	11700-11705	motor	_	
80-45	11706-11713	network	_	
80-46	11714-11717	and	_	
80-47	11718-11726	auditory	_	
80-48	11727-11734	network	_	
80-49	11735-11736	(	_	
80-50	11736-11749	Supplementary	_	
80-51	11750-11757	figures	_	
80-52	11758-11759	1	_	
80-53	11759-11760	–	_	
80-54	11760-11761	7	_	
80-55	11761-11762	)	_	
80-56	11762-11763	.	_	

#Text=Left Frontoparietal Network
#Text=Schizophrenia patients showed significantly decreased functional connectivity in the left frontoparietal network compared to control subjects in the brain regions including lateral occipital cortex, superior parietal lobule, angular gyrus, precuneus cortex and occipital pole (Fig. 1a and Table 3).
81-1	11764-11768	Left	_	
81-2	11769-11783	Frontoparietal	_	
81-3	11784-11791	Network	_	
81-4	11792-11805	Schizophrenia	_	
81-5	11806-11814	patients	_	
81-6	11815-11821	showed	_	
81-7	11822-11835	significantly	_	
81-8	11836-11845	decreased	_	
81-9	11846-11856	functional	_	
81-10	11857-11869	connectivity	_	
81-11	11870-11872	in	_	
81-12	11873-11876	the	_	
81-13	11877-11881	left	_	
81-14	11882-11896	frontoparietal	_	
81-15	11897-11904	network	_	
81-16	11905-11913	compared	_	
81-17	11914-11916	to	_	
81-18	11917-11924	control	_	
81-19	11925-11933	subjects	_	
81-20	11934-11936	in	_	
81-21	11937-11940	the	_	
81-22	11941-11946	brain	_	
81-23	11947-11954	regions	_	
81-24	11955-11964	including	_	
81-25	11965-11972	lateral	_	
81-26	11973-11982	occipital	_	
81-27	11983-11989	cortex	_	
81-28	11989-11990	,	_	
81-29	11991-11999	superior	_	
81-30	12000-12008	parietal	_	
81-31	12009-12015	lobule	_	
81-32	12015-12016	,	_	
81-33	12017-12024	angular	_	
81-34	12025-12030	gyrus	_	
81-35	12030-12031	,	_	
81-36	12032-12041	precuneus	_	
81-37	12042-12048	cortex	_	
81-38	12049-12052	and	_	
81-39	12053-12062	occipital	_	
81-40	12063-12067	pole	_	
81-41	12068-12069	(	_	
81-42	12069-12072	Fig	_	
81-43	12072-12073	.	_	
81-44	12074-12076	1a	_	
81-45	12077-12080	and	_	
81-46	12081-12086	Table	_	
81-47	12087-12088	3	_	
81-48	12088-12089	)	_	
81-49	12089-12090	.	_	

#Text=Medial Visual Network
#Text=Significantly decreased connectivity within the medial visual network including lateral occipital cortex, occipital pole, cingulate gyrus and precuneus cortex was observed in schizophrenia (Fig. 1b and Table 3).
82-1	12091-12097	Medial	_	
82-2	12098-12104	Visual	_	
82-3	12105-12112	Network	_	
82-4	12113-12126	Significantly	_	
82-5	12127-12136	decreased	_	
82-6	12137-12149	connectivity	_	
82-7	12150-12156	within	_	
82-8	12157-12160	the	_	
82-9	12161-12167	medial	_	
82-10	12168-12174	visual	_	
82-11	12175-12182	network	_	
82-12	12183-12192	including	_	
82-13	12193-12200	lateral	_	
82-14	12201-12210	occipital	_	
82-15	12211-12217	cortex	_	
82-16	12217-12218	,	_	
82-17	12219-12228	occipital	_	
82-18	12229-12233	pole	_	
82-19	12233-12234	,	_	
82-20	12235-12244	cingulate	_	
82-21	12245-12250	gyrus	_	
82-22	12251-12254	and	_	
82-23	12255-12264	precuneus	_	
82-24	12265-12271	cortex	_	
82-25	12272-12275	was	_	
82-26	12276-12284	observed	_	
82-27	12285-12287	in	_	
82-28	12288-12301	schizophrenia	_	
82-29	12302-12303	(	_	
82-30	12303-12306	Fig	_	
82-31	12306-12307	.	_	
82-32	12308-12310	1b	_	
82-33	12311-12314	and	_	
82-34	12315-12320	Table	_	
82-35	12321-12322	3	_	
82-36	12322-12323	)	_	
82-37	12323-12324	.	_	

#Text=Motor Network
#Text=Decreased connectivity within the motor network among schizophrenia cases was seen in the precentral and postcentral gyri, and superior frontal gyrus (Fig. 1c and Table 3).
83-1	12325-12330	Motor	_	
83-2	12331-12338	Network	_	
83-3	12339-12348	Decreased	_	
83-4	12349-12361	connectivity	_	
83-5	12362-12368	within	_	
83-6	12369-12372	the	_	
83-7	12373-12378	motor	_	
83-8	12379-12386	network	_	
83-9	12387-12392	among	_	
83-10	12393-12406	schizophrenia	_	
83-11	12407-12412	cases	_	
83-12	12413-12416	was	_	
83-13	12417-12421	seen	_	
83-14	12422-12424	in	_	
83-15	12425-12428	the	_	
83-16	12429-12439	precentral	_	
83-17	12440-12443	and	_	
83-18	12444-12455	postcentral	_	
83-19	12456-12460	gyri	_	
83-20	12460-12461	,	_	
83-21	12462-12465	and	_	
83-22	12466-12474	superior	_	
83-23	12475-12482	frontal	_	
83-24	12483-12488	gyrus	_	
83-25	12489-12490	(	_	
83-26	12490-12493	Fig	_	
83-27	12493-12494	.	_	
83-28	12495-12497	1c	_	
83-29	12498-12501	and	_	
83-30	12502-12507	Table	_	
83-31	12508-12509	3	_	
83-32	12509-12510	)	_	
83-33	12510-12511	.	_	

#Text=Lateral Visual Network
#Text=The regions of the lateral visual network in which the schizophrenia participants specifically showed significantly decreased temporal correlation compared to controls included temporal occipital cortices, inferior temporal gyrus, supplementary motor area, cingulate gyrus, lateral occipital cortex, angular gyrus, and superior parietal lobule (Fig. 1d and Table 3).
84-1	12512-12519	Lateral	_	
84-2	12520-12526	Visual	_	
84-3	12527-12534	Network	_	
84-4	12535-12538	The	_	
84-5	12539-12546	regions	_	
84-6	12547-12549	of	_	
84-7	12550-12553	the	_	
84-8	12554-12561	lateral	_	
84-9	12562-12568	visual	_	
84-10	12569-12576	network	_	
84-11	12577-12579	in	_	
84-12	12580-12585	which	_	
84-13	12586-12589	the	_	
84-14	12590-12603	schizophrenia	_	
84-15	12604-12616	participants	_	
84-16	12617-12629	specifically	_	
84-17	12630-12636	showed	_	
84-18	12637-12650	significantly	_	
84-19	12651-12660	decreased	_	
84-20	12661-12669	temporal	_	
84-21	12670-12681	correlation	_	
84-22	12682-12690	compared	_	
84-23	12691-12693	to	_	
84-24	12694-12702	controls	_	
84-25	12703-12711	included	_	
84-26	12712-12720	temporal	_	
84-27	12721-12730	occipital	_	
84-28	12731-12739	cortices	_	
84-29	12739-12740	,	_	
84-30	12741-12749	inferior	_	
84-31	12750-12758	temporal	_	
84-32	12759-12764	gyrus	_	
84-33	12764-12765	,	_	
84-34	12766-12779	supplementary	_	
84-35	12780-12785	motor	_	
84-36	12786-12790	area	_	
84-37	12790-12791	,	_	
84-38	12792-12801	cingulate	_	
84-39	12802-12807	gyrus	_	
84-40	12807-12808	,	_	
84-41	12809-12816	lateral	_	
84-42	12817-12826	occipital	_	
84-43	12827-12833	cortex	_	
84-44	12833-12834	,	_	
84-45	12835-12842	angular	_	
84-46	12843-12848	gyrus	_	
84-47	12848-12849	,	_	
84-48	12850-12853	and	_	
84-49	12854-12862	superior	_	
84-50	12863-12871	parietal	_	
84-51	12872-12878	lobule	_	
84-52	12879-12880	(	_	
84-53	12880-12883	Fig	_	
84-54	12883-12884	.	_	
84-55	12885-12887	1d	_	
84-56	12888-12891	and	_	
84-57	12892-12897	Table	_	
84-58	12898-12899	3	_	
84-59	12899-12900	)	_	
84-60	12900-12901	.	_	

#Text=Auditory Network
#Text=Schizophrenia participants showed reduced connectivity among the insular cortex, the Heschl’s gyrus, the central opercular cortex, and parietal operculum cortex (Fig. 1e and Table 3).
85-1	12902-12910	Auditory	_	
85-2	12911-12918	Network	_	
85-3	12919-12932	Schizophrenia	_	
85-4	12933-12945	participants	_	
85-5	12946-12952	showed	_	
85-6	12953-12960	reduced	_	
85-7	12961-12973	connectivity	_	
85-8	12974-12979	among	_	
85-9	12980-12983	the	_	
85-10	12984-12991	insular	_	
85-11	12992-12998	cortex	_	
85-12	12998-12999	,	_	
85-13	13000-13003	the	_	
85-14	13004-13010	Heschl	_	
85-15	13010-13011	’	_	
85-16	13011-13012	s	_	
85-17	13013-13018	gyrus	_	
85-18	13018-13019	,	_	
85-19	13020-13023	the	_	
85-20	13024-13031	central	_	
85-21	13032-13041	opercular	_	
85-22	13042-13048	cortex	_	
85-23	13048-13049	,	_	
85-24	13050-13053	and	_	
85-25	13054-13062	parietal	_	
85-26	13063-13072	operculum	_	
85-27	13073-13079	cortex	_	
85-28	13080-13081	(	_	
85-29	13081-13084	Fig	_	
85-30	13084-13085	.	_	
85-31	13086-13088	1e	_	
85-32	13089-13092	and	_	
85-33	13093-13098	Table	_	
85-34	13099-13100	3	_	
85-35	13100-13101	)	_	
85-36	13101-13102	.	_	

#Text=Default Mode Network
#Text=In DMN, schizophrenia patients showed reduced connectivity in the cingulate gyrus, precentral gyrus, juxtapositional lobule cortex (formerly Supplementary Motor Cortex), precuneus cortex, lateral occipital cortices, temporal gyrus and subcallosal cortex (Fig. 1f and Table 3).
86-1	13103-13110	Default	_	
86-2	13111-13115	Mode	_	
86-3	13116-13123	Network	_	
86-4	13124-13126	In	_	
86-5	13127-13130	DMN	_	
86-6	13130-13131	,	_	
86-7	13132-13145	schizophrenia	_	
86-8	13146-13154	patients	_	
86-9	13155-13161	showed	_	
86-10	13162-13169	reduced	_	
86-11	13170-13182	connectivity	_	
86-12	13183-13185	in	_	
86-13	13186-13189	the	_	
86-14	13190-13199	cingulate	_	
86-15	13200-13205	gyrus	_	
86-16	13205-13206	,	_	
86-17	13207-13217	precentral	_	
86-18	13218-13223	gyrus	_	
86-19	13223-13224	,	_	
86-20	13225-13240	juxtapositional	_	
86-21	13241-13247	lobule	_	
86-22	13248-13254	cortex	_	
86-23	13255-13256	(	_	
86-24	13256-13264	formerly	_	
86-25	13265-13278	Supplementary	_	
86-26	13279-13284	Motor	_	
86-27	13285-13291	Cortex	_	
86-28	13291-13292	)	_	
86-29	13292-13293	,	_	
86-30	13294-13303	precuneus	_	
86-31	13304-13310	cortex	_	
86-32	13310-13311	,	_	
86-33	13312-13319	lateral	_	
86-34	13320-13329	occipital	_	
86-35	13330-13338	cortices	_	
86-36	13338-13339	,	_	
86-37	13340-13348	temporal	_	
86-38	13349-13354	gyrus	_	
86-39	13355-13358	and	_	
86-40	13359-13370	subcallosal	_	
86-41	13371-13377	cortex	_	
86-42	13378-13379	(	_	
86-43	13379-13382	Fig	_	
86-44	13382-13383	.	_	
86-45	13384-13386	1f	_	
86-46	13387-13390	and	_	
86-47	13391-13396	Table	_	
86-48	13397-13398	3	_	
86-49	13398-13399	)	_	
86-50	13399-13400	.	_	

#Text=Relationship between functional connectivity and clinical variables
#Text=No significant correlation was found between occupation status and resting state function connectivity in any network.
87-1	13401-13413	Relationship	_	
87-2	13414-13421	between	_	
87-3	13422-13432	functional	_	
87-4	13433-13445	connectivity	_	
87-5	13446-13449	and	_	
87-6	13450-13458	clinical	_	
87-7	13459-13468	variables	_	
87-8	13469-13471	No	_	
87-9	13472-13483	significant	_	
87-10	13484-13495	correlation	_	
87-11	13496-13499	was	_	
87-12	13500-13505	found	_	
87-13	13506-13513	between	_	
87-14	13514-13524	occupation	_	
87-15	13525-13531	status	_	
87-16	13532-13535	and	_	
87-17	13536-13543	resting	_	
87-18	13544-13549	state	_	
87-19	13550-13558	function	_	
87-20	13559-13571	connectivity	_	
87-21	13572-13574	in	_	
87-22	13575-13578	any	_	
87-23	13579-13586	network	_	
87-24	13586-13587	.	_	

#Text=The decreased connectivity of the four networks did not significantly correlate with sub-syndrome or total scores on SANS and SAPS, duration of illness, age of onset or the GAF scores on repeating functional imaging analysis to correlate the SANS and SAPS sub scores and total scores.
#Text=4.
88-1	13588-13591	The	_	
88-2	13592-13601	decreased	_	
88-3	13602-13614	connectivity	_	
88-4	13615-13617	of	_	
88-5	13618-13621	the	_	
88-6	13622-13626	four	_	
88-7	13627-13635	networks	_	
88-8	13636-13639	did	_	
88-9	13640-13643	not	_	
88-10	13644-13657	significantly	_	
88-11	13658-13667	correlate	_	
88-12	13668-13672	with	_	
88-13	13673-13685	sub-syndrome	_	
88-14	13686-13688	or	_	
88-15	13689-13694	total	_	
88-16	13695-13701	scores	_	
88-17	13702-13704	on	_	
88-18	13705-13709	SANS	_	
88-19	13710-13713	and	_	
88-20	13714-13718	SAPS	_	
88-21	13718-13719	,	_	
88-22	13720-13728	duration	_	
88-23	13729-13731	of	_	
88-24	13732-13739	illness	_	
88-25	13739-13740	,	_	
88-26	13741-13744	age	_	
88-27	13745-13747	of	_	
88-28	13748-13753	onset	_	
88-29	13754-13756	or	_	
88-30	13757-13760	the	_	
88-31	13761-13764	GAF	_	
88-32	13765-13771	scores	_	
88-33	13772-13774	on	_	
88-34	13775-13784	repeating	_	
88-35	13785-13795	functional	_	
88-36	13796-13803	imaging	_	
88-37	13804-13812	analysis	_	
88-38	13813-13815	to	_	
88-39	13816-13825	correlate	_	
88-40	13826-13829	the	_	
88-41	13830-13834	SANS	_	
88-42	13835-13838	and	_	
88-43	13839-13843	SAPS	_	
88-44	13844-13847	sub	_	
88-45	13848-13854	scores	_	
88-46	13855-13858	and	_	
88-47	13859-13864	total	_	
88-48	13865-13871	scores	_	
88-49	13871-13872	.	_	
88-50	13873-13874	4	_	
88-51	13874-13875	.	_	

#Text=Discussion
#Text=Our study reports decreased functional connectivity in six RSNs including left frontoparietal network, lateral visual network, medial visual network, motor network, DMN, and auditory network, in early course schizophrenia patients compared to healthy controls.
89-1	13876-13886	Discussion	_	
89-2	13887-13890	Our	_	
89-3	13891-13896	study	_	
89-4	13897-13904	reports	_	
89-5	13905-13914	decreased	_	
89-6	13915-13925	functional	_	
89-7	13926-13938	connectivity	_	
89-8	13939-13941	in	_	
89-9	13942-13945	six	_	
89-10	13946-13950	RSNs	_	
89-11	13951-13960	including	_	
89-12	13961-13965	left	_	
89-13	13966-13980	frontoparietal	_	
89-14	13981-13988	network	_	
89-15	13988-13989	,	_	
89-16	13990-13997	lateral	_	
89-17	13998-14004	visual	_	
89-18	14005-14012	network	_	
89-19	14012-14013	,	_	
89-20	14014-14020	medial	_	
89-21	14021-14027	visual	_	
89-22	14028-14035	network	_	
89-23	14035-14036	,	_	
89-24	14037-14042	motor	_	
89-25	14043-14050	network	_	
89-26	14050-14051	,	_	
89-27	14052-14055	DMN	_	
89-28	14055-14056	,	_	
89-29	14057-14060	and	_	
89-30	14061-14069	auditory	_	
89-31	14070-14077	network	_	
89-32	14077-14078	,	_	
89-33	14079-14081	in	_	
89-34	14082-14087	early	_	
89-35	14088-14094	course	_	
89-36	14095-14108	schizophrenia	_	
89-37	14109-14117	patients	_	
89-38	14118-14126	compared	_	
89-39	14127-14129	to	_	
89-40	14130-14137	healthy	_	
89-41	14138-14146	controls	_	
89-42	14146-14147	.	_	

#Text=Our focus on patients in the early course of illness (mean illness duration 3.75 years) makes it more distinctive and may address possible confounding factors of chronicity and exposure to long-term psychotropic medications.
90-1	14148-14151	Our	_	
90-2	14152-14157	focus	_	
90-3	14158-14160	on	_	
90-4	14161-14169	patients	_	
90-5	14170-14172	in	_	
90-6	14173-14176	the	_	
90-7	14177-14182	early	_	
90-8	14183-14189	course	_	
90-9	14190-14192	of	_	
90-10	14193-14200	illness	_	
90-11	14201-14202	(	_	
90-12	14202-14206	mean	_	
90-13	14207-14214	illness	_	
90-14	14215-14223	duration	_	
90-15	14224-14228	3.75	_	
90-16	14229-14234	years	_	
90-17	14234-14235	)	_	
90-18	14236-14241	makes	_	
90-19	14242-14244	it	_	
90-20	14245-14249	more	_	
90-21	14250-14261	distinctive	_	
90-22	14262-14265	and	_	
90-23	14266-14269	may	_	
90-24	14270-14277	address	_	
90-25	14278-14286	possible	_	
90-26	14287-14298	confounding	_	
90-27	14299-14306	factors	_	
90-28	14307-14309	of	_	
90-29	14310-14320	chronicity	_	
90-30	14321-14324	and	_	
90-31	14325-14333	exposure	_	
90-32	14334-14336	to	_	
90-33	14337-14346	long-term	_	
90-34	14347-14359	psychotropic	_	
90-35	14360-14371	medications	_	
90-36	14371-14372	.	_	

#Text=Schizophrenia patients were experiencing moderately severe positive and more severe negative symptoms that may be related to unique findings reported here.
91-1	14373-14386	Schizophrenia	_	
91-2	14387-14395	patients	_	
91-3	14396-14400	were	_	
91-4	14401-14413	experiencing	_	
91-5	14414-14424	moderately	_	
91-6	14425-14431	severe	_	
91-7	14432-14440	positive	_	
91-8	14441-14444	and	_	
91-9	14445-14449	more	_	
91-10	14450-14456	severe	_	
91-11	14457-14465	negative	_	
91-12	14466-14474	symptoms	_	
91-13	14475-14479	that	_	
91-14	14480-14483	may	_	
91-15	14484-14486	be	_	
91-16	14487-14494	related	_	
91-17	14495-14497	to	_	
91-18	14498-14504	unique	_	
91-19	14505-14513	findings	_	
91-20	14514-14522	reported	_	
91-21	14523-14527	here	_	
91-22	14527-14528	.	_	

#Text=Zhou examined almost similar patients but examined the dorsolateral prefrontal cortex connectivity by seeding this region-of-interest.
92-1	14529-14533	Zhou	_	
92-2	14534-14542	examined	_	
92-3	14543-14549	almost	_	
92-4	14550-14557	similar	_	
92-5	14558-14566	patients	_	
92-6	14567-14570	but	_	
92-7	14571-14579	examined	_	
92-8	14580-14583	the	_	
92-9	14584-14596	dorsolateral	_	
92-10	14597-14607	prefrontal	_	
92-11	14608-14614	cortex	_	
92-12	14615-14627	connectivity	_	
92-13	14628-14630	by	_	
92-14	14631-14638	seeding	_	
92-15	14639-14643	this	_	
92-16	14644-14662	region-of-interest	_	
92-17	14662-14663	.	_	

#Text=They found reduced connectivity of the dorsolateral prefrontal cortex with the parietal, posterior cingulate, thalamus and striatum in schizophrenia patients.
93-1	14664-14668	They	_	
93-2	14669-14674	found	_	
93-3	14675-14682	reduced	_	
93-4	14683-14695	connectivity	_	
93-5	14696-14698	of	_	
93-6	14699-14702	the	_	
93-7	14703-14715	dorsolateral	_	
93-8	14716-14726	prefrontal	_	
93-9	14727-14733	cortex	_	
93-10	14734-14738	with	_	
93-11	14739-14742	the	_	
93-12	14743-14751	parietal	_	
93-13	14751-14752	,	_	
93-14	14753-14762	posterior	_	
93-15	14763-14772	cingulate	_	
93-16	14772-14773	,	_	
93-17	14774-14782	thalamus	_	
93-18	14783-14786	and	_	
93-19	14787-14795	striatum	_	
93-20	14796-14798	in	_	
93-21	14799-14812	schizophrenia	_	
93-22	14813-14821	patients	_	
93-23	14821-14822	.	_	

#Text=We used a whole-brain approach agnostic to any particular region-of-interest.
94-1	14823-14825	We	_	
94-2	14826-14830	used	_	
94-3	14831-14832	a	_	
94-4	14833-14844	whole-brain	_	
94-5	14845-14853	approach	_	
94-6	14854-14862	agnostic	_	
94-7	14863-14865	to	_	
94-8	14866-14869	any	_	
94-9	14870-14880	particular	_	
94-10	14881-14899	region-of-interest	_	
94-11	14899-14900	.	_	

#Text=This suggests that networks other than those involving the dorsolateral prefrontal cortex may still be associated with schizophrenia.
95-1	14901-14905	This	_	
95-2	14906-14914	suggests	_	
95-3	14915-14919	that	_	
95-4	14920-14928	networks	_	
95-5	14929-14934	other	_	
95-6	14935-14939	than	_	
95-7	14940-14945	those	_	
95-8	14946-14955	involving	_	
95-9	14956-14959	the	_	
95-10	14960-14972	dorsolateral	_	
95-11	14973-14983	prefrontal	_	
95-12	14984-14990	cortex	_	
95-13	14991-14994	may	_	
95-14	14995-15000	still	_	
95-15	15001-15003	be	_	
95-16	15004-15014	associated	_	
95-17	15015-15019	with	_	
95-18	15020-15033	schizophrenia	_	
95-19	15033-15034	.	_	

#Text=Implicated regions in our study concur with previous studies on the resting state alterations, which are manifestations of SLFF with schizophrenia providing evidence of their future usefulness as biomarkers of schizophrenia.
96-1	15035-15045	Implicated	_	
96-2	15046-15053	regions	_	
96-3	15054-15056	in	_	
96-4	15057-15060	our	_	
96-5	15061-15066	study	_	
96-6	15067-15073	concur	_	
96-7	15074-15078	with	_	
96-8	15079-15087	previous	_	
96-9	15088-15095	studies	_	
96-10	15096-15098	on	_	
96-11	15099-15102	the	_	
96-12	15103-15110	resting	_	
96-13	15111-15116	state	_	
96-14	15117-15128	alterations	_	
96-15	15128-15129	,	_	
96-16	15130-15135	which	_	
96-17	15136-15139	are	_	
96-18	15140-15154	manifestations	_	
96-19	15155-15157	of	_	
96-20	15158-15162	SLFF	_	
96-21	15163-15167	with	_	
96-22	15168-15181	schizophrenia	_	
96-23	15182-15191	providing	_	
96-24	15192-15200	evidence	_	
96-25	15201-15203	of	_	
96-26	15204-15209	their	_	
96-27	15210-15216	future	_	
96-28	15217-15227	usefulness	_	
96-29	15228-15230	as	_	
96-30	15231-15241	biomarkers	_	
96-31	15242-15244	of	_	
96-32	15245-15258	schizophrenia	_	
96-33	15258-15259	.	_	

#Text=The frontoparietal networks are associated with higher order cognitive functions.
97-1	15260-15263	The	_	
97-2	15264-15278	frontoparietal	_	
97-3	15279-15287	networks	_	
97-4	15288-15291	are	_	
97-5	15292-15302	associated	_	
97-6	15303-15307	with	_	
97-7	15308-15314	higher	_	
97-8	15315-15320	order	_	
97-9	15321-15330	cognitive	_	
97-10	15331-15340	functions	_	
97-11	15340-15341	.	_	

#Text=Specifically, the left frontoparietal network displays a functional association with language processing, as well as visual working memory, attention and episodic memory retrieval.
98-1	15342-15354	Specifically	_	
98-2	15354-15355	,	_	
98-3	15356-15359	the	_	
98-4	15360-15364	left	_	
98-5	15365-15379	frontoparietal	_	
98-6	15380-15387	network	_	
98-7	15388-15396	displays	_	
98-8	15397-15398	a	_	
98-9	15399-15409	functional	_	
98-10	15410-15421	association	_	
98-11	15422-15426	with	_	
98-12	15427-15435	language	_	
98-13	15436-15446	processing	_	
98-14	15446-15447	,	_	
98-15	15448-15450	as	_	
98-16	15451-15455	well	_	
98-17	15456-15458	as	_	
98-18	15459-15465	visual	_	
98-19	15466-15473	working	_	
98-20	15474-15480	memory	_	
98-21	15480-15481	,	_	
98-22	15482-15491	attention	_	
98-23	15492-15495	and	_	
98-24	15496-15504	episodic	_	
98-25	15505-15511	memory	_	
98-26	15512-15521	retrieval	_	
98-27	15521-15522	.	_	

#Text=Our findings indicated that the lateral occipital cortex, superior parietal lobule, angular gyrus, precuneus cortex and occipital pole showed decreased functional connectivity in schizophrenia patients compared with healthy controls.
99-1	15523-15526	Our	_	
99-2	15527-15535	findings	_	
99-3	15536-15545	indicated	_	
99-4	15546-15550	that	_	
99-5	15551-15554	the	_	
99-6	15555-15562	lateral	_	
99-7	15563-15572	occipital	_	
99-8	15573-15579	cortex	_	
99-9	15579-15580	,	_	
99-10	15581-15589	superior	_	
99-11	15590-15598	parietal	_	
99-12	15599-15605	lobule	_	
99-13	15605-15606	,	_	
99-14	15607-15614	angular	_	
99-15	15615-15620	gyrus	_	
99-16	15620-15621	,	_	
99-17	15622-15631	precuneus	_	
99-18	15632-15638	cortex	_	
99-19	15639-15642	and	_	
99-20	15643-15652	occipital	_	
99-21	15653-15657	pole	_	
99-22	15658-15664	showed	_	
99-23	15665-15674	decreased	_	
99-24	15675-15685	functional	_	
99-25	15686-15698	connectivity	_	
99-26	15699-15701	in	_	
99-27	15702-15715	schizophrenia	_	
99-28	15716-15724	patients	_	
99-29	15725-15733	compared	_	
99-30	15734-15738	with	_	
99-31	15739-15746	healthy	_	
99-32	15747-15755	controls	_	
99-33	15755-15756	.	_	

#Text=Various resting state fMRI studies have shown reduced cluster of activations in frontal and parietal nodes of functional networks in schizophrenia.
100-1	15757-15764	Various	_	
100-2	15765-15772	resting	_	
100-3	15773-15778	state	_	
100-4	15779-15783	fMRI	_	
100-5	15784-15791	studies	_	
100-6	15792-15796	have	_	
100-7	15797-15802	shown	_	
100-8	15803-15810	reduced	_	
100-9	15811-15818	cluster	_	
100-10	15819-15821	of	_	
100-11	15822-15833	activations	_	
100-12	15834-15836	in	_	
100-13	15837-15844	frontal	_	
100-14	15845-15848	and	_	
100-15	15849-15857	parietal	_	
100-16	15858-15863	nodes	_	
100-17	15864-15866	of	_	
100-18	15867-15877	functional	_	
100-19	15878-15886	networks	_	
100-20	15887-15889	in	_	
100-21	15890-15903	schizophrenia	_	
100-22	15903-15904	.	_	

#Text=DTI studies have also reported anatomical disconnection in several brain regions in frontal and parietal lobe in schizophrenia patients.
101-1	15905-15908	DTI	_	
101-2	15909-15916	studies	_	
101-3	15917-15921	have	_	
101-4	15922-15926	also	_	
101-5	15927-15935	reported	_	
101-6	15936-15946	anatomical	_	
101-7	15947-15960	disconnection	_	
101-8	15961-15963	in	_	
101-9	15964-15971	several	_	
101-10	15972-15977	brain	_	
101-11	15978-15985	regions	_	
101-12	15986-15988	in	_	
101-13	15989-15996	frontal	_	
101-14	15997-16000	and	_	
101-15	16001-16009	parietal	_	
101-16	16010-16014	lobe	_	
101-17	16015-16017	in	_	
101-18	16018-16031	schizophrenia	_	
101-19	16032-16040	patients	_	
101-20	16040-16041	.	_	

#Text=In line with these studies, the reduced functional connectivity in the left frontoparietal network is suggestive of possible deficits in cognitive functions associated with the schizophrenia.
102-1	16042-16044	In	_	
102-2	16045-16049	line	_	
102-3	16050-16054	with	_	
102-4	16055-16060	these	_	
102-5	16061-16068	studies	_	
102-6	16068-16069	,	_	
102-7	16070-16073	the	_	
102-8	16074-16081	reduced	_	
102-9	16082-16092	functional	_	
102-10	16093-16105	connectivity	_	
102-11	16106-16108	in	_	
102-12	16109-16112	the	_	
102-13	16113-16117	left	_	
102-14	16118-16132	frontoparietal	_	
102-15	16133-16140	network	_	
102-16	16141-16143	is	_	
102-17	16144-16154	suggestive	_	
102-18	16155-16157	of	_	
102-19	16158-16166	possible	_	
102-20	16167-16175	deficits	_	
102-21	16176-16178	in	_	
102-22	16179-16188	cognitive	_	
102-23	16189-16198	functions	_	
102-24	16199-16209	associated	_	
102-25	16210-16214	with	_	
102-26	16215-16218	the	_	
102-27	16219-16232	schizophrenia	_	
102-28	16232-16233	.	_	

#Text=Reduced connectivity in the lateral and medial visual networks was present, seen through significant alteration of the occipital cortex and associated regions and manifesting in both visual networks and motor network.
103-1	16234-16241	Reduced	_	
103-2	16242-16254	connectivity	_	
103-3	16255-16257	in	_	
103-4	16258-16261	the	_	
103-5	16262-16269	lateral	_	
103-6	16270-16273	and	_	
103-7	16274-16280	medial	_	
103-8	16281-16287	visual	_	
103-9	16288-16296	networks	_	
103-10	16297-16300	was	_	
103-11	16301-16308	present	_	
103-12	16308-16309	,	_	
103-13	16310-16314	seen	_	
103-14	16315-16322	through	_	
103-15	16323-16334	significant	_	
103-16	16335-16345	alteration	_	
103-17	16346-16348	of	_	
103-18	16349-16352	the	_	
103-19	16353-16362	occipital	_	
103-20	16363-16369	cortex	_	
103-21	16370-16373	and	_	
103-22	16374-16384	associated	_	
103-23	16385-16392	regions	_	
103-24	16393-16396	and	_	
103-25	16397-16408	manifesting	_	
103-26	16409-16411	in	_	
103-27	16412-16416	both	_	
103-28	16417-16423	visual	_	
103-29	16424-16432	networks	_	
103-30	16433-16436	and	_	
103-31	16437-16442	motor	_	
103-32	16443-16450	network	_	
103-33	16450-16451	.	_	

#Text=Traditionally considered synonymous with visual processing, emerging evidence from functional and structural studies validates the subtle occipital lobe abnormalities including primary visual processing deficits in schizophrenia.
104-1	16452-16465	Traditionally	_	
104-2	16466-16476	considered	_	
104-3	16477-16487	synonymous	_	
104-4	16488-16492	with	_	
104-5	16493-16499	visual	_	
104-6	16500-16510	processing	_	
104-7	16510-16511	,	_	
104-8	16512-16520	emerging	_	
104-9	16521-16529	evidence	_	
104-10	16530-16534	from	_	
104-11	16535-16545	functional	_	
104-12	16546-16549	and	_	
104-13	16550-16560	structural	_	
104-14	16561-16568	studies	_	
104-15	16569-16578	validates	_	
104-16	16579-16582	the	_	
104-17	16583-16589	subtle	_	
104-18	16590-16599	occipital	_	
104-19	16600-16604	lobe	_	
104-20	16605-16618	abnormalities	_	
104-21	16619-16628	including	_	
104-22	16629-16636	primary	_	
104-23	16637-16643	visual	_	
104-24	16644-16654	processing	_	
104-25	16655-16663	deficits	_	
104-26	16664-16666	in	_	
104-27	16667-16680	schizophrenia	_	
104-28	16680-16681	.	_	

#Text=However, the directionality remains debated.
105-1	16682-16689	However	_	
105-2	16689-16690	,	_	
105-3	16691-16694	the	_	
105-4	16695-16709	directionality	_	
105-5	16710-16717	remains	_	
105-6	16718-16725	debated	_	
105-7	16725-16726	.	_	

#Text=Task-based fMRI studies revealed reduced activation in the fusiform, lentiform, and middle occipital gyri during emotion processing tasks.
106-1	16727-16737	Task-based	_	
106-2	16738-16742	fMRI	_	
106-3	16743-16750	studies	_	
106-4	16751-16759	revealed	_	
106-5	16760-16767	reduced	_	
106-6	16768-16778	activation	_	
106-7	16779-16781	in	_	
106-8	16782-16785	the	_	
106-9	16786-16794	fusiform	_	
106-10	16794-16795	,	_	
106-11	16796-16805	lentiform	_	
106-12	16805-16806	,	_	
106-13	16807-16810	and	_	
106-14	16811-16817	middle	_	
106-15	16818-16827	occipital	_	
106-16	16828-16832	gyri	_	
106-17	16833-16839	during	_	
106-18	16840-16847	emotion	_	
106-19	16848-16858	processing	_	
106-20	16859-16864	tasks	_	
106-21	16864-16865	.	_	

#Text=Argyelan also found greater disconnectivity in the temporal-occipital fusiform cortex in schizophrenia compared to controls.
107-1	16866-16874	Argyelan	_	
107-2	16875-16879	also	_	
107-3	16880-16885	found	_	
107-4	16886-16893	greater	_	
107-5	16894-16909	disconnectivity	_	
107-6	16910-16912	in	_	
107-7	16913-16916	the	_	
107-8	16917-16935	temporal-occipital	_	
107-9	16936-16944	fusiform	_	
107-10	16945-16951	cortex	_	
107-11	16952-16954	in	_	
107-12	16955-16968	schizophrenia	_	
107-13	16969-16977	compared	_	
107-14	16978-16980	to	_	
107-15	16981-16989	controls	_	
107-16	16989-16990	.	_	

#Text=Our findings support the involvement of primary visual processing abnormalities in schizophrenia.
108-1	16991-16994	Our	_	
108-2	16995-17003	findings	_	
108-3	17004-17011	support	_	
108-4	17012-17015	the	_	
108-5	17016-17027	involvement	_	
108-6	17028-17030	of	_	
108-7	17031-17038	primary	_	
108-8	17039-17045	visual	_	
108-9	17046-17056	processing	_	
108-10	17057-17070	abnormalities	_	
108-11	17071-17073	in	_	
108-12	17074-17087	schizophrenia	_	
108-13	17087-17088	.	_	

#Text=Thus, negative symptoms like apathy and affective blunting may reflect poor facial emotion processing linked to occipital cortex dysconnectivities.
109-1	17089-17093	Thus	_	
109-2	17093-17094	,	_	
109-3	17095-17103	negative	_	
109-4	17104-17112	symptoms	_	
109-5	17113-17117	like	_	
109-6	17118-17124	apathy	_	
109-7	17125-17128	and	_	
109-8	17129-17138	affective	_	
109-9	17139-17147	blunting	_	
109-10	17148-17151	may	_	
109-11	17152-17159	reflect	_	
109-12	17160-17164	poor	_	
109-13	17165-17171	facial	_	
109-14	17172-17179	emotion	_	
109-15	17180-17190	processing	_	
109-16	17191-17197	linked	_	
109-17	17198-17200	to	_	
109-18	17201-17210	occipital	_	
109-19	17211-17217	cortex	_	
109-20	17218-17235	dysconnectivities	_	
109-21	17235-17236	.	_	

#Text=Further, hypoconnectivity of the right middle and superior temporal gyrus in first-episode schizophrenia subjects correlated with the severity of positive and negative symptoms.
110-1	17237-17244	Further	_	
110-2	17244-17245	,	_	
110-3	17246-17262	hypoconnectivity	_	
110-4	17263-17265	of	_	
110-5	17266-17269	the	_	
110-6	17270-17275	right	_	
110-7	17276-17282	middle	_	
110-8	17283-17286	and	_	
110-9	17287-17295	superior	_	
110-10	17296-17304	temporal	_	
110-11	17305-17310	gyrus	_	
110-12	17311-17313	in	_	
110-13	17314-17327	first-episode	_	
110-14	17328-17341	schizophrenia	_	
110-15	17342-17350	subjects	_	
110-16	17351-17361	correlated	_	
110-17	17362-17366	with	_	
110-18	17367-17370	the	_	
110-19	17371-17379	severity	_	
110-20	17380-17382	of	_	
110-21	17383-17391	positive	_	
110-22	17392-17395	and	_	
110-23	17396-17404	negative	_	
110-24	17405-17413	symptoms	_	
110-25	17413-17414	.	_	

#Text=Hypoconnectivity in the auditory network was notable because all participants, except two, reported auditory hallucinations during the course of their illness, although not while scanning.
111-1	17415-17431	Hypoconnectivity	_	
111-2	17432-17434	in	_	
111-3	17435-17438	the	_	
111-4	17439-17447	auditory	_	
111-5	17448-17455	network	_	
111-6	17456-17459	was	_	
111-7	17460-17467	notable	_	
111-8	17468-17475	because	_	
111-9	17476-17479	all	_	
111-10	17480-17492	participants	_	
111-11	17492-17493	,	_	
111-12	17494-17500	except	_	
111-13	17501-17504	two	_	
111-14	17504-17505	,	_	
111-15	17506-17514	reported	_	
111-16	17515-17523	auditory	_	
111-17	17524-17538	hallucinations	_	
111-18	17539-17545	during	_	
111-19	17546-17549	the	_	
111-20	17550-17556	course	_	
111-21	17557-17559	of	_	
111-22	17560-17565	their	_	
111-23	17566-17573	illness	_	
111-24	17573-17574	,	_	
111-25	17575-17583	although	_	
111-26	17584-17587	not	_	
111-27	17588-17593	while	_	
111-28	17594-17602	scanning	_	
111-29	17602-17603	.	_	

#Text=This hypoconnectivity did not correlate with hallucination sub-score on SAPS.
112-1	17604-17608	This	_	
112-2	17609-17625	hypoconnectivity	_	
112-3	17626-17629	did	_	
112-4	17630-17633	not	_	
112-5	17634-17643	correlate	_	
112-6	17644-17648	with	_	
112-7	17649-17662	hallucination	_	
112-8	17663-17672	sub-score	_	
112-9	17673-17675	on	_	
112-10	17676-17680	SAPS	_	
112-11	17680-17681	.	_	

#Text=A similar network encompassing the temporo-parietal junction, inferior frontal gyrus, anterior cingulate cortex (ACC), amygdala, and insula known to be associated with speech processing and verbal working memory was previously reported.
113-1	17682-17683	A	_	
113-2	17684-17691	similar	_	
113-3	17692-17699	network	_	
113-4	17700-17712	encompassing	_	
113-5	17713-17716	the	_	
113-6	17717-17733	temporo-parietal	_	
113-7	17734-17742	junction	_	
113-8	17742-17743	,	_	
113-9	17744-17752	inferior	_	
113-10	17753-17760	frontal	_	
113-11	17761-17766	gyrus	_	
113-12	17766-17767	,	_	
113-13	17768-17776	anterior	_	
113-14	17777-17786	cingulate	_	
113-15	17787-17793	cortex	_	
113-16	17794-17795	(	_	
113-17	17795-17798	ACC	_	
113-18	17798-17799	)	_	
113-19	17799-17800	,	_	
113-20	17801-17809	amygdala	_	
113-21	17809-17810	,	_	
113-22	17811-17814	and	_	
113-23	17815-17821	insula	_	
113-24	17822-17827	known	_	
113-25	17828-17830	to	_	
113-26	17831-17833	be	_	
113-27	17834-17844	associated	_	
113-28	17845-17849	with	_	
113-29	17850-17856	speech	_	
113-30	17857-17867	processing	_	
113-31	17868-17871	and	_	
113-32	17872-17878	verbal	_	
113-33	17879-17886	working	_	
113-34	17887-17893	memory	_	
113-35	17894-17897	was	_	
113-36	17898-17908	previously	_	
113-37	17909-17917	reported	_	
113-38	17917-17918	.	_	

#Text=Our network consisted of the same areas, along with the opercular cortex, postcentral gyrus and lateral occipital cortex, suggesting inner speech related problems in schizophrenia implicated in the neurobiology of auditory hallucinations.
114-1	17919-17922	Our	_	
114-2	17923-17930	network	_	
114-3	17931-17940	consisted	_	
114-4	17941-17943	of	_	
114-5	17944-17947	the	_	
114-6	17948-17952	same	_	
114-7	17953-17958	areas	_	
114-8	17958-17959	,	_	
114-9	17960-17965	along	_	
114-10	17966-17970	with	_	
114-11	17971-17974	the	_	
114-12	17975-17984	opercular	_	
114-13	17985-17991	cortex	_	
114-14	17991-17992	,	_	
114-15	17993-18004	postcentral	_	
114-16	18005-18010	gyrus	_	
114-17	18011-18014	and	_	
114-18	18015-18022	lateral	_	
114-19	18023-18032	occipital	_	
114-20	18033-18039	cortex	_	
114-21	18039-18040	,	_	
114-22	18041-18051	suggesting	_	
114-23	18052-18057	inner	_	
114-24	18058-18064	speech	_	
114-25	18065-18072	related	_	
114-26	18073-18081	problems	_	
114-27	18082-18084	in	_	
114-28	18085-18098	schizophrenia	_	
114-29	18099-18109	implicated	_	
114-30	18110-18112	in	_	
114-31	18113-18116	the	_	
114-32	18117-18129	neurobiology	_	
114-33	18130-18132	of	_	
114-34	18133-18141	auditory	_	
114-35	18142-18156	hallucinations	_	
114-36	18156-18157	.	_	

#Text=We observed hypoconnectivity in the motor network.
115-1	18158-18160	We	_	
115-2	18161-18169	observed	_	
115-3	18170-18186	hypoconnectivity	_	
115-4	18187-18189	in	_	
115-5	18190-18193	the	_	
115-6	18194-18199	motor	_	
115-7	18200-18207	network	_	
115-8	18207-18208	.	_	

#Text=It comprised of different regions of the frontal cortex, considered the anatomical basis of executive and motivation-guided behavior.
116-1	18209-18211	It	_	
116-2	18212-18221	comprised	_	
116-3	18222-18224	of	_	
116-4	18225-18234	different	_	
116-5	18235-18242	regions	_	
116-6	18243-18245	of	_	
116-7	18246-18249	the	_	
116-8	18250-18257	frontal	_	
116-9	18258-18264	cortex	_	
116-10	18264-18265	,	_	
116-11	18266-18276	considered	_	
116-12	18277-18280	the	_	
116-13	18281-18291	anatomical	_	
116-14	18292-18297	basis	_	
116-15	18298-18300	of	_	
116-16	18301-18310	executive	_	
116-17	18311-18314	and	_	
116-18	18315-18332	motivation-guided	_	
116-19	18333-18341	behavior	_	
116-20	18341-18342	.	_	

#Text=Welsh et al. reported significantly reduced thalamo-cortical connectivity in schizophrenia, which is hypothesized to be connected to the motor network.
117-1	18343-18348	Welsh	_	
117-2	18349-18351	et	_	
117-3	18352-18354	al	_	
117-4	18354-18355	.	_	
117-5	18356-18364	reported	_	
117-6	18365-18378	significantly	_	
117-7	18379-18386	reduced	_	
117-8	18387-18403	thalamo-cortical	_	
117-9	18404-18416	connectivity	_	
117-10	18417-18419	in	_	
117-11	18420-18433	schizophrenia	_	
117-12	18433-18434	,	_	
117-13	18435-18440	which	_	
117-14	18441-18443	is	_	
117-15	18444-18456	hypothesized	_	
117-16	18457-18459	to	_	
117-17	18460-18462	be	_	
117-18	18463-18472	connected	_	
117-19	18473-18475	to	_	
117-20	18476-18479	the	_	
117-21	18480-18485	motor	_	
117-22	18486-18493	network	_	
117-23	18493-18494	.	_	

#Text=A study on 49 first episode, drug-naïve schizophrenia patients also implicated decreased inter-hemispheric coordination in the precentral gyrus, middle occipital gyrus and precuneus of the superior parietal lobule, which are components of our motor network as well.
118-1	18495-18496	A	_	
118-2	18497-18502	study	_	
118-3	18503-18505	on	_	
118-4	18506-18508	49	_	
118-5	18509-18514	first	_	
118-6	18515-18522	episode	_	
118-7	18522-18523	,	_	
118-8	18524-18534	drug-naïve	_	
118-9	18535-18548	schizophrenia	_	
118-10	18549-18557	patients	_	
118-11	18558-18562	also	_	
118-12	18563-18573	implicated	_	
118-13	18574-18583	decreased	_	
118-14	18584-18601	inter-hemispheric	_	
118-15	18602-18614	coordination	_	
118-16	18615-18617	in	_	
118-17	18618-18621	the	_	
118-18	18622-18632	precentral	_	
118-19	18633-18638	gyrus	_	
118-20	18638-18639	,	_	
118-21	18640-18646	middle	_	
118-22	18647-18656	occipital	_	
118-23	18657-18662	gyrus	_	
118-24	18663-18666	and	_	
118-25	18667-18676	precuneus	_	
118-26	18677-18679	of	_	
118-27	18680-18683	the	_	
118-28	18684-18692	superior	_	
118-29	18693-18701	parietal	_	
118-30	18702-18708	lobule	_	
118-31	18708-18709	,	_	
118-32	18710-18715	which	_	
118-33	18716-18719	are	_	
118-34	18720-18730	components	_	
118-35	18731-18733	of	_	
118-36	18734-18737	our	_	
118-37	18738-18743	motor	_	
118-38	18744-18751	network	_	
118-39	18752-18754	as	_	
118-40	18755-18759	well	_	
118-41	18759-18760	.	_	

#Text=This could be suggestive of neurobiological changes underlying negative symptoms, considering the predominance of those symptoms in our sample.
119-1	18761-18765	This	_	
119-2	18766-18771	could	_	
119-3	18772-18774	be	_	
119-4	18775-18785	suggestive	_	
119-5	18786-18788	of	_	
119-6	18789-18804	neurobiological	_	
119-7	18805-18812	changes	_	
119-8	18813-18823	underlying	_	
119-9	18824-18832	negative	_	
119-10	18833-18841	symptoms	_	
119-11	18841-18842	,	_	
119-12	18843-18854	considering	_	
119-13	18855-18858	the	_	
119-14	18859-18871	predominance	_	
119-15	18872-18874	of	_	
119-16	18875-18880	those	_	
119-17	18881-18889	symptoms	_	
119-18	18890-18892	in	_	
119-19	18893-18896	our	_	
119-20	18897-18903	sample	_	
119-21	18903-18904	.	_	

#Text=We also found evidence for less functional integrity of the DMN in schizophrenia patients, relative to healthy controls.
120-1	18905-18907	We	_	
120-2	18908-18912	also	_	
120-3	18913-18918	found	_	
120-4	18919-18927	evidence	_	
120-5	18928-18931	for	_	
120-6	18932-18936	less	_	
120-7	18937-18947	functional	_	
120-8	18948-18957	integrity	_	
120-9	18958-18960	of	_	
120-10	18961-18964	the	_	
120-11	18965-18968	DMN	_	
120-12	18969-18971	in	_	
120-13	18972-18985	schizophrenia	_	
120-14	18986-18994	patients	_	
120-15	18994-18995	,	_	
120-16	18996-19004	relative	_	
120-17	19005-19007	to	_	
120-18	19008-19015	healthy	_	
120-19	19016-19024	controls	_	
120-20	19024-19025	.	_	

#Text=In DMN network, schizophrenia patients showed clusters of reduced resting state functional connectivity in the cingulate gyrus, precentral gyrus, Juxtapositional Lobule Cortex (formerly Supplementary Motor Cortex), precuneus cortex, lateral occipital cortices, temporal gyrus and subcallosal cortex.
121-1	19026-19028	In	_	
121-2	19029-19032	DMN	_	
121-3	19033-19040	network	_	
121-4	19040-19041	,	_	
121-5	19042-19055	schizophrenia	_	
121-6	19056-19064	patients	_	
121-7	19065-19071	showed	_	
121-8	19072-19080	clusters	_	
121-9	19081-19083	of	_	
121-10	19084-19091	reduced	_	
121-11	19092-19099	resting	_	
121-12	19100-19105	state	_	
121-13	19106-19116	functional	_	
121-14	19117-19129	connectivity	_	
121-15	19130-19132	in	_	
121-16	19133-19136	the	_	
121-17	19137-19146	cingulate	_	
121-18	19147-19152	gyrus	_	
121-19	19152-19153	,	_	
121-20	19154-19164	precentral	_	
121-21	19165-19170	gyrus	_	
121-22	19170-19171	,	_	
121-23	19172-19187	Juxtapositional	_	
121-24	19188-19194	Lobule	_	
121-25	19195-19201	Cortex	_	
121-26	19202-19203	(	_	
121-27	19203-19211	formerly	_	
121-28	19212-19225	Supplementary	_	
121-29	19226-19231	Motor	_	
121-30	19232-19238	Cortex	_	
121-31	19238-19239	)	_	
121-32	19239-19240	,	_	
121-33	19241-19250	precuneus	_	
121-34	19251-19257	cortex	_	
121-35	19257-19258	,	_	
121-36	19259-19266	lateral	_	
121-37	19267-19276	occipital	_	
121-38	19277-19285	cortices	_	
121-39	19285-19286	,	_	
121-40	19287-19295	temporal	_	
121-41	19296-19301	gyrus	_	
121-42	19302-19305	and	_	
121-43	19306-19317	subcallosal	_	
121-44	19318-19324	cortex	_	
121-45	19324-19325	.	_	

#Text=Default mode network (DMN) is the set of brain regions that are consistently more activated during resting condition and routinely exhibit a decrease in activity during task performance.
122-1	19326-19333	Default	_	
122-2	19334-19338	mode	_	
122-3	19339-19346	network	_	
122-4	19347-19348	(	_	
122-5	19348-19351	DMN	_	
122-6	19351-19352	)	_	
122-7	19353-19355	is	_	
122-8	19356-19359	the	_	
122-9	19360-19363	set	_	
122-10	19364-19366	of	_	
122-11	19367-19372	brain	_	
122-12	19373-19380	regions	_	
122-13	19381-19385	that	_	
122-14	19386-19389	are	_	
122-15	19390-19402	consistently	_	
122-16	19403-19407	more	_	
122-17	19408-19417	activated	_	
122-18	19418-19424	during	_	
122-19	19425-19432	resting	_	
122-20	19433-19442	condition	_	
122-21	19443-19446	and	_	
122-22	19447-19456	routinely	_	
122-23	19457-19464	exhibit	_	
122-24	19465-19466	a	_	
122-25	19467-19475	decrease	_	
122-26	19476-19478	in	_	
122-27	19479-19487	activity	_	
122-28	19488-19494	during	_	
122-29	19495-19499	task	_	
122-30	19500-19511	performance	_	
122-31	19511-19512	.	_	

#Text=It is often described as a unitary, homogeneous system that is largely responsible for many aspects of internally-directed cognition, such as episodic memory, theory of mind, self-evaluation, and introspection.
123-1	19513-19515	It	_	
123-2	19516-19518	is	_	
123-3	19519-19524	often	_	
123-4	19525-19534	described	_	
123-5	19535-19537	as	_	
123-6	19538-19539	a	_	
123-7	19540-19547	unitary	_	
123-8	19547-19548	,	_	
123-9	19549-19560	homogeneous	_	
123-10	19561-19567	system	_	
123-11	19568-19572	that	_	
123-12	19573-19575	is	_	
123-13	19576-19583	largely	_	
123-14	19584-19595	responsible	_	
123-15	19596-19599	for	_	
123-16	19600-19604	many	_	
123-17	19605-19612	aspects	_	
123-18	19613-19615	of	_	
123-19	19616-19635	internally-directed	_	
123-20	19636-19645	cognition	_	
123-21	19645-19646	,	_	
123-22	19647-19651	such	_	
123-23	19652-19654	as	_	
123-24	19655-19663	episodic	_	
123-25	19664-19670	memory	_	
123-26	19670-19671	,	_	
123-27	19672-19678	theory	_	
123-28	19679-19681	of	_	
123-29	19682-19686	mind	_	
123-30	19686-19687	,	_	
123-31	19688-19703	self-evaluation	_	
123-32	19703-19704	,	_	
123-33	19705-19708	and	_	
123-34	19709-19722	introspection	_	
123-35	19722-19723	.	_	

#Text=Our results are well supported by earlier resting state fMRI study that has shown altered functional connectivity in schizophrenia patients.
124-1	19724-19727	Our	_	
124-2	19728-19735	results	_	
124-3	19736-19739	are	_	
124-4	19740-19744	well	_	
124-5	19745-19754	supported	_	
124-6	19755-19757	by	_	
124-7	19758-19765	earlier	_	
124-8	19766-19773	resting	_	
124-9	19774-19779	state	_	
124-10	19780-19784	fMRI	_	
124-11	19785-19790	study	_	
124-12	19791-19795	that	_	
124-13	19796-19799	has	_	
124-14	19800-19805	shown	_	
124-15	19806-19813	altered	_	
124-16	19814-19824	functional	_	
124-17	19825-19837	connectivity	_	
124-18	19838-19840	in	_	
124-19	19841-19854	schizophrenia	_	
124-20	19855-19863	patients	_	
124-21	19863-19864	.	_	

#Text=None of the networks correlated statistically significantly with severity/duration of illness or the functional status.
125-1	19865-19869	None	_	
125-2	19870-19872	of	_	
125-3	19873-19876	the	_	
125-4	19877-19885	networks	_	
125-5	19886-19896	correlated	_	
125-6	19897-19910	statistically	_	
125-7	19911-19924	significantly	_	
125-8	19925-19929	with	_	
125-9	19930-19938	severity	_	
125-10	19938-19939	/	_	
125-11	19939-19947	duration	_	
125-12	19948-19950	of	_	
125-13	19951-19958	illness	_	
125-14	19959-19961	or	_	
125-15	19962-19965	the	_	
125-16	19966-19976	functional	_	
125-17	19977-19983	status	_	
125-18	19983-19984	.	_	

#Text=Absence of correlation suggests that a wider array of clinical and demographic features need to be examined.
126-1	19985-19992	Absence	_	
126-2	19993-19995	of	_	
126-3	19996-20007	correlation	_	
126-4	20008-20016	suggests	_	
126-5	20017-20021	that	_	
126-6	20022-20023	a	_	
126-7	20024-20029	wider	_	
126-8	20030-20035	array	_	
126-9	20036-20038	of	_	
126-10	20039-20047	clinical	_	
126-11	20048-20051	and	_	
126-12	20052-20063	demographic	_	
126-13	20064-20072	features	_	
126-14	20073-20077	need	_	
126-15	20078-20080	to	_	
126-16	20081-20083	be	_	
126-17	20084-20092	examined	_	
126-18	20092-20093	.	_	

#Text=In addition, the hypoconnectivity may be a consequence of treatment and course of the illness.
127-1	20094-20096	In	_	
127-2	20097-20105	addition	_	
127-3	20105-20106	,	_	
127-4	20107-20110	the	_	
127-5	20111-20127	hypoconnectivity	_	
127-6	20128-20131	may	_	
127-7	20132-20134	be	_	
127-8	20135-20136	a	_	
127-9	20137-20148	consequence	_	
127-10	20149-20151	of	_	
127-11	20152-20161	treatment	_	
127-12	20162-20165	and	_	
127-13	20166-20172	course	_	
127-14	20173-20175	of	_	
127-15	20176-20179	the	_	
127-16	20180-20187	illness	_	
127-17	20187-20188	.	_	

#Text=This is supported by a recent study that reported increased network homogeneity in the posterior cingulate and cerebellum among first-episode medication-naïve schizophrenia patients correlated with positive and negative symptoms.
128-1	20189-20193	This	_	
128-2	20194-20196	is	_	
128-3	20197-20206	supported	_	
128-4	20207-20209	by	_	
128-5	20210-20211	a	_	
128-6	20212-20218	recent	_	
128-7	20219-20224	study	_	
128-8	20225-20229	that	_	
128-9	20230-20238	reported	_	
128-10	20239-20248	increased	_	
128-11	20249-20256	network	_	
128-12	20257-20268	homogeneity	_	
128-13	20269-20271	in	_	
128-14	20272-20275	the	_	
128-15	20276-20285	posterior	_	
128-16	20286-20295	cingulate	_	
128-17	20296-20299	and	_	
128-18	20300-20310	cerebellum	_	
128-19	20311-20316	among	_	
128-20	20317-20330	first-episode	_	
128-21	20331-20347	medication-naïve	_	
128-22	20348-20361	schizophrenia	_	
128-23	20362-20370	patients	_	
128-24	20371-20381	correlated	_	
128-25	20382-20386	with	_	
128-26	20387-20395	positive	_	
128-27	20396-20399	and	_	
128-28	20400-20408	negative	_	
128-29	20409-20417	symptoms	_	
128-30	20417-20418	.	_	

#Text=A longitudinal design could address such questions.
129-1	20419-20420	A	_	
129-2	20421-20433	longitudinal	_	
129-3	20434-20440	design	_	
129-4	20441-20446	could	_	
129-5	20447-20454	address	_	
129-6	20455-20459	such	_	
129-7	20460-20469	questions	_	
129-8	20469-20470	.	_	

#Text=Trends were noticed in the correlation of DMN and right fronto-parietal network with severity of psychopathology.
130-1	20471-20477	Trends	_	
130-2	20478-20482	were	_	
130-3	20483-20490	noticed	_	
130-4	20491-20493	in	_	
130-5	20494-20497	the	_	
130-6	20498-20509	correlation	_	
130-7	20510-20512	of	_	
130-8	20513-20516	DMN	_	
130-9	20517-20520	and	_	
130-10	20521-20526	right	_	
130-11	20527-20542	fronto-parietal	_	
130-12	20543-20550	network	_	
130-13	20551-20555	with	_	
130-14	20556-20564	severity	_	
130-15	20565-20567	of	_	
130-16	20568-20583	psychopathology	_	
130-17	20583-20584	.	_	

#Text=A sample with adequate power could address such relationship with treatment.
131-1	20585-20586	A	_	
131-2	20587-20593	sample	_	
131-3	20594-20598	with	_	
131-4	20599-20607	adequate	_	
131-5	20608-20613	power	_	
131-6	20614-20619	could	_	
131-7	20620-20627	address	_	
131-8	20628-20632	such	_	
131-9	20633-20645	relationship	_	
131-10	20646-20650	with	_	
131-11	20651-20660	treatment	_	
131-12	20660-20661	.	_	

#Text=The limitations of our study include a cross-sectional design and varying dose, duration and type of medication.
132-1	20662-20665	The	_	
132-2	20666-20677	limitations	_	
132-3	20678-20680	of	_	
132-4	20681-20684	our	_	
132-5	20685-20690	study	_	
132-6	20691-20698	include	_	
132-7	20699-20700	a	_	
132-8	20701-20716	cross-sectional	_	
132-9	20717-20723	design	_	
132-10	20724-20727	and	_	
132-11	20728-20735	varying	_	
132-12	20736-20740	dose	_	
132-13	20740-20741	,	_	
132-14	20742-20750	duration	_	
132-15	20751-20754	and	_	
132-16	20755-20759	type	_	
132-17	20760-20762	of	_	
132-18	20763-20773	medication	_	
132-19	20773-20774	.	_	

#Text=However, early course of the illness among schizophrenia participants mitigate this to some extent.
133-1	20775-20782	However	_	
133-2	20782-20783	,	_	
133-3	20784-20789	early	_	
133-4	20790-20796	course	_	
133-5	20797-20799	of	_	
133-6	20800-20803	the	_	
133-7	20804-20811	illness	_	
133-8	20812-20817	among	_	
133-9	20818-20831	schizophrenia	_	
133-10	20832-20844	participants	_	
133-11	20845-20853	mitigate	_	
133-12	20854-20858	this	_	
133-13	20859-20861	to	_	
133-14	20862-20866	some	_	
133-15	20867-20873	extent	_	
133-16	20873-20874	.	_	

#Text=As nicotine use is a common comorbidity in schizophrenia with 48% prevalence in Indian studies, for feasibility of recruitment nicotine dependence was not used as an exclusion criterion, and only few participants were nicotine dependent.
134-1	20875-20877	As	_	
134-2	20878-20886	nicotine	_	
134-3	20887-20890	use	_	
134-4	20891-20893	is	_	
134-5	20894-20895	a	_	
134-6	20896-20902	common	_	
134-7	20903-20914	comorbidity	_	
134-8	20915-20917	in	_	
134-9	20918-20931	schizophrenia	_	
134-10	20932-20936	with	_	
134-11	20937-20940	48%	_	
134-12	20941-20951	prevalence	_	
134-13	20952-20954	in	_	
134-14	20955-20961	Indian	_	
134-15	20962-20969	studies	_	
134-16	20969-20970	,	_	
134-17	20971-20974	for	_	
134-18	20975-20986	feasibility	_	
134-19	20987-20989	of	_	
134-20	20990-21001	recruitment	_	
134-21	21002-21010	nicotine	_	
134-22	21011-21021	dependence	_	
134-23	21022-21025	was	_	
134-24	21026-21029	not	_	
134-25	21030-21034	used	_	
134-26	21035-21037	as	_	
134-27	21038-21040	an	_	
134-28	21041-21050	exclusion	_	
134-29	21051-21060	criterion	_	
134-30	21060-21061	,	_	
134-31	21062-21065	and	_	
134-32	21066-21070	only	_	
134-33	21071-21074	few	_	
134-34	21075-21087	participants	_	
134-35	21088-21092	were	_	
134-36	21093-21101	nicotine	_	
134-37	21102-21111	dependent	_	
134-38	21111-21112	.	_	

#Text=Correlation with cognitive performance could be useful in future studies.
135-1	21113-21124	Correlation	_	
135-2	21125-21129	with	_	
135-3	21130-21139	cognitive	_	
135-4	21140-21151	performance	_	
135-5	21152-21157	could	_	
135-6	21158-21160	be	_	
135-7	21161-21167	useful	_	
135-8	21168-21170	in	_	
135-9	21171-21177	future	_	
135-10	21178-21185	studies	_	
135-11	21185-21186	.	_	

#Text=We could not formally measure socioeconomic status of the participants which could be a limitation of the study but on occupation status, there was no significant difference between patients and controls.
136-1	21187-21189	We	_	
136-2	21190-21195	could	_	
136-3	21196-21199	not	_	
136-4	21200-21208	formally	_	
136-5	21209-21216	measure	_	
136-6	21217-21230	socioeconomic	_	
136-7	21231-21237	status	_	
136-8	21238-21240	of	_	
136-9	21241-21244	the	_	
136-10	21245-21257	participants	_	
136-11	21258-21263	which	_	
136-12	21264-21269	could	_	
136-13	21270-21272	be	_	
136-14	21273-21274	a	_	
136-15	21275-21285	limitation	_	
136-16	21286-21288	of	_	
136-17	21289-21292	the	_	
136-18	21293-21298	study	_	
136-19	21299-21302	but	_	
136-20	21303-21305	on	_	
136-21	21306-21316	occupation	_	
136-22	21317-21323	status	_	
136-23	21323-21324	,	_	
136-24	21325-21330	there	_	
136-25	21331-21334	was	_	
136-26	21335-21337	no	_	
136-27	21338-21349	significant	_	
136-28	21350-21360	difference	_	
136-29	21361-21368	between	_	
136-30	21369-21377	patients	_	
136-31	21378-21381	and	_	
136-32	21382-21390	controls	_	
136-33	21390-21391	.	_	

#Text=The present study showed altered resting-state functional connectivity networks, including the left frontoparietal network, lateral and medial visual network, motor network, DMN and auditory network in early-course schizophrenia patients compared to controls.
137-1	21392-21395	The	_	
137-2	21396-21403	present	_	
137-3	21404-21409	study	_	
137-4	21410-21416	showed	_	
137-5	21417-21424	altered	_	
137-6	21425-21438	resting-state	_	
137-7	21439-21449	functional	_	
137-8	21450-21462	connectivity	_	
137-9	21463-21471	networks	_	
137-10	21471-21472	,	_	
137-11	21473-21482	including	_	
137-12	21483-21486	the	_	
137-13	21487-21491	left	_	
137-14	21492-21506	frontoparietal	_	
137-15	21507-21514	network	_	
137-16	21514-21515	,	_	
137-17	21516-21523	lateral	_	
137-18	21524-21527	and	_	
137-19	21528-21534	medial	_	
137-20	21535-21541	visual	_	
137-21	21542-21549	network	_	
137-22	21549-21550	,	_	
137-23	21551-21556	motor	_	
137-24	21557-21564	network	_	
137-25	21564-21565	,	_	
137-26	21566-21569	DMN	_	
137-27	21570-21573	and	_	
137-28	21574-21582	auditory	_	
137-29	21583-21590	network	_	
137-30	21591-21593	in	_	
137-31	21594-21606	early-course	_	
137-32	21607-21620	schizophrenia	_	
137-33	21621-21629	patients	_	
137-34	21630-21638	compared	_	
137-35	21639-21641	to	_	
137-36	21642-21650	controls	_	
137-37	21650-21651	.	_	

#Text=These network abnormalities did not correlate with positive/negative symptoms or illness duration suggesting that the network hypoconnectivities may not be sufficient for these symptoms.
138-1	21652-21657	These	_	
138-2	21658-21665	network	_	
138-3	21666-21679	abnormalities	_	
138-4	21680-21683	did	_	
138-5	21684-21687	not	_	
138-6	21688-21697	correlate	_	
138-7	21698-21702	with	_	
138-8	21703-21711	positive	_	
138-9	21711-21712	/	_	
138-10	21712-21720	negative	_	
138-11	21721-21729	symptoms	_	
138-12	21730-21732	or	_	
138-13	21733-21740	illness	_	
138-14	21741-21749	duration	_	
138-15	21750-21760	suggesting	_	
138-16	21761-21765	that	_	
138-17	21766-21769	the	_	
138-18	21770-21777	network	_	
138-19	21778-21796	hypoconnectivities	_	
138-20	21797-21800	may	_	
138-21	21801-21804	not	_	
138-22	21805-21807	be	_	
138-23	21808-21818	sufficient	_	
138-24	21819-21822	for	_	
138-25	21823-21828	these	_	
138-26	21829-21837	symptoms	_	
138-27	21837-21838	.	_	

#Text=Supplementary Material
#Text=           Contributors         
#Text=Aastha Sharma: Data acquisition, Review of literature, preparation of manuscript.
139-1	21839-21852	Supplementary	_	
139-2	21853-21861	Material	_	
139-3	21873-21885	Contributors	_	
139-4	21895-21901	Aastha	_	
139-5	21902-21908	Sharma	_	
139-6	21908-21909	:	_	
139-7	21910-21914	Data	_	
139-8	21915-21926	acquisition	_	
139-9	21926-21927	,	_	
139-10	21928-21934	Review	_	
139-11	21935-21937	of	_	
139-12	21938-21948	literature	_	
139-13	21948-21949	,	_	
139-14	21950-21961	preparation	_	
139-15	21962-21964	of	_	
139-16	21965-21975	manuscript	_	
139-17	21975-21976	.	_	

#Text=Arvind Kumar: Review of literature, manuscript editing.
140-1	21977-21983	Arvind	_	
140-2	21984-21989	Kumar	_	
140-3	21989-21990	:	_	
140-4	21991-21997	Review	_	
140-5	21998-22000	of	_	
140-6	22001-22011	literature	_	
140-7	22011-22012	,	_	
140-8	22013-22023	manuscript	_	
140-9	22024-22031	editing	_	
140-10	22031-22032	.	_	

#Text=Sadhana Singh: MRI data collection, analysis.
141-1	22033-22040	Sadhana	_	
141-2	22041-22046	Singh	_	
141-3	22046-22047	:	_	
141-4	22048-22051	MRI	_	
141-5	22052-22056	data	_	
141-6	22057-22067	collection	_	
141-7	22067-22068	,	_	
141-8	22069-22077	analysis	_	
141-9	22077-22078	.	_	

#Text=Triptish Bhatia: Concept, manuscript review and editing.
142-1	22079-22087	Triptish	_	
142-2	22088-22094	Bhatia	_	
142-3	22094-22095	:	_	
142-4	22096-22103	Concept	_	
142-5	22103-22104	,	_	
142-6	22105-22115	manuscript	_	
142-7	22116-22122	review	_	
142-8	22123-22126	and	_	
142-9	22127-22134	editing	_	
142-10	22134-22135	.	_	

#Text=R.
143-1	22136-22137	R	_	
143-2	22137-22138	.	_	

#Text=P.
144-1	22139-22140	P	_	
144-2	22140-22141	.	_	

#Text=Beniwal: Design, manuscript editing, review.
145-1	22142-22149	Beniwal	_	
145-2	22149-22150	:	_	
145-3	22151-22157	Design	_	
145-4	22157-22158	,	_	
145-5	22159-22169	manuscript	_	
145-6	22170-22177	editing	_	
145-7	22177-22178	,	_	
145-8	22179-22185	review	_	
145-9	22185-22186	.	_	

#Text=Subhash Khushu: MRI review, analysis.
146-1	22187-22194	Subhash	_	
146-2	22195-22201	Khushu	_	
146-3	22201-22202	:	_	
146-4	22203-22206	MRI	_	
146-5	22207-22213	review	_	
146-6	22213-22214	,	_	
146-7	22215-22223	analysis	_	
146-8	22223-22224	.	_	

#Text=Konasale M.
147-1	22225-22233	Konasale	_	
147-2	22234-22235	M	_	
147-3	22235-22236	.	_	

#Text=Prasad: Manuscript review and editing.
148-1	22237-22243	Prasad	_	
148-2	22243-22244	:	_	
148-3	22245-22255	Manuscript	_	
148-4	22256-22262	review	_	
148-5	22263-22266	and	_	
148-6	22267-22274	editing	_	
148-7	22274-22275	.	_	

#Text=Smita N Deshpande: Concept, design, manuscript editing, review.
149-1	22276-22281	Smita	_	
149-2	22282-22283	N	_	
149-3	22284-22293	Deshpande	_	
149-4	22293-22294	:	_	
149-5	22295-22302	Concept	_	
149-6	22302-22303	,	_	
149-7	22304-22310	design	_	
149-8	22310-22311	,	_	
149-9	22312-22322	manuscript	_	
149-10	22323-22330	editing	_	
149-11	22330-22331	,	_	
149-12	22332-22338	review	_	
149-13	22338-22339	.	_	

#Text=Conflict of interest         
#Text=There is no conflict of interest reported by any of the authors.
150-1	22351-22359	Conflict	_	
150-2	22360-22362	of	_	
150-3	22363-22371	interest	_	
150-4	22381-22386	There	_	
150-5	22387-22389	is	_	
150-6	22390-22392	no	_	
150-7	22393-22401	conflict	_	
150-8	22402-22404	of	_	
150-9	22405-22413	interest	_	
150-10	22414-22422	reported	_	
150-11	22423-22425	by	_	
150-12	22426-22429	any	_	
150-13	22430-22432	of	_	
150-14	22433-22436	the	_	
150-15	22437-22444	authors	_	
150-16	22444-22445	.	_	

#Text=Appendix A.
151-1	22446-22454	Appendix	_	
151-2	22455-22456	A	_	
151-3	22456-22457	.	_	

#Text=Supplementary material
#Text=Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.pscychresns.2017.11.013.
152-1	22458-22471	Supplementary	_	
152-2	22472-22480	material	_	
152-3	22481-22494	Supplementary	_	
152-4	22495-22499	data	_	
152-5	22500-22510	associated	_	
152-6	22511-22515	with	_	
152-7	22516-22520	this	_	
152-8	22521-22528	article	_	
152-9	22529-22532	can	_	
152-10	22533-22535	be	_	
152-11	22536-22541	found	_	
152-12	22542-22544	in	_	
152-13	22545-22548	the	_	
152-14	22549-22555	online	_	
152-15	22556-22563	version	_	
152-16	22564-22566	at	_	
152-17	22567-22571	http	_	
152-18	22571-22572	:	_	
152-19	22572-22573	/	_	
152-20	22573-22574	/	_	
152-21	22574-22584	dx.doi.org	_	
152-22	22584-22585	/	_	
152-23	22585-22592	10.1016	_	
152-24	22592-22593	/	_	
152-25	22593-22606	j.pscychresns	_	
152-26	22606-22618	.2017.11.013	_	
152-27	22618-22619	.	_	

#Text=The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations
#Text=Negative v positive schizophrenia.
153-1	22620-22623	The	_	
153-2	22624-22629	Scale	_	
153-3	22630-22633	for	_	
153-4	22634-22637	the	_	
153-5	22638-22648	Assessment	_	
153-6	22649-22651	of	_	
153-7	22652-22660	Negative	_	
153-8	22661-22669	Symptoms	_	
153-9	22670-22671	(	_	
153-10	22671-22675	SANS	_	
153-11	22675-22676	)	_	
153-12	22676-22677	:	_	
153-13	22678-22688	conceptual	_	
153-14	22689-22692	and	_	
153-15	22693-22704	theoretical	_	
153-16	22705-22716	foundations	_	
153-17	22717-22725	Negative	_	
153-18	22726-22727	v	_	
153-19	22728-22736	positive	_	
153-20	22737-22750	schizophrenia	_	
153-21	22750-22751	.	_	

#Text=Definition and validation
#Text=Resting-state fMRI connectivity impairment in schizophrenia and bipolar disorder
#Text=Investigations into resting-state connectivity using independent component analysis
#Text=Do inter-regional gray-matter volumetric correlations reflect altered functional connectivity in high-risk offspring of schizophrenia patients?
154-1	22752-22762	Definition	_	
154-2	22763-22766	and	_	
154-3	22767-22777	validation	_	
154-4	22778-22791	Resting-state	_	
154-5	22792-22796	fMRI	_	
154-6	22797-22809	connectivity	_	
154-7	22810-22820	impairment	_	
154-8	22821-22823	in	_	
154-9	22824-22837	schizophrenia	_	
154-10	22838-22841	and	_	
154-11	22842-22849	bipolar	_	
154-12	22850-22858	disorder	_	
154-13	22859-22873	Investigations	_	
154-14	22874-22878	into	_	
154-15	22879-22892	resting-state	_	
154-16	22893-22905	connectivity	_	
154-17	22906-22911	using	_	
154-18	22912-22923	independent	_	
154-19	22924-22933	component	_	
154-20	22934-22942	analysis	_	
154-21	22943-22945	Do	_	
154-22	22946-22960	inter-regional	_	
154-23	22961-22972	gray-matter	_	
154-24	22973-22983	volumetric	_	
154-25	22984-22996	correlations	_	
154-26	22997-23004	reflect	_	
154-27	23005-23012	altered	_	
154-28	23013-23023	functional	_	
154-29	23024-23036	connectivity	_	
154-30	23037-23039	in	_	
154-31	23040-23049	high-risk	_	
154-32	23050-23059	offspring	_	
154-33	23060-23062	of	_	
154-34	23063-23076	schizophrenia	_	
154-35	23077-23085	patients	_	
154-36	23085-23086	?	_	

#Text=Functional connectivity in the motor cortex of resting human brain using echo ‐ planar mri
#Text=Modulation of temporally coherent brain networks estimated using ICA at rest and during cognitive tasks
#Text=A fronot-parietal network for rapid visual information processing: a PET study of sustained attention and working memory
#Text=Consistent resting-state networks across healthy subjects
#Text=A Hindi version of the diagnostic interview for genetic studies
#Text=Regional atrophy of transcallosal prefrontal connections in cognitively normal APOE epsilon4 carriers
#Text=Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging
#Text=Clinical applications of resting state functional connectivity
#Text=Spatial registration and normalization of images
#Text=Aberrant “default mode” functional connectivity in schizophrenia
#Text=Decreased resting-state interhemispheric functional connectivity in unaffected siblings of schizophrenia patients
#Text=Dissociation of anatomical and functional alterations of the default-mode network in first-episode, drug-naive schizophrenia
#Text=Abnormal default-mode network homogeneity in first-episode, drug-naive schizophrenia at rest
#Text=Improved optimization for the robust and accurate linear registration and motion correction of brain images
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=White matter impairments in autism, evidence from voxel-based morphometry and diffusion tensor imaging
#Text=Relationship between white matter integrity, attention, and memory in schizophrenia: a diffusion tensor imaging study
#Text=DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity
#Text=Uncinate fasciculus findings in schizophrenia: a magnetic resonance diffusion tensor imaging study
#Text=Resting-state fMRI: a review of methods and clinical applications
#Text=Association of cerebral deficits with clinical symptoms in antipsychotic-naive first-episode schizophrenia: an optimized voxel-based morphometry and resting state functional connectivity study
#Text=Functional connectivity and brain networks in schizophrenia
#Text=Default mode network activity in schizophrenia studied at resting state using probabilistic ICA
#Text=Progressive changes of white matter integrity in schizophrenia revealed by diffusion tensor imaging
#Text=The diminished interhemispheric connectivity correlates with negative symptoms and cognitive impairment in first-episode schizophrenia
#Text=Nonparametric permutation tests for functional neuroimaging: a primer with examples
#Text=Diagnostic interview for genetic studies.
155-1	23087-23097	Functional	_	
155-2	23098-23110	connectivity	_	
155-3	23111-23113	in	_	
155-4	23114-23117	the	_	
155-5	23118-23123	motor	_	
155-6	23124-23130	cortex	_	
155-7	23131-23133	of	_	
155-8	23134-23141	resting	_	
155-9	23142-23147	human	_	
155-10	23148-23153	brain	_	
155-11	23154-23159	using	_	
155-12	23160-23164	echo	_	
155-13	23165-23166	‐	_	
155-14	23167-23173	planar	_	
155-15	23174-23177	mri	_	
155-16	23178-23188	Modulation	_	
155-17	23189-23191	of	_	
155-18	23192-23202	temporally	_	
155-19	23203-23211	coherent	_	
155-20	23212-23217	brain	_	
155-21	23218-23226	networks	_	
155-22	23227-23236	estimated	_	
155-23	23237-23242	using	_	
155-24	23243-23246	ICA	_	
155-25	23247-23249	at	_	
155-26	23250-23254	rest	_	
155-27	23255-23258	and	_	
155-28	23259-23265	during	_	
155-29	23266-23275	cognitive	_	
155-30	23276-23281	tasks	_	
155-31	23282-23283	A	_	
155-32	23284-23299	fronot-parietal	_	
155-33	23300-23307	network	_	
155-34	23308-23311	for	_	
155-35	23312-23317	rapid	_	
155-36	23318-23324	visual	_	
155-37	23325-23336	information	_	
155-38	23337-23347	processing	_	
155-39	23347-23348	:	_	
155-40	23349-23350	a	_	
155-41	23351-23354	PET	_	
155-42	23355-23360	study	_	
155-43	23361-23363	of	_	
155-44	23364-23373	sustained	_	
155-45	23374-23383	attention	_	
155-46	23384-23387	and	_	
155-47	23388-23395	working	_	
155-48	23396-23402	memory	_	
155-49	23403-23413	Consistent	_	
155-50	23414-23427	resting-state	_	
155-51	23428-23436	networks	_	
155-52	23437-23443	across	_	
155-53	23444-23451	healthy	_	
155-54	23452-23460	subjects	_	
155-55	23461-23462	A	_	
155-56	23463-23468	Hindi	_	
155-57	23469-23476	version	_	
155-58	23477-23479	of	_	
155-59	23480-23483	the	_	
155-60	23484-23494	diagnostic	_	
155-61	23495-23504	interview	_	
155-62	23505-23508	for	_	
155-63	23509-23516	genetic	_	
155-64	23517-23524	studies	_	
155-65	23525-23533	Regional	_	
155-66	23534-23541	atrophy	_	
155-67	23542-23544	of	_	
155-68	23545-23558	transcallosal	_	
155-69	23559-23569	prefrontal	_	
155-70	23570-23581	connections	_	
155-71	23582-23584	in	_	
155-72	23585-23596	cognitively	_	
155-73	23597-23603	normal	_	
155-74	23604-23608	APOE	_	
155-75	23609-23617	epsilon4	_	
155-76	23618-23626	carriers	_	
155-77	23627-23638	Spontaneous	_	
155-78	23639-23651	fluctuations	_	
155-79	23652-23654	in	_	
155-80	23655-23660	brain	_	
155-81	23661-23669	activity	_	
155-82	23670-23678	observed	_	
155-83	23679-23683	with	_	
155-84	23684-23694	functional	_	
155-85	23695-23703	magnetic	_	
155-86	23704-23713	resonance	_	
155-87	23714-23721	imaging	_	
155-88	23722-23730	Clinical	_	
155-89	23731-23743	applications	_	
155-90	23744-23746	of	_	
155-91	23747-23754	resting	_	
155-92	23755-23760	state	_	
155-93	23761-23771	functional	_	
155-94	23772-23784	connectivity	_	
155-95	23785-23792	Spatial	_	
155-96	23793-23805	registration	_	
155-97	23806-23809	and	_	
155-98	23810-23823	normalization	_	
155-99	23824-23826	of	_	
155-100	23827-23833	images	_	
155-101	23834-23842	Aberrant	_	
155-102	23843-23844	“	_	
155-103	23844-23851	default	_	
155-104	23852-23856	mode	_	
155-105	23856-23857	”	_	
155-106	23858-23868	functional	_	
155-107	23869-23881	connectivity	_	
155-108	23882-23884	in	_	
155-109	23885-23898	schizophrenia	_	
155-110	23899-23908	Decreased	_	
155-111	23909-23922	resting-state	_	
155-112	23923-23939	interhemispheric	_	
155-113	23940-23950	functional	_	
155-114	23951-23963	connectivity	_	
155-115	23964-23966	in	_	
155-116	23967-23977	unaffected	_	
155-117	23978-23986	siblings	_	
155-118	23987-23989	of	_	
155-119	23990-24003	schizophrenia	_	
155-120	24004-24012	patients	_	
155-121	24013-24025	Dissociation	_	
155-122	24026-24028	of	_	
155-123	24029-24039	anatomical	_	
155-124	24040-24043	and	_	
155-125	24044-24054	functional	_	
155-126	24055-24066	alterations	_	
155-127	24067-24069	of	_	
155-128	24070-24073	the	_	
155-129	24074-24086	default-mode	_	
155-130	24087-24094	network	_	
155-131	24095-24097	in	_	
155-132	24098-24111	first-episode	_	
155-133	24111-24112	,	_	
155-134	24113-24123	drug-naive	_	
155-135	24124-24137	schizophrenia	_	
155-136	24138-24146	Abnormal	_	
155-137	24147-24159	default-mode	_	
155-138	24160-24167	network	_	
155-139	24168-24179	homogeneity	_	
155-140	24180-24182	in	_	
155-141	24183-24196	first-episode	_	
155-142	24196-24197	,	_	
155-143	24198-24208	drug-naive	_	
155-144	24209-24222	schizophrenia	_	
155-145	24223-24225	at	_	
155-146	24226-24230	rest	_	
155-147	24231-24239	Improved	_	
155-148	24240-24252	optimization	_	
155-149	24253-24256	for	_	
155-150	24257-24260	the	_	
155-151	24261-24267	robust	_	
155-152	24268-24271	and	_	
155-153	24272-24280	accurate	_	
155-154	24281-24287	linear	_	
155-155	24288-24300	registration	_	
155-156	24301-24304	and	_	
155-157	24305-24311	motion	_	
155-158	24312-24322	correction	_	
155-159	24323-24325	of	_	
155-160	24326-24331	brain	_	
155-161	24332-24338	images	_	
155-162	24339-24342	The	_	
155-163	24343-24351	positive	_	
155-164	24352-24355	and	_	
155-165	24356-24364	negative	_	
155-166	24365-24373	syndrome	_	
155-167	24374-24379	scale	_	
155-168	24380-24381	(	_	
155-169	24381-24386	PANSS	_	
155-170	24386-24387	)	_	
155-171	24388-24391	for	_	
155-172	24392-24405	schizophrenia	_	
155-173	24406-24411	White	_	
155-174	24412-24418	matter	_	
155-175	24419-24430	impairments	_	
155-176	24431-24433	in	_	
155-177	24434-24440	autism	_	
155-178	24440-24441	,	_	
155-179	24442-24450	evidence	_	
155-180	24451-24455	from	_	
155-181	24456-24467	voxel-based	_	
155-182	24468-24479	morphometry	_	
155-183	24480-24483	and	_	
155-184	24484-24493	diffusion	_	
155-185	24494-24500	tensor	_	
155-186	24501-24508	imaging	_	
155-187	24509-24521	Relationship	_	
155-188	24522-24529	between	_	
155-189	24530-24535	white	_	
155-190	24536-24542	matter	_	
155-191	24543-24552	integrity	_	
155-192	24552-24553	,	_	
155-193	24554-24563	attention	_	
155-194	24563-24564	,	_	
155-195	24565-24568	and	_	
155-196	24569-24575	memory	_	
155-197	24576-24578	in	_	
155-198	24579-24592	schizophrenia	_	
155-199	24592-24593	:	_	
155-200	24594-24595	a	_	
155-201	24596-24605	diffusion	_	
155-202	24606-24612	tensor	_	
155-203	24613-24620	imaging	_	
155-204	24621-24626	study	_	
155-205	24627-24630	DTI	_	
155-206	24631-24634	and	_	
155-207	24635-24638	MTR	_	
155-208	24639-24652	abnormalities	_	
155-209	24653-24655	in	_	
155-210	24656-24669	schizophrenia	_	
155-211	24669-24670	:	_	
155-212	24671-24679	analysis	_	
155-213	24680-24682	of	_	
155-214	24683-24688	white	_	
155-215	24689-24695	matter	_	
155-216	24696-24705	integrity	_	
155-217	24706-24714	Uncinate	_	
155-218	24715-24725	fasciculus	_	
155-219	24726-24734	findings	_	
155-220	24735-24737	in	_	
155-221	24738-24751	schizophrenia	_	
155-222	24751-24752	:	_	
155-223	24753-24754	a	_	
155-224	24755-24763	magnetic	_	
155-225	24764-24773	resonance	_	
155-226	24774-24783	diffusion	_	
155-227	24784-24790	tensor	_	
155-228	24791-24798	imaging	_	
155-229	24799-24804	study	_	
155-230	24805-24818	Resting-state	_	
155-231	24819-24823	fMRI	_	
155-232	24823-24824	:	_	
155-233	24825-24826	a	_	
155-234	24827-24833	review	_	
155-235	24834-24836	of	_	
155-236	24837-24844	methods	_	
155-237	24845-24848	and	_	
155-238	24849-24857	clinical	_	
155-239	24858-24870	applications	_	
155-240	24871-24882	Association	_	
155-241	24883-24885	of	_	
155-242	24886-24894	cerebral	_	
155-243	24895-24903	deficits	_	
155-244	24904-24908	with	_	
155-245	24909-24917	clinical	_	
155-246	24918-24926	symptoms	_	
155-247	24927-24929	in	_	
155-248	24930-24949	antipsychotic-naive	_	
155-249	24950-24963	first-episode	_	
155-250	24964-24977	schizophrenia	_	
155-251	24977-24978	:	_	
155-252	24979-24981	an	_	
155-253	24982-24991	optimized	_	
155-254	24992-25003	voxel-based	_	
155-255	25004-25015	morphometry	_	
155-256	25016-25019	and	_	
155-257	25020-25027	resting	_	
155-258	25028-25033	state	_	
155-259	25034-25044	functional	_	
155-260	25045-25057	connectivity	_	
155-261	25058-25063	study	_	
155-262	25064-25074	Functional	_	
155-263	25075-25087	connectivity	_	
155-264	25088-25091	and	_	
155-265	25092-25097	brain	_	
155-266	25098-25106	networks	_	
155-267	25107-25109	in	_	
155-268	25110-25123	schizophrenia	_	
155-269	25124-25131	Default	_	
155-270	25132-25136	mode	_	
155-271	25137-25144	network	_	
155-272	25145-25153	activity	_	
155-273	25154-25156	in	_	
155-274	25157-25170	schizophrenia	_	
155-275	25171-25178	studied	_	
155-276	25179-25181	at	_	
155-277	25182-25189	resting	_	
155-278	25190-25195	state	_	
155-279	25196-25201	using	_	
155-280	25202-25215	probabilistic	_	
155-281	25216-25219	ICA	_	
155-282	25220-25231	Progressive	_	
155-283	25232-25239	changes	_	
155-284	25240-25242	of	_	
155-285	25243-25248	white	_	
155-286	25249-25255	matter	_	
155-287	25256-25265	integrity	_	
155-288	25266-25268	in	_	
155-289	25269-25282	schizophrenia	_	
155-290	25283-25291	revealed	_	
155-291	25292-25294	by	_	
155-292	25295-25304	diffusion	_	
155-293	25305-25311	tensor	_	
155-294	25312-25319	imaging	_	
155-295	25320-25323	The	_	
155-296	25324-25334	diminished	_	
155-297	25335-25351	interhemispheric	_	
155-298	25352-25364	connectivity	_	
155-299	25365-25375	correlates	_	
155-300	25376-25380	with	_	
155-301	25381-25389	negative	_	
155-302	25390-25398	symptoms	_	
155-303	25399-25402	and	_	
155-304	25403-25412	cognitive	_	
155-305	25413-25423	impairment	_	
155-306	25424-25426	in	_	
155-307	25427-25440	first-episode	_	
155-308	25441-25454	schizophrenia	_	
155-309	25455-25468	Nonparametric	_	
155-310	25469-25480	permutation	_	
155-311	25481-25486	tests	_	
155-312	25487-25490	for	_	
155-313	25491-25501	functional	_	
155-314	25502-25514	neuroimaging	_	
155-315	25514-25515	:	_	
155-316	25516-25517	a	_	
155-317	25518-25524	primer	_	
155-318	25525-25529	with	_	
155-319	25530-25538	examples	_	
155-320	25539-25549	Diagnostic	_	
155-321	25550-25559	interview	_	
155-322	25560-25563	for	_	
155-323	25564-25571	genetic	_	
155-324	25572-25579	studies	_	
155-325	25579-25580	.	_	

#Text=Rationale, unique features, and training.
156-1	25581-25590	Rationale	_	
156-2	25590-25591	,	_	
156-3	25592-25598	unique	_	
156-4	25599-25607	features	_	
156-5	25607-25608	,	_	
156-6	25609-25612	and	_	
156-7	25613-25621	training	_	
156-8	25621-25622	.	_	

#Text=NIMH Genetics Initiative
#Text=Morphometry and connectivity of the fronto-parietal verbal working memory network in development
#Text=Episodic memory retrieval, parietal cortex, and the Default Mode Network: functional and topographic analyses
#Text=Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference
#Text=Aberrant default mode functional connectivity in early onset schizophrenia
#Text=Alterations of the occipital lobe in schizophrenia
#Text=Patterns of tobacco consumption among indian men with schizophrenia compared to their male siblings
#Text=Exploring the brain network: a review on resting-state fMRI functional connectivity
#Text=Whole brain resting state functional connectivity abnormalities in schizophrenia
#Text=Functional connectivity of the temporo-parietal region in schizophrenia: effects of rTMS treatment of auditory hallucinations
#Text=Low-frequency BOLD fluctuations demonstrate altered thalamocortical connectivity in schizophrenia
#Text=Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
#Text=Functional resting-state networks are differentially affected in schizophrenia
#Text=Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer’s disease: patterns of linkage disequilibrium and disease/marker association
#Text=Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer’s disease
#Text=Functional dysconnectivity of the dorsolateral prefrontal cortex in first-episode schizophrenia using resting-state fMRI
#Text=Decreased functional connectivity in brain regions of (a) Left Frontoparietal Network (b) Medial Visual Network, (c) Motor Network, (d) Lateral Visual Network, (e) Auditory Network and (f) Default Mode Network.
157-1	25623-25627	NIMH	_	
157-2	25628-25636	Genetics	_	
157-3	25637-25647	Initiative	_	
157-4	25648-25659	Morphometry	_	
157-5	25660-25663	and	_	
157-6	25664-25676	connectivity	_	
157-7	25677-25679	of	_	
157-8	25680-25683	the	_	
157-9	25684-25699	fronto-parietal	_	
157-10	25700-25706	verbal	_	
157-11	25707-25714	working	_	
157-12	25715-25721	memory	_	
157-13	25722-25729	network	_	
157-14	25730-25732	in	_	
157-15	25733-25744	development	_	
157-16	25745-25753	Episodic	_	
157-17	25754-25760	memory	_	
157-18	25761-25770	retrieval	_	
157-19	25770-25771	,	_	
157-20	25772-25780	parietal	_	
157-21	25781-25787	cortex	_	
157-22	25787-25788	,	_	
157-23	25789-25792	and	_	
157-24	25793-25796	the	_	
157-25	25797-25804	Default	_	
157-26	25805-25809	Mode	_	
157-27	25810-25817	Network	_	
157-28	25817-25818	:	_	
157-29	25819-25829	functional	_	
157-30	25830-25833	and	_	
157-31	25834-25845	topographic	_	
157-32	25846-25854	analyses	_	
157-33	25855-25869	Threshold-free	_	
157-34	25870-25877	cluster	_	
157-35	25878-25889	enhancement	_	
157-36	25889-25890	:	_	
157-37	25891-25901	addressing	_	
157-38	25902-25910	problems	_	
157-39	25911-25913	of	_	
157-40	25914-25923	smoothing	_	
157-41	25923-25924	,	_	
157-42	25925-25934	threshold	_	
157-43	25935-25945	dependence	_	
157-44	25946-25949	and	_	
157-45	25950-25962	localisation	_	
157-46	25963-25965	in	_	
157-47	25966-25973	cluster	_	
157-48	25974-25983	inference	_	
157-49	25984-25992	Aberrant	_	
157-50	25993-26000	default	_	
157-51	26001-26005	mode	_	
157-52	26006-26016	functional	_	
157-53	26017-26029	connectivity	_	
157-54	26030-26032	in	_	
157-55	26033-26038	early	_	
157-56	26039-26044	onset	_	
157-57	26045-26058	schizophrenia	_	
157-58	26059-26070	Alterations	_	
157-59	26071-26073	of	_	
157-60	26074-26077	the	_	
157-61	26078-26087	occipital	_	
157-62	26088-26092	lobe	_	
157-63	26093-26095	in	_	
157-64	26096-26109	schizophrenia	_	
157-65	26110-26118	Patterns	_	
157-66	26119-26121	of	_	
157-67	26122-26129	tobacco	_	
157-68	26130-26141	consumption	_	
157-69	26142-26147	among	_	
157-70	26148-26154	indian	_	
157-71	26155-26158	men	_	
157-72	26159-26163	with	_	
157-73	26164-26177	schizophrenia	_	
157-74	26178-26186	compared	_	
157-75	26187-26189	to	_	
157-76	26190-26195	their	_	
157-77	26196-26200	male	_	
157-78	26201-26209	siblings	_	
157-79	26210-26219	Exploring	_	
157-80	26220-26223	the	_	
157-81	26224-26229	brain	_	
157-82	26230-26237	network	_	
157-83	26237-26238	:	_	
157-84	26239-26240	a	_	
157-85	26241-26247	review	_	
157-86	26248-26250	on	_	
157-87	26251-26264	resting-state	_	
157-88	26265-26269	fMRI	_	
157-89	26270-26280	functional	_	
157-90	26281-26293	connectivity	_	
157-91	26294-26299	Whole	_	
157-92	26300-26305	brain	_	
157-93	26306-26313	resting	_	
157-94	26314-26319	state	_	
157-95	26320-26330	functional	_	
157-96	26331-26343	connectivity	_	
157-97	26344-26357	abnormalities	_	
157-98	26358-26360	in	_	
157-99	26361-26374	schizophrenia	_	
157-100	26375-26385	Functional	_	
157-101	26386-26398	connectivity	_	
157-102	26399-26401	of	_	
157-103	26402-26405	the	_	
157-104	26406-26422	temporo-parietal	_	
157-105	26423-26429	region	_	
157-106	26430-26432	in	_	
157-107	26433-26446	schizophrenia	_	
157-108	26446-26447	:	_	
157-109	26448-26455	effects	_	
157-110	26456-26458	of	_	
157-111	26459-26463	rTMS	_	
157-112	26464-26473	treatment	_	
157-113	26474-26476	of	_	
157-114	26477-26485	auditory	_	
157-115	26486-26500	hallucinations	_	
157-116	26501-26514	Low-frequency	_	
157-117	26515-26519	BOLD	_	
157-118	26520-26532	fluctuations	_	
157-119	26533-26544	demonstrate	_	
157-120	26545-26552	altered	_	
157-121	26553-26568	thalamocortical	_	
157-122	26569-26581	connectivity	_	
157-123	26582-26584	in	_	
157-124	26585-26598	schizophrenia	_	
157-125	26599-26612	Hyperactivity	_	
157-126	26613-26616	and	_	
157-127	26617-26634	hyperconnectivity	_	
157-128	26635-26637	of	_	
157-129	26638-26641	the	_	
157-130	26642-26649	default	_	
157-131	26650-26657	network	_	
157-132	26658-26660	in	_	
157-133	26661-26674	schizophrenia	_	
157-134	26675-26678	and	_	
157-135	26679-26681	in	_	
157-136	26682-26694	first-degree	_	
157-137	26695-26704	relatives	_	
157-138	26705-26707	of	_	
157-139	26708-26715	persons	_	
157-140	26716-26720	with	_	
157-141	26721-26734	schizophrenia	_	
157-142	26735-26745	Functional	_	
157-143	26746-26759	resting-state	_	
157-144	26760-26768	networks	_	
157-145	26769-26772	are	_	
157-146	26773-26787	differentially	_	
157-147	26788-26796	affected	_	
157-148	26797-26799	in	_	
157-149	26800-26813	schizophrenia	_	
157-150	26814-26827	Comprehensive	_	
157-151	26828-26836	analysis	_	
157-152	26837-26839	of	_	
157-153	26840-26844	APOE	_	
157-154	26845-26848	and	_	
157-155	26849-26857	selected	_	
157-156	26858-26867	proximate	_	
157-157	26868-26875	markers	_	
157-158	26876-26879	for	_	
157-159	26880-26890	late-onset	_	
157-160	26891-26900	Alzheimer	_	
157-161	26900-26901	’	_	
157-162	26901-26902	s	_	
157-163	26903-26910	disease	_	
157-164	26910-26911	:	_	
157-165	26912-26920	patterns	_	
157-166	26921-26923	of	_	
157-167	26924-26931	linkage	_	
157-168	26932-26946	disequilibrium	_	
157-169	26947-26950	and	_	
157-170	26951-26958	disease	_	
157-171	26958-26959	/	_	
157-172	26959-26965	marker	_	
157-173	26966-26977	association	_	
157-174	26978-26987	Divergent	_	
157-175	26988-26995	network	_	
157-176	26996-27008	connectivity	_	
157-177	27009-27016	changes	_	
157-178	27017-27019	in	_	
157-179	27020-27031	behavioural	_	
157-180	27032-27039	variant	_	
157-181	27040-27054	frontotemporal	_	
157-182	27055-27063	dementia	_	
157-183	27064-27067	and	_	
157-184	27068-27077	Alzheimer	_	
157-185	27077-27078	’	_	
157-186	27078-27079	s	_	
157-187	27080-27087	disease	_	
157-188	27088-27098	Functional	_	
157-189	27099-27114	dysconnectivity	_	
157-190	27115-27117	of	_	
157-191	27118-27121	the	_	
157-192	27122-27134	dorsolateral	_	
157-193	27135-27145	prefrontal	_	
157-194	27146-27152	cortex	_	
157-195	27153-27155	in	_	
157-196	27156-27169	first-episode	_	
157-197	27170-27183	schizophrenia	_	
157-198	27184-27189	using	_	
157-199	27190-27203	resting-state	_	
157-200	27204-27208	fMRI	_	
157-201	27209-27218	Decreased	_	
157-202	27219-27229	functional	_	
157-203	27230-27242	connectivity	_	
157-204	27243-27245	in	_	
157-205	27246-27251	brain	_	
157-206	27252-27259	regions	_	
157-207	27260-27262	of	_	
157-208	27263-27264	(	_	
157-209	27264-27265	a	_	
157-210	27265-27266	)	_	
157-211	27267-27271	Left	_	
157-212	27272-27286	Frontoparietal	_	
157-213	27287-27294	Network	_	
157-214	27295-27296	(	_	
157-215	27296-27297	b	_	
157-216	27297-27298	)	_	
157-217	27299-27305	Medial	_	
157-218	27306-27312	Visual	_	
157-219	27313-27320	Network	_	
157-220	27320-27321	,	_	
157-221	27322-27323	(	_	
157-222	27323-27324	c	_	
157-223	27324-27325	)	_	
157-224	27326-27331	Motor	_	
157-225	27332-27339	Network	_	
157-226	27339-27340	,	_	
157-227	27341-27342	(	_	
157-228	27342-27343	d	_	
157-229	27343-27344	)	_	
157-230	27345-27352	Lateral	_	
157-231	27353-27359	Visual	_	
157-232	27360-27367	Network	_	
157-233	27367-27368	,	_	
157-234	27369-27370	(	_	
157-235	27370-27371	e	_	
157-236	27371-27372	)	_	
157-237	27373-27381	Auditory	_	
157-238	27382-27389	Network	_	
157-239	27390-27393	and	_	
157-240	27394-27395	(	_	
157-241	27395-27396	f	_	
157-242	27396-27397	)	_	
157-243	27398-27405	Default	_	
157-244	27406-27410	Mode	_	
157-245	27411-27418	Network	_	
157-246	27418-27419	.	_	

#Text=Socio-demographic profile of the schizophrenia and control sample.
158-1	27420-27437	Socio-demographic	_	
158-2	27438-27445	profile	_	
158-3	27446-27448	of	_	
158-4	27449-27452	the	_	
158-5	27453-27466	schizophrenia	_	
158-6	27467-27470	and	_	
158-7	27471-27478	control	_	
158-8	27479-27485	sample	_	
158-9	27485-27486	.	_	

#Text=Schizophrenia n = 34\tControls n = 19\tChi square/t-test\tp value\t \tGender (M/F)\t22/12\t12/7\tχ2 = 0.13\t1.000\t \tAge (Mean ± Std. deviation)\t29.324 ± 7.078\t31.526 ± 6.979\tt = 1.092\t0.280\t \tMarital Status (Ever married/Never married)\t17/17\t12/7\tχ2 = 0.852\t0.401\t \tYears of School (Mean ± Std.deviation)\t10.794 ± 3.649\t11.263 ± 3.997\tt = 0.434\t0.666\t \tOccupation (Unemployed/Employed/Student)\t25/7/2\t0/17/2\tχ2 = 27.091\t<0.001\t \tHead Motion (in mm) (Mean ± Std.deviation)\t0.13 ± 0.08\t0.09 ± 0.08\tt = 1.744\t0.09\t \t
#Text=Clinical profile of the schizophrenia sample (n = 34).
159-1	27488-27501	Schizophrenia	_	
159-2	27502-27503	n	_	
159-3	27504-27505	=	_	
159-4	27506-27508	34	_	
159-5	27509-27517	Controls	_	
159-6	27518-27519	n	_	
159-7	27520-27521	=	_	
159-8	27522-27524	19	_	
159-9	27525-27528	Chi	_	
159-10	27529-27535	square	_	
159-11	27535-27536	/	_	
159-12	27536-27542	t-test	_	
159-13	27543-27544	p	_	
159-14	27545-27550	value	_	
159-15	27553-27559	Gender	_	
159-16	27560-27561	(	_	
159-17	27561-27562	M	_	
159-18	27562-27563	/	_	
159-19	27563-27564	F	_	
159-20	27564-27565	)	_	
159-21	27566-27568	22	_	
159-22	27568-27569	/	_	
159-23	27569-27571	12	_	
159-24	27572-27574	12	_	
159-25	27574-27575	/	_	
159-26	27575-27576	7	_	
159-27	27577-27579	χ2	_	
159-28	27580-27581	=	_	
159-29	27582-27586	0.13	_	
159-30	27587-27592	1.000	_	
159-31	27595-27598	Age	_	
159-32	27599-27600	(	_	
159-33	27600-27604	Mean	_	
159-34	27605-27606	±	_	
159-35	27607-27610	Std	_	
159-36	27610-27611	.	_	
159-37	27612-27621	deviation	_	
159-38	27621-27622	)	_	
159-39	27623-27629	29.324	_	
159-40	27630-27631	±	_	
159-41	27632-27637	7.078	_	
159-42	27638-27644	31.526	_	
159-43	27645-27646	±	_	
159-44	27647-27652	6.979	_	
159-45	27653-27654	t	_	
159-46	27655-27656	=	_	
159-47	27657-27662	1.092	_	
159-48	27663-27668	0.280	_	
159-49	27671-27678	Marital	_	
159-50	27679-27685	Status	_	
159-51	27686-27687	(	_	
159-52	27687-27691	Ever	_	
159-53	27692-27699	married	_	
159-54	27699-27700	/	_	
159-55	27700-27705	Never	_	
159-56	27706-27713	married	_	
159-57	27713-27714	)	_	
159-58	27715-27717	17	_	
159-59	27717-27718	/	_	
159-60	27718-27720	17	_	
159-61	27721-27723	12	_	
159-62	27723-27724	/	_	
159-63	27724-27725	7	_	
159-64	27726-27728	χ2	_	
159-65	27729-27730	=	_	
159-66	27731-27736	0.852	_	
159-67	27737-27742	0.401	_	
159-68	27745-27750	Years	_	
159-69	27751-27753	of	_	
159-70	27754-27760	School	_	
159-71	27761-27762	(	_	
159-72	27762-27766	Mean	_	
159-73	27767-27768	±	_	
159-74	27769-27782	Std.deviation	_	
159-75	27782-27783	)	_	
159-76	27784-27790	10.794	_	
159-77	27791-27792	±	_	
159-78	27793-27798	3.649	_	
159-79	27799-27805	11.263	_	
159-80	27806-27807	±	_	
159-81	27808-27813	3.997	_	
159-82	27814-27815	t	_	
159-83	27816-27817	=	_	
159-84	27818-27823	0.434	_	
159-85	27824-27829	0.666	_	
159-86	27832-27842	Occupation	_	
159-87	27843-27844	(	_	
159-88	27844-27854	Unemployed	_	
159-89	27854-27855	/	_	
159-90	27855-27863	Employed	_	
159-91	27863-27864	/	_	
159-92	27864-27871	Student	_	
159-93	27871-27872	)	_	
159-94	27873-27875	25	_	
159-95	27875-27876	/	_	
159-96	27876-27877	7	_	
159-97	27877-27878	/	_	
159-98	27878-27879	2	_	
159-99	27880-27881	0	_	
159-100	27881-27882	/	_	
159-101	27882-27884	17	_	
159-102	27884-27885	/	_	
159-103	27885-27886	2	_	
159-104	27887-27889	χ2	_	
159-105	27890-27891	=	_	
159-106	27892-27898	27.091	_	
159-107	27899-27900	<	_	
159-108	27900-27905	0.001	_	
159-109	27908-27912	Head	_	
159-110	27913-27919	Motion	_	
159-111	27920-27921	(	_	
159-112	27921-27923	in	_	
159-113	27924-27926	mm	_	
159-114	27926-27927	)	_	
159-115	27928-27929	(	_	
159-116	27929-27933	Mean	_	
159-117	27934-27935	±	_	
159-118	27936-27949	Std.deviation	_	
159-119	27949-27950	)	_	
159-120	27951-27955	0.13	_	
159-121	27956-27957	±	_	
159-122	27958-27962	0.08	_	
159-123	27963-27967	0.09	_	
159-124	27968-27969	±	_	
159-125	27970-27974	0.08	_	
159-126	27975-27976	t	_	
159-127	27977-27978	=	_	
159-128	27979-27984	1.744	_	
159-129	27985-27989	0.09	_	
159-130	27993-28001	Clinical	_	
159-131	28002-28009	profile	_	
159-132	28010-28012	of	_	
159-133	28013-28016	the	_	
159-134	28017-28030	schizophrenia	_	
159-135	28031-28037	sample	_	
159-136	28038-28039	(	_	
159-137	28039-28040	n	_	
159-138	28041-28042	=	_	
159-139	28043-28045	34	_	
159-140	28045-28046	)	_	
159-141	28046-28047	.	_	

#Text=Mean ± SD\tRANGE\t \tAge at onset (in years)\t24.676 ± 7.23\t18–44\t \tDuration of illness (in weeks)\t194.71 ± 93.28\t50–442\t \tCurrent Episode Global Assessment Scale (GAS) score\t20.588 ± 5.716\t7–41\t \tSANS total score\t31.74 ± 18.51\t0–74\t \tAffective flattening\t2.50 ± 1.66\t0–5\t \tAlogia\t1.94 ± 1.69\t0–5\t \tAvolition/apathy\t3.35 ± 1.32\t0–5\t \tAnhedonia/asociality\t3.37 ± 1.69\t0–5\t \tAttention\t1.24 ± 1.54\t0–4\t \tSAPS total score\t15.00 ± 10.55\t0–51\t \tHallucinations\t1.24 ± 1.54\t0–5\t \tDelusions\t3.53 ± 1.69\t0–9\t \tBizarre behavior\t1.41 ± 1.62\t0–5\t \tFormal thought disorder\t0.21 ± 0.84\t0–4\t \t
#Text=Summary of the differences detected in control vs schizophrenia patient group contrast.
160-1	28049-28053	Mean	_	
160-2	28054-28055	±	_	
160-3	28056-28058	SD	_	
160-4	28059-28064	RANGE	_	
160-5	28067-28070	Age	_	
160-6	28071-28073	at	_	
160-7	28074-28079	onset	_	
160-8	28080-28081	(	_	
160-9	28081-28083	in	_	
160-10	28084-28089	years	_	
160-11	28089-28090	)	_	
160-12	28091-28097	24.676	_	
160-13	28098-28099	±	_	
160-14	28100-28104	7.23	_	
160-15	28105-28107	18	_	
160-16	28107-28108	–	_	
160-17	28108-28110	44	_	
160-18	28113-28121	Duration	_	
160-19	28122-28124	of	_	
160-20	28125-28132	illness	_	
160-21	28133-28134	(	_	
160-22	28134-28136	in	_	
160-23	28137-28142	weeks	_	
160-24	28142-28143	)	_	
160-25	28144-28150	194.71	_	
160-26	28151-28152	±	_	
160-27	28153-28158	93.28	_	
160-28	28159-28161	50	_	
160-29	28161-28162	–	_	
160-30	28162-28165	442	_	
160-31	28168-28175	Current	_	
160-32	28176-28183	Episode	_	
160-33	28184-28190	Global	_	
160-34	28191-28201	Assessment	_	
160-35	28202-28207	Scale	_	
160-36	28208-28209	(	_	
160-37	28209-28212	GAS	_	
160-38	28212-28213	)	_	
160-39	28214-28219	score	_	
160-40	28220-28226	20.588	_	
160-41	28227-28228	±	_	
160-42	28229-28234	5.716	_	
160-43	28235-28236	7	_	
160-44	28236-28237	–	_	
160-45	28237-28239	41	_	
160-46	28242-28246	SANS	_	
160-47	28247-28252	total	_	
160-48	28253-28258	score	_	
160-49	28259-28264	31.74	_	
160-50	28265-28266	±	_	
160-51	28267-28272	18.51	_	
160-52	28273-28274	0	_	
160-53	28274-28275	–	_	
160-54	28275-28277	74	_	
160-55	28280-28289	Affective	_	
160-56	28290-28300	flattening	_	
160-57	28301-28305	2.50	_	
160-58	28306-28307	±	_	
160-59	28308-28312	1.66	_	
160-60	28313-28314	0	_	
160-61	28314-28315	–	_	
160-62	28315-28316	5	_	
160-63	28319-28325	Alogia	_	
160-64	28326-28330	1.94	_	
160-65	28331-28332	±	_	
160-66	28333-28337	1.69	_	
160-67	28338-28339	0	_	
160-68	28339-28340	–	_	
160-69	28340-28341	5	_	
160-70	28344-28353	Avolition	_	
160-71	28353-28354	/	_	
160-72	28354-28360	apathy	_	
160-73	28361-28365	3.35	_	
160-74	28366-28367	±	_	
160-75	28368-28372	1.32	_	
160-76	28373-28374	0	_	
160-77	28374-28375	–	_	
160-78	28375-28376	5	_	
160-79	28379-28388	Anhedonia	_	
160-80	28388-28389	/	_	
160-81	28389-28399	asociality	_	
160-82	28400-28404	3.37	_	
160-83	28405-28406	±	_	
160-84	28407-28411	1.69	_	
160-85	28412-28413	0	_	
160-86	28413-28414	–	_	
160-87	28414-28415	5	_	
160-88	28418-28427	Attention	_	
160-89	28428-28432	1.24	_	
160-90	28433-28434	±	_	
160-91	28435-28439	1.54	_	
160-92	28440-28441	0	_	
160-93	28441-28442	–	_	
160-94	28442-28443	4	_	
160-95	28446-28450	SAPS	_	
160-96	28451-28456	total	_	
160-97	28457-28462	score	_	
160-98	28463-28468	15.00	_	
160-99	28469-28470	±	_	
160-100	28471-28476	10.55	_	
160-101	28477-28478	0	_	
160-102	28478-28479	–	_	
160-103	28479-28481	51	_	
160-104	28484-28498	Hallucinations	_	
160-105	28499-28503	1.24	_	
160-106	28504-28505	±	_	
160-107	28506-28510	1.54	_	
160-108	28511-28512	0	_	
160-109	28512-28513	–	_	
160-110	28513-28514	5	_	
160-111	28517-28526	Delusions	_	
160-112	28527-28531	3.53	_	
160-113	28532-28533	±	_	
160-114	28534-28538	1.69	_	
160-115	28539-28540	0	_	
160-116	28540-28541	–	_	
160-117	28541-28542	9	_	
160-118	28545-28552	Bizarre	_	
160-119	28553-28561	behavior	_	
160-120	28562-28566	1.41	_	
160-121	28567-28568	±	_	
160-122	28569-28573	1.62	_	
160-123	28574-28575	0	_	
160-124	28575-28576	–	_	
160-125	28576-28577	5	_	
160-126	28580-28586	Formal	_	
160-127	28587-28594	thought	_	
160-128	28595-28603	disorder	_	
160-129	28604-28608	0.21	_	
160-130	28609-28610	±	_	
160-131	28611-28615	0.84	_	
160-132	28616-28617	0	_	
160-133	28617-28618	–	_	
160-134	28618-28619	4	_	
160-135	28623-28630	Summary	_	
160-136	28631-28633	of	_	
160-137	28634-28637	the	_	
160-138	28638-28649	differences	_	
160-139	28650-28658	detected	_	
160-140	28659-28661	in	_	
160-141	28662-28669	control	_	
160-142	28670-28672	vs	_	
160-143	28673-28686	schizophrenia	_	
160-144	28687-28694	patient	_	
160-145	28695-28700	group	_	
160-146	28701-28709	contrast	_	
160-147	28709-28710	.	_	

#Text=Hemisphere\tCluster voxels\tMNI (x,y,z)\t\t#Mean probability\t \tRight Frontoparietal Network\t\t\t\t\t\t\t\t\t \tLateral Occipital Cortex (superior division)\t\t\t\t\t\t\t\t39.96\t \tPrecuneus Cortex\t\t\t\t\t\t\t\t10.54\t \tAngular Gyrus\t\t\t\t\t\t\t\t1.61\t \tSuperior Parietal Lobule\tR\t82\t30\t− 62\t\t\t40\t1.15\t \tLateral Occipital Cortex (superior division)\t\t60\t26\t− 82\t\t\t40\t61.22\t \tOccipital Pole\tR\t\t\t\t\t\t\t1.42\t \tLateral Visual Network\t\t\t\t\t\t\t\t\t \tTemporal Occipital Fusiform Cortex\t\t\t\t\t\t\t\t21.24\t \tTemporal Fusiform Cortex, posterior division\t\t\t\t\t\t\t\t14.02\t \tInferior Temporal Gyrus, temporooccipital part\tL\t231\t− 38\t− 46\t\t\t− 12\t12.81\t \tInferior Temporal Gyrus, posterior division\t\t\t\t\t\t\t\t5.14\t \tCingulate Gyrus, anterior division\t\t\t\t\t\t\t\t42.87\t \tJuxtapositional Lobule Cortex (formerly Supplementary Motor Cortex)\tR\t178\t6\t\t−6\t\t48\t25.31\t \tCingulate Gyrus, posterior division\t\t\t\t\t\t\t\t6.60\t \tLateral Occipital Cortex, superior division\t\t\t\t\t\t\t\t44.65\t \tSuperior Parietal Lobule\tL\t93\t− 30\t− 62\t\t\t44\t7.53\t \tAngular Gyrus\t\t\t\t\t\t\t\t4.74\t \tMedial Visual Network\t\t\t\t\t\t\t\t\t \tLateral Occipital Cortex (superior division)\tR\t73\t38\t− 26\t\t20\t\t41.32\t \tOccipital Pole\t\t\t\t\t\t\t\t23.45\t \tCingulate Gyrus, posterior division\t\t\t\t\t\t\t\t63.44\t \tPrecuneus Cortex\tR\t29\t6\t− 30\t\t− 36\t\t1.58\t \tMotor Network\t\t\t\t\t\t\t\t\t \tPrecentral Gyrus\tL\t291\t− 30\t− 14\t\t48\t\t33.25\t \tSuperior Frontal Gyrus\t\t\t\t\t\t\t\t14.22\t \tPostcentral Gyrus\t\t\t\t\t\t\t\t3.92\t \tDefault Mode Network (DMN)\t\t\t\t\t\t\t\t\t \tCingulate Gyrus, posterior division\t\t\t\t\t\t\t\t35.22\t \tPrecentral Gyrus\t\t\t\t\t\t\t\t23.57\t \tJuxtapositional Lobule Cortex (formerly Supplementary Motor Cortex)\tR\t692\t6\t− 26\t\t48\t\t7.54\t \tCingulate Gyrus, anterior division\t\t\t\t\t\t\t\t2.78\t \tPrecuneus Cortex\t\t\t\t\t\t\t\t1.65\t \tLateral Occipital Cortex, inferior division\t\t\t\t\t\t\t\t35\t \tSuperior Temporal Gyrus, posterior division\t\t\t\t\t\t\t\t23.29\t \tMiddle Temporal Gyrus, posterior division\tL\t40\t− 38\t− 70\t\t4\t\t15.06\t \tSuperior Temporal Gyrus, anterior division\t\t\t\t\t\t\t\t1.41\t \tSubcallosal Cortex\tR\t18\t2\t22\t\t−16\t\t72\t \tAuditory Network\t\t\t\t\t\t\t\t\t \tInsular Cortex\t\t\t\t\t\t\t\t35.64\t \tHeschl’s Gyrus (includes H1 and H2)\t\t\t\t\t\t\t\t14.86\t \tCentral Opercular Cortex\tL\t392\t− 38\t− 18\t\t12\t\t6.45\t \tParietal Operculum Cortex\t\t\t\t\t\t\t\t1.78\t \t
#Text=Note:
#Text=p < 0.05 FWE corrected.
161-1	28712-28722	Hemisphere	_	
161-2	28723-28730	Cluster	_	
161-3	28731-28737	voxels	_	
161-4	28738-28741	MNI	_	
161-5	28742-28743	(	_	
161-6	28743-28744	x	_	
161-7	28744-28745	,	_	
161-8	28745-28746	y	_	
161-9	28746-28747	,	_	
161-10	28747-28748	z	_	
161-11	28748-28749	)	_	
161-12	28751-28752	#	_	
161-13	28752-28756	Mean	_	
161-14	28757-28768	probability	_	
161-15	28771-28776	Right	_	
161-16	28777-28791	Frontoparietal	_	
161-17	28792-28799	Network	_	
161-18	28810-28817	Lateral	_	
161-19	28818-28827	Occipital	_	
161-20	28828-28834	Cortex	_	
161-21	28835-28836	(	_	
161-22	28836-28844	superior	_	
161-23	28845-28853	division	_	
161-24	28853-28854	)	_	
161-25	28862-28867	39.96	_	
161-26	28870-28879	Precuneus	_	
161-27	28880-28886	Cortex	_	
161-28	28894-28899	10.54	_	
161-29	28902-28909	Angular	_	
161-30	28910-28915	Gyrus	_	
161-31	28923-28927	1.61	_	
161-32	28930-28938	Superior	_	
161-33	28939-28947	Parietal	_	
161-34	28948-28954	Lobule	_	
161-35	28955-28956	R	_	
161-36	28957-28959	82	_	
161-37	28960-28962	30	_	
161-38	28963-28964	−	_	
161-39	28965-28967	62	_	
161-40	28970-28972	40	_	
161-41	28973-28977	1.15	_	
161-42	28980-28987	Lateral	_	
161-43	28988-28997	Occipital	_	
161-44	28998-29004	Cortex	_	
161-45	29005-29006	(	_	
161-46	29006-29014	superior	_	
161-47	29015-29023	division	_	
161-48	29023-29024	)	_	
161-49	29026-29028	60	_	
161-50	29029-29031	26	_	
161-51	29032-29033	−	_	
161-52	29034-29036	82	_	
161-53	29039-29041	40	_	
161-54	29042-29047	61.22	_	
161-55	29050-29059	Occipital	_	
161-56	29060-29064	Pole	_	
161-57	29065-29066	R	_	
161-58	29073-29077	1.42	_	
161-59	29080-29087	Lateral	_	
161-60	29088-29094	Visual	_	
161-61	29095-29102	Network	_	
161-62	29113-29121	Temporal	_	
161-63	29122-29131	Occipital	_	
161-64	29132-29140	Fusiform	_	
161-65	29141-29147	Cortex	_	
161-66	29155-29160	21.24	_	
161-67	29163-29171	Temporal	_	
161-68	29172-29180	Fusiform	_	
161-69	29181-29187	Cortex	_	
161-70	29187-29188	,	_	
161-71	29189-29198	posterior	_	
161-72	29199-29207	division	_	
161-73	29215-29220	14.02	_	
161-74	29223-29231	Inferior	_	
161-75	29232-29240	Temporal	_	
161-76	29241-29246	Gyrus	_	
161-77	29246-29247	,	_	
161-78	29248-29264	temporooccipital	_	
161-79	29265-29269	part	_	
161-80	29270-29271	L	_	
161-81	29272-29275	231	_	
161-82	29276-29277	−	_	
161-83	29278-29280	38	_	
161-84	29281-29282	−	_	
161-85	29283-29285	46	_	
161-86	29288-29289	−	_	
161-87	29290-29292	12	_	
161-88	29293-29298	12.81	_	
161-89	29301-29309	Inferior	_	
161-90	29310-29318	Temporal	_	
161-91	29319-29324	Gyrus	_	
161-92	29324-29325	,	_	
161-93	29326-29335	posterior	_	
161-94	29336-29344	division	_	
161-95	29352-29356	5.14	_	
161-96	29359-29368	Cingulate	_	
161-97	29369-29374	Gyrus	_	
161-98	29374-29375	,	_	
161-99	29376-29384	anterior	_	
161-100	29385-29393	division	_	
161-101	29401-29406	42.87	_	
161-102	29409-29424	Juxtapositional	_	
161-103	29425-29431	Lobule	_	
161-104	29432-29438	Cortex	_	
161-105	29439-29440	(	_	
161-106	29440-29448	formerly	_	
161-107	29449-29462	Supplementary	_	
161-108	29463-29468	Motor	_	
161-109	29469-29475	Cortex	_	
161-110	29475-29476	)	_	
161-111	29477-29478	R	_	
161-112	29479-29482	178	_	
161-113	29483-29484	6	_	
161-114	29486-29487	−	_	
161-115	29487-29488	6	_	
161-116	29490-29492	48	_	
161-117	29493-29498	25.31	_	
161-118	29501-29510	Cingulate	_	
161-119	29511-29516	Gyrus	_	
161-120	29516-29517	,	_	
161-121	29518-29527	posterior	_	
161-122	29528-29536	division	_	
161-123	29544-29548	6.60	_	
161-124	29551-29558	Lateral	_	
161-125	29559-29568	Occipital	_	
161-126	29569-29575	Cortex	_	
161-127	29575-29576	,	_	
161-128	29577-29585	superior	_	
161-129	29586-29594	division	_	
161-130	29602-29607	44.65	_	
161-131	29610-29618	Superior	_	
161-132	29619-29627	Parietal	_	
161-133	29628-29634	Lobule	_	
161-134	29635-29636	L	_	
161-135	29637-29639	93	_	
161-136	29640-29641	−	_	
161-137	29642-29644	30	_	
161-138	29645-29646	−	_	
161-139	29647-29649	62	_	
161-140	29652-29654	44	_	
161-141	29655-29659	7.53	_	
161-142	29662-29669	Angular	_	
161-143	29670-29675	Gyrus	_	
161-144	29683-29687	4.74	_	
161-145	29690-29696	Medial	_	
161-146	29697-29703	Visual	_	
161-147	29704-29711	Network	_	
161-148	29722-29729	Lateral	_	
161-149	29730-29739	Occipital	_	
161-150	29740-29746	Cortex	_	
161-151	29747-29748	(	_	
161-152	29748-29756	superior	_	
161-153	29757-29765	division	_	
161-154	29765-29766	)	_	
161-155	29767-29768	R	_	
161-156	29769-29771	73	_	
161-157	29772-29774	38	_	
161-158	29775-29776	−	_	
161-159	29777-29779	26	_	
161-160	29781-29783	20	_	
161-161	29785-29790	41.32	_	
161-162	29793-29802	Occipital	_	
161-163	29803-29807	Pole	_	
161-164	29815-29820	23.45	_	
161-165	29823-29832	Cingulate	_	
161-166	29833-29838	Gyrus	_	
161-167	29838-29839	,	_	
161-168	29840-29849	posterior	_	
161-169	29850-29858	division	_	
161-170	29866-29871	63.44	_	
161-171	29874-29883	Precuneus	_	
161-172	29884-29890	Cortex	_	
161-173	29891-29892	R	_	
161-174	29893-29895	29	_	
161-175	29896-29897	6	_	
161-176	29898-29899	−	_	
161-177	29900-29902	30	_	
161-178	29904-29905	−	_	
161-179	29906-29908	36	_	
161-180	29910-29914	1.58	_	
161-181	29917-29922	Motor	_	
161-182	29923-29930	Network	_	
161-183	29941-29951	Precentral	_	
161-184	29952-29957	Gyrus	_	
161-185	29958-29959	L	_	
161-186	29960-29963	291	_	
161-187	29964-29965	−	_	
161-188	29966-29968	30	_	
161-189	29969-29970	−	_	
161-190	29971-29973	14	_	
161-191	29975-29977	48	_	
161-192	29979-29984	33.25	_	
161-193	29987-29995	Superior	_	
161-194	29996-30003	Frontal	_	
161-195	30004-30009	Gyrus	_	
161-196	30017-30022	14.22	_	
161-197	30025-30036	Postcentral	_	
161-198	30037-30042	Gyrus	_	
161-199	30050-30054	3.92	_	
161-200	30057-30064	Default	_	
161-201	30065-30069	Mode	_	
161-202	30070-30077	Network	_	
161-203	30078-30079	(	_	
161-204	30079-30082	DMN	_	
161-205	30082-30083	)	_	
161-206	30094-30103	Cingulate	_	
161-207	30104-30109	Gyrus	_	
161-208	30109-30110	,	_	
161-209	30111-30120	posterior	_	
161-210	30121-30129	division	_	
161-211	30137-30142	35.22	_	
161-212	30145-30155	Precentral	_	
161-213	30156-30161	Gyrus	_	
161-214	30169-30174	23.57	_	
161-215	30177-30192	Juxtapositional	_	
161-216	30193-30199	Lobule	_	
161-217	30200-30206	Cortex	_	
161-218	30207-30208	(	_	
161-219	30208-30216	formerly	_	
161-220	30217-30230	Supplementary	_	
161-221	30231-30236	Motor	_	
161-222	30237-30243	Cortex	_	
161-223	30243-30244	)	_	
161-224	30245-30246	R	_	
161-225	30247-30250	692	_	
161-226	30251-30252	6	_	
161-227	30253-30254	−	_	
161-228	30255-30257	26	_	
161-229	30259-30261	48	_	
161-230	30263-30267	7.54	_	
161-231	30270-30279	Cingulate	_	
161-232	30280-30285	Gyrus	_	
161-233	30285-30286	,	_	
161-234	30287-30295	anterior	_	
161-235	30296-30304	division	_	
161-236	30312-30316	2.78	_	
161-237	30319-30328	Precuneus	_	
161-238	30329-30335	Cortex	_	
161-239	30343-30347	1.65	_	
161-240	30350-30357	Lateral	_	
161-241	30358-30367	Occipital	_	
161-242	30368-30374	Cortex	_	
161-243	30374-30375	,	_	
161-244	30376-30384	inferior	_	
161-245	30385-30393	division	_	
161-246	30401-30403	35	_	
161-247	30406-30414	Superior	_	
161-248	30415-30423	Temporal	_	
161-249	30424-30429	Gyrus	_	
161-250	30429-30430	,	_	
161-251	30431-30440	posterior	_	
161-252	30441-30449	division	_	
161-253	30457-30462	23.29	_	
161-254	30465-30471	Middle	_	
161-255	30472-30480	Temporal	_	
161-256	30481-30486	Gyrus	_	
161-257	30486-30487	,	_	
161-258	30488-30497	posterior	_	
161-259	30498-30506	division	_	
161-260	30507-30508	L	_	
161-261	30509-30511	40	_	
161-262	30512-30513	−	_	
161-263	30514-30516	38	_	
161-264	30517-30518	−	_	
161-265	30519-30521	70	_	
161-266	30523-30524	4	_	
161-267	30526-30531	15.06	_	
161-268	30534-30542	Superior	_	
161-269	30543-30551	Temporal	_	
161-270	30552-30557	Gyrus	_	
161-271	30557-30558	,	_	
161-272	30559-30567	anterior	_	
161-273	30568-30576	division	_	
161-274	30584-30588	1.41	_	
161-275	30591-30602	Subcallosal	_	
161-276	30603-30609	Cortex	_	
161-277	30610-30611	R	_	
161-278	30612-30614	18	_	
161-279	30615-30616	2	_	
161-280	30617-30619	22	_	
161-281	30621-30622	−	_	
161-282	30622-30624	16	_	
161-283	30626-30628	72	_	
161-284	30631-30639	Auditory	_	
161-285	30640-30647	Network	_	
161-286	30658-30665	Insular	_	
161-287	30666-30672	Cortex	_	
161-288	30680-30685	35.64	_	
161-289	30688-30694	Heschl	_	
161-290	30694-30695	’	_	
161-291	30695-30696	s	_	
161-292	30697-30702	Gyrus	_	
161-293	30703-30704	(	_	
161-294	30704-30712	includes	_	
161-295	30713-30715	H1	_	
161-296	30716-30719	and	_	
161-297	30720-30722	H2	_	
161-298	30722-30723	)	_	
161-299	30731-30736	14.86	_	
161-300	30739-30746	Central	_	
161-301	30747-30756	Opercular	_	
161-302	30757-30763	Cortex	_	
161-303	30764-30765	L	_	
161-304	30766-30769	392	_	
161-305	30770-30771	−	_	
161-306	30772-30774	38	_	
161-307	30775-30776	−	_	
161-308	30777-30779	18	_	
161-309	30781-30783	12	_	
161-310	30785-30789	6.45	_	
161-311	30792-30800	Parietal	_	
161-312	30801-30810	Operculum	_	
161-313	30811-30817	Cortex	_	
161-314	30825-30829	1.78	_	
161-315	30833-30837	Note	_	
161-316	30837-30838	:	_	
161-317	30839-30840	p	_	
161-318	30841-30842	<	_	
161-319	30843-30847	0.05	_	
161-320	30848-30851	FWE	_	
161-321	30852-30861	corrected	_	
161-322	30861-30862	.	_	

#Text=MNI (x,y,z): coordinates of peak locations in the space of Montreal Neurological Institute (MNI).
162-1	30863-30866	MNI	_	
162-2	30867-30868	(	_	
162-3	30868-30869	x	_	
162-4	30869-30870	,	_	
162-5	30870-30871	y	_	
162-6	30871-30872	,	_	
162-7	30872-30873	z	_	
162-8	30873-30874	)	_	
162-9	30874-30875	:	_	
162-10	30876-30887	coordinates	_	
162-11	30888-30890	of	_	
162-12	30891-30895	peak	_	
162-13	30896-30905	locations	_	
162-14	30906-30908	in	_	
162-15	30909-30912	the	_	
162-16	30913-30918	space	_	
162-17	30919-30921	of	_	
162-18	30922-30930	Montreal	_	
162-19	30931-30943	Neurological	_	
162-20	30944-30953	Institute	_	
162-21	30954-30955	(	_	
162-22	30955-30958	MNI	_	
162-23	30958-30959	)	_	
162-24	30959-30960	.	_	
